


















Agency for Healthcare Research and Quality 
 
Office of the Assistant Secretary for Public Affairs 
 
Office of the Assistant Secretary for Planning and Evaluation 
 
Centers for Disease Control and Prevention 
 
Centers for Medicare & Medicaid Services 
 
Food and Drug Administration 
 
National Institutes of Health 
 
Office of the National Coordinator for Health Information Technology 
 
























Executive Summary        Page 1 
 
Introduction         Page 7 
 
Prevention: Metrics and Targets      Page 12 
 
Prevention: Prioritized Recommendations     Page 22 
 
Research         Page 29 
 
Information Systems and Technology     Page 46 
 
Incentives and Oversight       Page 57 
 
Outreach and Messaging       Page 82 
 












AHRQ  Agency for Healthcare Research and Quality 
ASPA  Assistant Secretary for Public Affairs 
ASPE  Assistant Secretary for Planning and Evaluation 
CAUTI catheter-associated urinary tract infection 
CDC  Centers for Disease Control and Prevention 
CDI  Clostridium difficile infection 
CLABSI central line-associated bloodstream infection 
CMS  Centers for Medicare & Medicaid Services 
CoP  Condition of Participation 
EHR  electronic health record 
FDA  Food and Drug Administration 
FHISE  Federal Health Information Sharing Environment 
GAO  Government Accountability Office 
HAC  Hospital-Acquired Condition 
HAI  healthcare-associated infection 
HHS  Department of Health and Human Services 
HICPAC Healthcare Infection Control Practices Advisory Committee 
ICD-9  International Classification of Diseases, Ninth Revision 
MDRO multidrug-resistant organism 
MRSA  methicillin-resistant Staphylococcus aureus 
NHIN  Nationwide Health Information Network 
NHSN  National Healthcare Safety Network 
NIH  National Institutes of Health 
NNIS  National Nosocomial Infections Surveillance System 
ONC  Office of the National Coordinator for Health Information Technology 
OPHS  Office of Public Health and Science 
POA  present on admission 
QIO  Quality Improvement Organization 
SCIP  Surgical Care Improvement Project 
SSI  surgical site infection 
VAP  ventilator-associated pneumonia 
VBP  Value-Based Purchasing 
 
 
HHS Action Plan to Prevent Healthcare-Associated Infections 06222009 
Section 2: Executive Summary 
 
 




Background on Healthcare-Associated Infections 
 
The Department of Health and Human Services (HHS) “Action Plan to Prevent 
Healthcare-Associated Infections” represents a culmination of several months of 
research, deliberation, and public comment to identify the key actions needed to achieve 
and sustain progress in protecting patients from the transmission of serious, and in some 
cases, deadly infections. 
 
Healthcare-associated infections (HAIs) are infections that patients acquire while 
receiving treatment for medical or surgical conditions. HAIs occur in all settings of care, 
including acute care within hospitals and same day surgical centers, ambulatory 
outpatient care in healthcare clinics, and in long-term care facilities, such as nursing 
homes and rehabilitation facilities. HAIs are associated with a variety of causes, 
including (but not limited to) the use of medical devices, such as catheters and 
ventilators, complications following a surgical procedure, transmission between patients 
and healthcare workers, or the result of antibiotic overuse. 
 
Healthcare-associated infections exact a significant toll on human life. They are among 
the leading causes of death in the United States, accounting for an estimated 1.7 million 
infections and 99,000 associated deaths in 2002. In hospitals, they are a significant cause 
of morbidity and mortality.1 Hospital stays for methicillin-resistant Staphylococcus 
aureus (MRSA) infection have more than tripled since 2000 and have increased nearly 
ten-fold since 1995.2 
 
Four categories of infections account for approximately three quarters of HAIs in the 
acute care hospital setting. These four categories are: 1) Surgical site infections; 2) 
Central line-associated bloodstream infections; 3) Ventilator-associated pneumonia, and; 
4) Catheter-associated urinary tract infections. In addition, infections associated with 
Clostridium difficile and MRSA also contribute significantly to the overall problem. The 
frequency of HAIs varies by location. Currently, urinary tract infections comprise the 
highest percentage (34%) of HAIs followed by surgical site infections (17%), 
bloodstream infections (14%), and pneumonia (13%).3 
 
In addition to the substantial human suffering exacted by HAIs the financial burden 
attributable to these infections is staggering. It is estimated that HAIs incur an estimated 
                                                 
1 Klevens RM, Edwards J, Richards C, Horan T, Gaynes R, Pollock D, Cardo D. Estimating Health Care-Associated Infections and 
Deaths in U.S. Hospitals, 2002. Public Health Reports 2007; 122:160-166. 
2 Elixhauser A and Steiner C. Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals, 1993–2005. 
AHRQ Healthcare Cost and Utilization Project Statistical Brief 2007; 35:1-10. 
3 Klevens RM, Edwards J, Richards C, Horan T, Gaynes R, Pollock D, Cardo D. Estimating Health Care-Associated Infections and 
Deaths in U.S. Hospitals, 2002. Public Health Reports 2007; 122:160-166. 
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$28 to $33 billion in excess healthcare costs each year.4 Whereas not all Staphylococcus 
aureus infections are healthcare-associated, healthcare charges for Staphylococcus aureus 
bloodstream infections for Medicare patients exceeded $2.5 billion in 2005.5 
 
 
HHS Action Plan to Prevent Healthcare-Associated Infections 
 
In response to the increasing threat of HAIs and national and international concern, the 
Department has composed a Steering Committee of senior-level representatives from the 
Offices and Operating Divisions of HHS and conducted a number of in-person meetings 
and conferences with Federal experts. The Department’s Action Plan toward the 
prevention and elimination of HAIs includes goals toward which the healthcare and 
public health communities have been moving over the past several years. Despite 
uncertainty about whether there ultimately will be a limit on meeting this goal, the 
decision to move forward has been embraced by the Steering Committee. 
 
A five-point draft strategy was developed by HHS for the Action Plan and included: 
 
1) Establishing an HHS Steering Committee for the Prevention of Healthcare-
Associated Infections to develop an Action Plan. 
2) Beginning to prioritize, in partnership with the HHS Secretary’s Healthcare 
Infection Control Practices Advisory Committee (HICPAC), the significant 
scientific questions that need to be addressed to move the field forward rapidly 
and the current 1,200 recommended clinical practices to facilitate rapid 
implementation amongst healthcare organizations. 
3) Identifying and exploring policy options for regulatory oversight of recommended 
practices and providing critical compliance assistance to select hospitals. 
4) Working to establish greater consistency and compatibility of HAI data through 
developing standardized definitions and measures for HAIs. 
5) Striving to build on the principles of transparency and consumer choice to create 
incentives and motivate healthcare organizations and providers to provide better, 
more efficient care. 
 
Some of the most prominent clinicians, scientists, and other public health professionals 
within HHS in concert with key individuals from other federal Departments worked to 
develop a road-map for addressing this important public health and patient safety issue in 
the short- and long-term. Five working groups of the HHS Steering Committee met this 
past year, deliberated on known facts, research needs, and how to prevent HAIs. The 
primary topics of the five working groups with their respective agency leads were: 
 
 The Prevention and Implementation working group led by the Centers for 
Disease Control and Prevention (CDC), 
                                                 
4 Scott Rd. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention, 2009. 
Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, 
Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, February 2009. 
5 http://hcupnet.ahrq.gov/ 
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 The Research working group led by the Agency for Healthcare Research and 
Quality (AHRQ), 
 The Information Systems and Technology working group co-chaired by the 
Office of the National Coordinator for Health Information Technology (ONC) 
and CDC, 
 The Incentives and Oversight working group led by the Centers for Medicare & 
Medicaid Services (CMS), and, 
 The Outreach and Messaging working group led by the Office of Public Health 
and Science (OPHS). 
 
The HHS Steering Committee and its sub-groups, which composed the Action Plan to 
Prevent Healthcare-Associated Infections, accomplished the following: 
 
 Identified metrics with corresponding national 5-year prevention targets 
 Identified gaps in the current knowledge of HAIs and created an agenda for 
current and future research on HAIs 
 Recommended standardization of data elements and adoption and use of data and 
technology standards to track HAIs 
 Documented the current regulatory and administrative authority and 
initiatives/strategies of CMS (working with other HHS Operating Divisions and 
federal partners) used to prevent and combat HAIs 
 Developed a progressive campaign to release and publicize the Action Plan in 
concert with a number of national partners in the federal, academic, non-profit, 
and private sectors. This messaging and communications strategy will target a 
number of audiences using the principles of social marketing and risk 
communication to also reach the public at large. 
 
 
Top Ten Messages on HAIs and the Action Plan6 
 
 Many healthcare-associated infections are preventable. 
 A systemic approach to reducing the transmission of disease can be more 
effective than disease-specific approaches. 
 Developing and supporting basic and translational studies to address the gaps in 
the science in this field will allow generation of additional strategies to reduce the 
risks of HAI transmission. 
 It will take a strong partnership between federal and local/state governments and 
communities to truly help prevent HAIs. HHS is committed to this partnership 
and many of its Operating Divisions are and will be involved. 
 The education of best practices for providers and other healthcare personnel is 
critical to prevent HAIs. 
 Specific metrics and national targets have been developed by HHS in concert with 
national experts on controlling infections. 
                                                 
6 That HHS and Collaborators will communicate these to many stakeholders and the public – including healthcare organizations, 
professional provider organizations, governmental agencies, non-profit public health organizations, and the public. 
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 Educating patients on HAIs and how to prevent them is a critical part of the 
national effort. 
 An informed media can help promote the education of the American public about 
the need to prevent HAIs and what HHS and its partners are doing. 
 Preventive steps to control and prevent HAIs are cost-effective, save lives, and 
reduce disability for Americans.   
 The time to act on HAIs is now, and HHS and its partners are working closely 




Priority Recommendations of the Prevention and Implementation Group 
 
 Progress towards 5-year national prevention targets 
 Use and improve the metrics and supporting systems needed to assess progress 
towards meeting the targets 




Priority Recommendations of the Research Group 
 
1) Perform Research Projects to Address Specific Knowledge Gaps (Basic Science, 
Epidemiology, and Practices)  
o Basic Science 
 Develop strategies for preventing and/or eliminating biofilms 
associated with medical devices 
o Epidemiology 
 Study the epidemiology of bloodstream infections that occur 
outside of the hospital 
 Establish the preventability of Clostridium difficile infection (CDI) 
through a regional hospital collaborative intervention 
 Establish the preventability of unnecessary antimicrobial use 
through a multi-center collaborative intervention 
 Establish the preventability of surgical site infection (SSI) through 
a multi-center collaborative intervention 
o Practices 
 Assess the effectiveness of the ICU-wide application of a MRSA 
decolonization strategy 
 
2) Perform Research Projects to Enhance the Implementation and Impact of 
Existing, Evidence-Based Infection Control Practices 
o Investigate the human cultural and organizational barriers to successful 
implementation of practices at the unit and institutional levels 
o Develop and evaluate novel and automatable strategies for measuring 
HAIs 
4 
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o Evaluate and validate standardized post-discharge surveillance 
methodology 
o Develop proxy measures for ventilator-associated pneumonia (VAP) (i.e., 
acute lung injury) for inter-facility comparisons 
o Develop standardized methods for measuring and reporting compliance 
with broad-based prevention practices (e.g., hand hygiene) 
 
 
Priority Recommendations of the Information Systems and Technology Group 
 
 Form an Interagency Working Group to enhance the federal capacity to lead a 
national prevention strategy 
 Conduct a comprehensive HAI database inventory to guide future plans for near-, 
mid-, and long-term integration and interoperability projects and to establish the 
extent of definitional alignment and data element standardization needed to link 
HAI data across the nation 
 Enhance individual agency systems to extend their coverage or establish new 
interfaces with other systems 
 Accelerate transition to electronic reporting by healthcare facilities to reduce their 
reporting burden and increase timeliness, efficiency, comprehensiveness, and 
reliability of the data 
 
 
Priority Recommendations of the Incentives and Oversight Group 
 
 Improve regulatory oversight of hospitals and CMS oversight of the hospital 
accreditation program by refining the current method of measuring Accreditation 
Organization performance, enhancing surveyor training and tools, and adding 
sources and uses of infection control data 
 Continue to incorporate measures of infection prevention and outcomes into 
Hospital Value-Based Purchasing (VBP) Plan methodology through 
implementing performance-based payment for hospitals, including measures of 
infection prevention and outcomes as a basis for payment 
 Expand measures in CMS Hospital Compare which improves the quality and 
transparency of hospital care by increasing public accountability and provides 
consumers access to important hospital quality of care measures 
 
 
Priority Objectives of the Outreach and Messaging Group 
 
 Increase support for the HHS Action Plan to Prevent Healthcare-Associated 
Infections 
 Increase knowledge and awareness of key messages and prevention practices 
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Conclusion and Contacts 
 
Healthcare-associated infections are one of the most preventable causes of leading 
mortality in the U.S. The infections also add a significant economic burden to the 
healthcare system. The Department, in conjunction with experts, has developed an action 
plan to help reduce, prevent, and eventually eliminate much of the significant burden to 
our nation, health systems, communities, and individuals of HAIs. 
 
We strongly encourage you to read the HHS Action Plan to Prevent Healthcare-
Associated Infections. For additional details on what is in the Action Plan or on what 
HHS is doing to address this critical public health issue, please contact the HHS Office of 
Public Health and Science. 
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Healthcare-associated infections (HAIs) are infections that patients acquire while 
receiving treatment for medical or surgical conditions. HAIs occur in all settings of care, 
including hospital acute care units and same day surgical centers, ambulatory outpatient 
care clinics, and long-term care facilities, such as nursing homes and rehabilitation 
centers. The infections are associated with a variety of causes, including but not limited 
to the use of medical devices, such as catheters and ventilators, complications following 
surgical procedures, transmission between patients and healthcare workers, or are the 
result of antibiotic overuse. Also, HAI are caused by a variety of infectious agents, 
including bacteria, fungi, and viruses. 
 
Healthcare-associated infections exact a significant toll on human life. They are among 
the top ten leading causes of death in the United States, accounting for an estimated 1.7 
million infections and 99,000 associated deaths in 2002.1 In hospitals, they are a 
significant cause of morbidity and mortality. Hospital stays for methicillin-resistant 
Staphylococcus aureus (MRSA) infection have more than tripled since 2000 and have 
increased nearly ten-fold since 1995.2 
 
Four categories of infections account for approximately three quarters of HAIs in the 
acute care hospital setting. The frequency of these infections varies by location. 
Currently, urinary tract infections comprise the highest percentage (34%) of HAIs 
followed by surgical site infections (17%), bloodstream infections (14%), and pneumonia 
(13%).3 The chart below indicates the leading types of HAI on a national scale. 
Leading Types of Healthcare-Associated Infections










                                                 
1 Klevens RM, Edwards J, Richards C, Horan T, Gaynes R, Pollock D, Cardo D. Estimating Health Care-Associated Infections and 
Deaths in U.S. Hospitals, 2002. Public Health Reports 2007; 122:160-166. 
2 Elixhauser A and Steiner C. Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals, 1993–2005. 
AHRQ Healthcare Cost and Utilization Project Statistical Brief 2007; 35:1-10. 
3 Klevens RM, Edwards J, Richards C, Horan T, Gaynes R, Pollock D, Cardo D. Estimating Health Care-Associated Infections and 
Deaths in U.S. Hospitals, 2002. Public Health Reports 2007; 122:160-166. 
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In addition to the substantial human suffering exacted by healthcare-associated 
infections, the financial burden attributable to these infections is staggering. It is 
estimated that healthcare-associated infections incur an estimated $28 to $33 billion in 
excess healthcare costs each year.4 Whereas not all Staphylococcus aureus infections are 
healthcare-associated, healthcare charges for Staphylococcus aureus bloodstream 
infections for Medicare patients exceeded $2.5 billion in 2005.5 The table below 
illustrates the estimated annual hospital cost per infection by infection site. 
 
Estimated Annual Hospital Cost of Healthcare-Associated Infections by Site of Infection6,7 
 









Surgical Site Infection 290,485 $25,546 $7,421 13,088 
Central Line-Associated 
Bloodstream Infection 248,678 $36,441 $9,062 30,665 
Ventilator-Associated 
Pneumonia (Lung Infection) 250,205 $9,969 $2,494 35,967 
Catheter-Associated Urinary 
Tract Infection 561,667 $1,006 $565 8,205 
 
 
Despite the sobering facts, healthcare-associated infections are largely preventable and 
can be drastically reduced in order to save lives and avoid excess costs. The growing 
demands on the healthcare system, coupled with concerns of antimicrobial-resistant 
pathogens and rising healthcare costs, reinforce the imperative to address this issue. 
 
 
HHS Steering Committee 
 
In recognition of this important public health and patient safety problem, the Department 
of Health and Human Services (HHS) is presenting a plan to prevent HAIs over the next 
several years. Successful infection prevention and elimination efforts have been 
underway for years at the various Operating Divisions of HHS. However, in 2008, HHS 
began a concerted, Departmental-wide effort to more comprehensively approach the 
issue. The goal is to marshal the extensive and diverse resources of HHS and collaborate 
effectively with public and private sector partners to accomplish the large-scale 
prevention of HAIs. 
 
                                                 
4 Scott Rd. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention, 2009. 
Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, 
Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, February 2009. 
5 http://hcupnet.ahrq.gov/ 
6 Stone PW, Braccia D, Larson E. Systematic Review of Economic Analysis of Health Care-Associated Infections. American Journal 
of Infection Control 2005; 33:501-509. 
7 Roberts RR, Scott RD, Cordell R, Solomon SL, Steele L, Kempe LM, Trick WE, Weinstein RA. The Use of Economic Modeling to 
Determine the Hospital Costs Associated with Nosocomial Infections. Clinical Infectious Diseases 2003; 36:1424-1432. 
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In March 2008, the Government Accountability Office (GAO) completed a review of 
HAIs in hospitals.8 The GAO acknowledged HHS-supported efforts and encouraged the 
Department to further its leadership of addressing HAIs through enhanced coordination 
of all prevention activities. In particular, the report directed the Department to prioritize 
existing recommended infection control practices to facilitate their implementation in 
healthcare facilities. The various information technology systems used to measure HAIs 
were also highlighted in the report. While there are numerous systems and databases 
collecting HAI-related data across HHS, the GAO noted a need for greater consistency 
and compatibility of the data to enhance the information provided, including national 
estimates of the major types of HAIs. 
 
The Department is committed to protecting the health and safety of all Americans and 
reducing unnecessary and exorbitant healthcare costs. In response to this important 
problem, HHS has undertaken several inter-agency initiatives to improve and expand 
HAI prevention efforts. One of these initiatives was the establishment of the HHS 
Steering Committee for the Prevention of Healthcare-Associated Infections (Steering 
Committee). 
 
The Steering Committee included senior-level representatives from the Offices and 
Operating Divisions of HHS and was chaired by the Principal Deputy Assistant Secretary 
for Health. The HHS Deputy Secretary charged the Steering Committee with developing 
an Action Plan to Prevent HAIs. This plan establishes national goals and outlines key 
actions for enhancing and coordinating HHS-supported efforts. In addition, the plan 
outlines opportunities for collaboration with external partners to maximize the efforts of 
all stakeholders. 
 
The Steering Committee utilized a working group structure to accomplish its charge. 
Each of the five working groups enumerated strategies for accomplishing a portion of the 
Action Plan: 
 
 The Prevention and Implementation group, in partnership with the HHS 
Healthcare Infection Control Practices Advisory Committee (HICPAC), 
prioritized existing recommended clinical practices to facilitate 
implementation in healthcare organizations. 
 
 The Research group identified gaps in the existing knowledge base of current 
infection control practices and developed a coordinated research agenda to 
strengthen the science for infection control prevention in hospitals. 
 
 The Incentive and Oversight group explored opportunities for evaluating 
compliance with infection control practices in hospitals through required 
certification processes and identified additional options for the use of payment 
policies and financial incentives to motivate organizations to provide better, 
more efficient care. 
 
                                                 
8 United States Government Accountability Office. Health-Care-Associated Infections in Hospitals. GAO-08-283, Washington, DC, 
April 2008. 
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 The Information Systems and Technology group established a plan to progress 
towards the standardized measures and data definitional alignment needed to 
measure HAIs across HHS Operating Divisions and provided opportunities to 
make the varied HHS data systems interoperable to enhance understanding of 
HAIs. 
 
 The Outreach and Messaging group developed a plan for national messaging 
regarding HAI prevention to raise awareness among various stakeholder 
groups across the United States. 
 
 
Tier One of the Initiative 
 
Given the substantial breadth and depth of HAIs, the Steering Committee decided to 
concentrate its activities on a first tier of six high priority HAI-related areas within the 
acute care hospital setting. Surgical site infections, central line-associated bloodstream 
infections, ventilator-associated pneumonia, and catheter-associated urinary tract 
infections account for approximately three quarters of HAIs in the acute care hospital 
setting.9 Thus, these four infection categories were included in the initiative’s first tier. 
 
In addition, the Steering Committee believed it was important to address an emerging 
HAI issue, and therefore decided to include two organism specific priorities: Clostridium 
difficile, as well as methicillin-resistant Staphylococcus aureus (MRSA) in its first tier 
efforts. A recent publication demonstrated that Clostridium difficile is occurring almost as 
frequently in the hospital setting as MRSA, impacting resource use and inpatient 
mortality.10 MRSA is addressed as a causative organism, given its contribution to the 
four HAI priority procedures. 
 
While remaining aware of the larger issues regarding HAI prevention, the Action Plan 
focuses on the setting, procedures, and organisms defined in the first phase. Subsequent 
stages of the initiative will address additional HAI areas and other types of healthcare 





Recognizing that the national prevention of HAIs is a shared responsibility of the 
government, healthcare industry, and consumers, partnerships are critical to making and 
sustaining progress in achieving the goals outlined in this plan. As an initial step, the 
Steering Committee has launched efforts to ensure appropriate stakeholder engagement 
and input into the development of its Action Plan. 
 
                                                 
9 Klevens RM, Edwards J, Richards C, Horan T, Gaynes R, Pollock D, Cardo D. Estimating Health Care-Associated Infections and 
Deaths in U.S. Hospitals, 2002. Public Health Reports 2007; 122:160-166. 
10 Elixhauser A and Jhung M. Clostridium Difficile-Associated Disease in U.S. Hospitals, 1993–2005. AHRQ Healthcare Cost and 
Utilization Project Statistical Brief 2008; 50:1-11. 
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In September 2008, the Department, led by the Centers for Disease Control and 
Prevention (CDC), convened a meeting of key stakeholders from academia, federal and 
state governments, consumer groups, etc. with the purpose of soliciting individual input 
on the setting of national potential prevention targets. At this meeting held in 
Washington, D.C., foremost experts across the nation identified near- and long-term 
process and outcome measures for benchmarking progress in the prevention of HAIs. 
 
As this plan begins to be implemented across the nation, HHS will look to its partners to 
help amplify key messages and the adoption of recommended practices. We can and will 
accomplish more together, working hand in hand, focused on the end goal of preventing 
unnecessary infections and their associated consequences. 
 
As with many current and emerging healthcare issues, the success of the nation’s 
healthcare system cannot be measured by the Department’s efforts alone. Rather, success 
in preventing HAIs will be directly dependent on the creation of effective partnerships 
across the federal government, states, communities, and other private and public 
organizations to help build and sustain capacity to promote the health and protect the 
safety of all Americans. 
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HHS Action Plan to Prevent Healthcare-Associated Infections: 





Ensuring safe healthcare in the United States is an essential part of realizing national goals 
for a healthy population. The elimination of healthcare-associated infections (HAIs) is an 
ambitious and challenging goal toward which the healthcare and public health communities 
have been moving gradually over the past several years. Despite uncertainty about whether 
there will ultimately be a limit to the extent to which this goal can be achieved, the decision 
to move toward it has increasingly been embraced. 
 
Although, this process is still imperfect, there continue to be improvements in technologic 
and procedural capabilities for healthcare delivery and public health surveillance that are 
gradually bringing us closer to realizing the goal of HAI elimination. The Department of 
Health and Human Services’ (HHS’) effort toward this goal is a valuable and timely 
opportunity to assess which national targets should be addressed first, and what actions 
should be given the highest priorities in patient care at the bedside, and on the larger scale of 
communities and health systems. The Action Plan will coordinate where possible and 
appropriate with existing Departmental efforts, including Healthy People 2020. 
 
The following section will discuss how the proposed national prevention targets were set and 
how a number of metrics (seven in total) were identified. The metrics should help measure 





In partnership with stakeholders from the medical, public health, and infection prevention 
and control communities, the Department’s Steering Committee for the Prevention of 
HAIs (Steering Committee) and the Centers for Disease Control and Prevention (CDC) 
convened a group of scientific experts in HAI prevention and public health in Arlington, 
VA, on September 25, 2008 in order to provide input on the: 
 
 Development of potential 5-year national prevention targets to be considered for 
the Action Plan to Prevent HAIs; and 
 Identification of potential metrics and systems to assess progress towards these 
targets. 
 
Participants included representatives from various federal agencies, the Healthcare 
Infection Control Practices Advisory Committee (HICPAC), professional and scientific 
organizations, researchers, and other stakeholders. The following is a summary of the 
outcome of that meeting. 
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III. Identification of Metrics and 5-year National Prevention Targets 
 
The group of experts was charged with identifying potential targets and metrics for six 
categories of healthcare-associated infections: 
 
 Central Line-associated Bloodstream Infections (CLABSI) 
 Clostridium difficile Infections (CDI) 
 Catheter-associated Urinary Tract Infections (CAUTI) 
 Methicillin-resistant Staphylococcus aureus (MRSA) Infections 
 Surgical Site Infections (SSI) 
 Ventilator-associated Pneumonia (VAP) 
 
By the conclusion of the meeting, a total of 17 potential metrics and associated 
measurement systems and national 5-year prevention targets were identified. These 
metrics include both process and outcome measures and covered all six categories of 
healthcare-associated infections. 
 
The finalized metrics and targets are shown in Table 1 below. (Note: The full list of 
considered metrics is available in Appendix A). Participants provided input and identified 
potential metrics using various criteria without attempting to reach consensus. At the 
meeting the participants divided into six focus groups, based on the six priorities 
identified earlier. Each of the six sub-groups developed the targets and metrics and 
brought them forward to the larger group for final discussion. 
 
A sub-set of the HHS Steering Committee reviewed the list of proposed metrics from the 
meeting participants and identified those metrics that were supported by existing HHS 
measurement systems. In addition, recognizing the importance of working synergistically 
with partners, the finalized metrics complement and support existing national metrics and 
targets identified and/or adopted by key national stakeholder organizations, such as the 
National Quality Forum (NQF), and many are included in the Society for Healthcare 
Epidemiologists of America (SHEA)/Infectious Diseases Society of America (IDSA) 
Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care 
Hospitals. (Note: The finalized metrics and targets with corresponding metrics from NQF 
and the SHEA/IDSA Compendium of Strategies are listed in Appendix B.) Having shared 
metrics promotes synergy and efficiency of all organizations working to reduce HAIs.  
 
In the field of infection control and prevention there are a number of abbreviations used 
by the experts that are often found in the targets and metrics. These abbreviations are: 
 
 ABCs: Active Bacterial Core surveillance 
 ADT: Admissions Discharge Transfer 
 CLIP: Central Line Insertion Practices 
 EIP: Emerging Infections Program 
 MDRO: Multidrug Resistant Organism 
 NHSN: National Healthcare Safety Network 
 SCIP: Surgical Care Improvement Project 
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National 5-Year Prevention Target 
1. CLABSI 1 CLABSIs per 1000 device 




discharge data1  
CLABSIs per 1,000 device days by 
ICU and other locations below 
present NHSN 25th percentile by 
location type (75% reduction in 
Stratified Infection Ratio) 





100% compliance with central line 
bundle (non-emergent insertions) 
3. C diff 1 Case rate per patient days; 
administrative/discharge 







30% reduction in the case rate per 
patient days and administrative / 
discharge data for ICD-9-CM 
coded Clostridium difficile 
Infections  
 
NOTE: Preventability of endemic 
CDI is unknown; therefore, the 
meeting attendee experts suggested 
that HHS revisit this target in 2 
years as prevention research 
findings may become available 
4. CAUTI 2 # of symptomatic UTI / 1,000 
urinary catheter days   
 
 
[Number of UTIs (ICD-9-
CM +not present on 
admission) / (# major 









25% reduction in the number of 
symptomatic UTI / 1,000 urinary 
catheter days 
 
25% reduction in the [Number of 
UTIs (ICD-9-CM+not present on 
admission) / (# major surgery ICD-
9-CM + urinary catheter ICD-9-
CM)]*100 discharges3 
5. MRSA 1 Incidence rate (number per 
100,000 persons) of invasive 
MRSA infections 
CDC EIP/ABCs 50% reduction in incidence rate of 
all healthcare-associated invasive 
MRSA infections 
6. SSI 1 Deep incision and organ 
space infection rates using 
NHSN definitions (SCIP 
procedures) 
CDC NHSN Median deep incision and organ 
space infection rate for each 
procedure/risk group will be at or 
below the current NHSN 25th 
percentile 
7. SSI 2 Adherence to SCIP/NQF 
infection process measures 
(perioperative antibiotics, 
hair removal, postoperative 
glucose control, 
normothermia) 
CMS SCIP 95% adherence rates to each 
SCIP/NQF infection process 
measure 
                                                 
1 Any source that would provide nationally representative hospital discharge coding (i.e., ICD9 or, in the future, ICD10) data, 
including such sources as the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project, the CDC 
National Center for Health Statistics or National Hospital Discharge Survey, and those in the Centers for Medicare and Medicaid 
Services (CMS). 
2 See above. 
3 Zhan C, et.al. Medical Care (in press) 
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IV. Central Line-associated Bloodstream Infections 
 
Four national 5-year prevention targets and metrics were proposed for central-line 
associated bloodstream infections (CLABSI). To be consistent with the targets and 
metrics currently outlined and/or adopted by other national organizations, including the 
NQF and the SHEA/IDSA Compendium of Strategies to Prevent Healthcare-Associated 
Infections in Acute Care Hospitals, the selected targets and metrics listed in Table 1 
include one outcome [Metric 1] and one process [Metric 2] metric: 
 
1) [Metric1] CLABSI 1: CLABSIs per 1,000 device days by ICU and other 
locations. [Target1] CLABSIs per 1,000 device days by ICU and other locations 
below present NHSN 25th percentile by location type (75% reduction in Stratified 
Infection Ratio). 
 
2) [Metric 2] CLABSI 4: Central line bundle compliance (non-emergent insertions). 
[Target 2] 100% compliance with central line bundle (non-emergent insertions). 
 
Meeting participants discussed several challenges and considerations related to the use of 
the metrics identified. 
 
 The group focused on ICUs with Metric 1, but proposed that other locations with 
other specific patient populations could also be used as the sample for the metric. 
The NHSN is a currently available data source that is designed and validated for 
this metric. Administrative data might be available as an additional electronic data 
source in the near future. 
 
 In addition, some participants suggested that standardized algorithms to detect 
CLABSI be applied to exclude common skin contaminants and other organisms. 
Participants identified that Metric 2 is challenging because of a lack of an existing 
data stream. However, the NHSN CLIP module was launched in September 2008. 
 
 Participants suggested several methods of reporting reductions in CLABSIs, 
including stratified infection ratios, a designated target rate, and a target that is 
based on performance percentiles within existing data. 
 
 Meeting participants also identified several future needs for CLABSI metrics. 
These include the need for multiple sampling strategies; better methods to identify 
changes over time, including assessment, risk stratification, and rates for different 
risk groups; and a crosswalk gap-analysis across national data sources to 
understand variables in data sets and data validity. 
 
 
V. Clostridium difficile Infections 
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One outcome metric [Metric 3] and 5-year prevention target for the reduction of 
Clostridium difficile infection (CDI) was identified after a review of possible metrics and 
targets. 
 
1) [Metric 3] C diff 1: Case rate per patient days and administrative/discharge data 
for ICD-9-CM coded Clostridium difficile Infections. [Target 3] 30% reduction in 
the case rate per patient days and administrative / discharge data for ICD-9-CM 
coded CDIs. (Note: Preventability of endemic CDI is unknown; therefore, the 
experts suggested that HHS revisit this target in two years as prevention research 
findings may become available). 
 
The identification of potential metrics was based on current science regarding the 
feasibility, validity, relevance, and availability of data. In addition to identifying metrics 
and targets for reduction of Clostridium difficile infections (CDI), meeting participants 
discussed other future needs and challenges summarized below. 
 
 With respect to Metric 3, participants felt that administrative discharge data is 
potentially valuable for measuring CDI rates, particularly in that it is readily 
available, nationally representative, and could be used to establish a baseline. 
However, many also felt that in the future an additional system will be necessary. 
One possible system is the NHSN MDRO/CDI module. 
 
 More broadly, participants noted that an urgent need exists to evaluate the 
preventability of CDI in endemic inpatient settings, preferably across a large 
number of hospitals and the role of patient care environment in transmission of 
Clostridium difficile. 
 
 In addition, they discussed the need for enhanced capability in U.S. hospitals to 
measure and improve inpatient antibiotic use. One possible initial step is to 
conduct a survey of U.S. hospitals to identify whether or not an antibiotic 
stewardship team is in place and, if so, what is the team’s purpose and functions 
at a given institution. 
 
 
VI. Catheter-Associated Urinary Tract Infections 
 
One specific outcome metric [Metric 4] and an associated target for the reduction of 
catheter-associated urinary tract infections was identified. 
 
1) [Metric 4] CAUTI 2: # of symptomatic UTI / 1,000 urinary catheter days; 
[Number of UTIs (ICD9+not present on admission) / (# major surgery ICD9+ 
urinary catheter ICD9)]*100 discharges). This metric includes two possible 
measurement systems (NHSN or CMS). [Target 4] 25% reduction in the number 
of symptomatic UTI / 1,000 urinary catheter days; 25% reduction in the [Number 
of UTIs (ICD9+not present on admission) / (# major surgery ICD9+ urinary 
catheter ICD9)]*100 discharges. 
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Several challenges and needs related to the measurement of CAUTIs were identified. 
 
 Participants suggested a comparison of NHSN symptomatic UTI (or available 
state data collecting similar variables) to administrative discharge data and a 
review of the UTI definition in non-acute care settings to validate data quality and 
ensure monitoring of the full burden of CAUTIs. Many experts pointed out 
current limitations of the UTI definition and proposed that the metric should focus 
only on bloodstream infections secondary to UTIs. 
 
 In addition, participants suggested that strategies to widely implement “best 
practices” in the prevention of CAUTIs in a range of settings be developed. 
Participants felt that these actions would help identify targets and play a vital role 
in the selection of future metrics. 
 
 
VII. Methicillin-resistant Staphylococcus aureus 
 
One national 5-year prevention target and associated outcome metric [Metric 5] for the 
reduction of MRSA infections was proposed. 
 
1) [Metric 5] MRSA 1: Incidence rate (number per 100,000 persons) of invasive 
MRSA infections. [Target]: 50% reduction in incidence rate of all healthcare-
associated invasive MRSA infections. 
 
Metric 5 is readily available and nationally representative data is available from an 
existing source. Future needs and challenges related to MRSA measurement are 
summarized below. 
 
 Participants identified other potential metrics, including a metric measuring the 
incidence rate of hospital-onset bacteremia based on the NHSN MDRO module. 
However, the MDRO module is a new component of NHSN without available 
baseline data. As baseline data is developed and participation in the MDRO 
module grows, this metric may be considered in the future. 
 
 Participants also felt that a “composite” target to improve sensitivity, reliability, 
and add confidence that the composite metric reflects reality should be considered 
in the future. 
 
 The group noted that ongoing evaluation may be needed to determine whether 
shorter average hospital stays in some healthcare facilities might affect the 
sensitivity of current measurements of the metric. 
 
 The experts recognized a need to move towards the use of electronic data sources 
(e.g., laboratory data). 
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 In addition, while administrative data may be valuable, concerns remain regarding 
the current administrative data systems’ sensitivity and precision in capturing 
disease related to hospital care. CMS administrative data collected via ICD-9-CM 
codes have historically been designed and used for reimbursement, rather than 
public health monitoring, and data is not available for most populations under age 
65. 
 
 Other potential next steps identified by the expert participants include 
implementation of a standardized vocabulary for electronic data capturing of 
notifiable diseases, antimicrobial susceptibility and clinical data that is used for 
algorithmic detection of MRSA and other HAIs; evaluation of the need for risk 
adjustment methods of administrative data from healthcare facilities with patient 
populations at a disproportionate risk for HAIs; and while the target identified is 
important, long term efforts may benefit from a broader MDRO prevention effort 
that would ideally capture both MRSA and other HAIs not currently captured. 
The steps above were suggested as steps to help improve the quality of MRSA 
data and assist progress towards the 5-year MRSA prevention targets. 
 
 
VIII. Surgical Site Infections 
 
Two national 5-year prevention targets and metrics were proposed for surgical site 
infections (SSI), including one outcome [Metric 6] and one process [Metric 7] metric. 
 
1) [Metric 6] SSI 1: Deep incision and organ space infection rates using NHSN 
definitions (SCIP procedures). [Target] Median deep incision and organ space 
infection rate for each procedure/risk group will be at or below the current NHSN 
25th percentile. 
 
2) [Metric 7] SSI 2: Adherence to SCIP/NQF infection process measures 
(perioperative antibiotics, hair removal, postoperative glucose control, and 
normothermia). [Target] 95% adherence rates to each SCIP/NQF infection 
process measure. 
 
Metric 7 consists of five subcomponents which correspond to the SCIP/NQF measures: 
 
1) Prophylactic antibiotic received within one our prior to surgical incision; 
2) Selection of appropriate prophylactic antibiotic; 
3) Prophylactic antibiotic discontinued within appropriate time frame after surgery; 
4) Appropriate post-operative glucose control for surgical patients; and, 
5) Appropriate hair removal and normothermia. 
 
Numerous other possible metrics and targets were considered in the process of 
identifying the SSI targets. Participants felt that while the metrics selected may be the 
best currently available, a number of challenges remain to be implemented for use of 
these metrics at the national and local levels.  
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 Participants felt that the validity and feasibility of both metrics needs to be further 
evaluated, including a cost benefit analysis. 
 
 Use of Metric 6 may require modifications in NHSN data collection, improved 
tools for collection of denominator data, and standardization of case finding. 
These improvements to the data collection will require staff and financial 
resources. Improvements to electronic data systems for surveillance (e.g., the 
ability to utilize inpatient pharmacy data for surgical site surveillance) should be 
incorporated into these systems to improve the efficiency and standardization of 
SSI case finding. 
 
 Other needs identified by participants include harmonization of NQF and SCIP 
data in order to use the metrics proposed, development of a composite metric to 
capture performance across the entire spectrum of procedures and risk groups 
including pediatric SSIs, and re-evaluation of metrics and targets as additional 
evidence on preventability becomes available. 
 
 
IX. Ventilator-Associated Pneumonia (VAP) 
 
At this time, no valid outcome or process metric has been identified for VAP. 
 
 
X. Other Considerations 
 
During the process of identifying national 5-year prevention targets and metrics, a 
number of considerations, challenges, and next steps to make progress towards meeting 
the prevention targets were elucidated. These factors are important to consider as 
recommendations as the proposed targets are further refined and implemented as a part of 
the HHS effort: 
 
 While it is recognized that the targets and metrics identified as a part of the HHS 
effort are to be national in nature, some scientific and professional experts 
commented that it is important that the national measures be linked to bedside 
actions. 
 
 The refinement of national targets needs further consideration, taking into account 
existing baselines of data, known interventions, measurement systems to assess 
progress, and the amount of resources invested. 
 
 There is concern over the potential use of aspirational targets as performance 
incentives without adequate development of the science base for prevention and 
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 Challenges remain related to resource allocation and workforce development. As 
HAIs are reduced, the cost of detecting each event will become increasingly great. 
In addition, the implementation of interventions designed to move towards the 
target will require resources. While data for some metrics are already being 
collected, data for others will require additional information to be collected. These 
new methods of collecting and evaluating data will require staff and financial 
resources. It is important to limit the additional data collection burden on staff (as 
much as possible) and healthcare facilities to ensure that the focus of the 
professionals will be the implementation of prevention interventions that have an 
impact. 
 
 It is important that existing national data sources identified for metric systems are 
validated. They need to avoid gaps in data for age groups and other population 
groups. The feasibility of use of various systems must also be carefully evaluated 
and used to inform research. 
 
 Process measures data on HAIs is available from multiple sources, including 
administrative CMS, Quality Improvement Organization (QIO), and CDC data, in 
addition to data from state organizations and private sector activities. 
Opportunities exist to improve the use of and explore new uses for this data 
through linkage, learning, and data validation. 
 
 “Cross-walking” will also be needed between data from systems with direct 
patient observations, laboratory data, and administrative data. 
 
 Opportunities to move towards electronic data capture and reporting should be 
evaluated and sought out when possible. Investment in implementation of 
standards and vocabulary should be considered, along with the development of an 
enhanced surveillance infrastructure. Collections of data for process metrics often 
have the potential to be automated. Multiple opportunities to develop and evaluate 
automated process measures should be considered in the future. 
 
 Development of improved performance measurement methods and systems for 
such cross-cutting infection control practices as compliance with hand hygiene 
and contact precautions is needed. 
 
 National efforts to both measure and improve antimicrobial use are needed. These 
efforts should have a major impact on prevention efforts. 
 
 Overarching targets that measure progress towards important practices and 
outcomes that indirectly impact HAI prevention should be developed, besides 
current targets that are fairly disease specific or type-infection specific. 
Organizational measures, such as nurse/patient ratio, should be explored and 
considered in developing overarching targets. 
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 There is a need to leverage and synergize efforts by government agencies, the 
NQF, the Joint Commission and other accreditation groups, state agencies, and 
other stakeholders to make an impact on HAI prevention. The identification of 
metrics and targets is the starting point of a broad effort that relies on the efforts 
of numerous federal agencies and organizations to reduce HAIs and meet the 5-
year prevention targets. These metrics and targets will assist in measuring the 
impact of these efforts throughout the next five years. 
 
 
XI. Conclusion and Possible Next Steps 
 
The group also began a discussion as to how the HHS Action Plan could be implemented 
to achieve the targets. Some key strategies or recommendations for reaching these goals 
include creating system-improvement programs and extending and improving distribution 
channels (e.g., states, professional societies, QIOs, health systems). These actions 
coupled with specific actions related to the metrics and targets would dramatically help 
prevent HAIs in the United States and reduce both morbidity and mortality. 
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HHS Action Plan to Prevent Healthcare-Associated Infections: 





A 2008 report by the Government Accountability Office (GAO) calls for prioritization of 
Centers for Disease Control and Prevention (CDC) recommendations for the prevention 
of healthcare-associated infections (HAIs). 
 
The report emphasized that there are 1,200 such recommendations, accompanied by 
limited guidance on implementation or prioritization. In response to that report, and as 
part of the ongoing effort to increase the impact of CDC recommendations, the 
Department’s Steering Committee for the Prevention of HAIs and the Healthcare 
Infection Control Practices Advisory Committee (HICPAC) has evaluated and prioritized 
recommendations from four key CDC guidelines. Prioritized recommendations come 
from guidelines for the prevention of catheter-associated urinary tract infections 
(CAUTI), surgical site infections (SSI), intravascular catheter-related bloodstream 
infections (BSI), and ventilator-associated pneumonia (VAP). The four infection types 
account for over 80% of all HAI. 
 
These guidelines reflect a range of publication dates and are updated on an ongoing basis.  
CDC’s guideline preparation process has been updated to ensure that scientific evidence 
is compiled and evaluated in a consistent, concise, and transparent way. 
 
The guideline for prevention of CAUTI (to be published in 2009) is the first example of 
this process and includes evidence tables as well as sections on implementation, auditing, 
and prioritization. As guidelines are updated and healthcare facilities implement 
recommended practices, priorities will be updated to address current prevention gaps and 





The framework for identifying implementation priorities is based on supporting scientific 
evidence that a practice is effective/beneficial, recognized gaps in current implementation 
(i.e., many important practices are fully implemented), synergy with other related 
practices (i.e., several practices need to be implemented together to have the desired 
effect), and potential impact. The following process was used for selection of high-
priority recommendations from the guidelines for the prevention of CAUTI, BSI, VAP 
and SSI: 
 
1) For each guideline, the pool of recommendations considered for prioritization was 
narrowed to only those with strong evidentiary support (Category 1A and 1B 
recommendations). Category 1C recommendations, which include state and 
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federal regulations regardless of evidentiary support, also were considered. 
However Category 2 recommendations, without strong evidence to support their 
efficacy, were not. The prioritization for VAP prevention includes recently 
compiled recommendations from the Society for Healthcare Epidemiology of 
America (SHEA)/Infectious Diseases Society of America (IDSA) Compendium of 
Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals in 
order to capture practices not included in the 2003 CDC guideline. 
 
2) CDC subject-matter experts in infectious diseases, infection control, and 
healthcare epidemiology assessed each recommendation for its urgency and 
relative importance for HAI prevention, the degree to which it is currently 
implemented by all healthcare facilities (i.e., whether there is a gap in current 
implementation), and how it is related in healthcare delivery to other 
recommendations. 
 
3) Recommendations were grouped based on interdependence in implementation. 
These groupings are referred to as “priority modules.” 
 
4) Priority modules, each of which contains interdependent and thematically-related 
recommendations for clinical practice, were then mapped to relevant 
recommendations for implementation and auditing. 
 
5) Finally, priority modules were reviewed and refined by an expanded CDC group 
and by HICPAC. 
 
 
III. Results  
 
Below are the lists of priority recommendations, grouped by priority modules, for each of 
the guidelines reviewed for prioritization. Most recommendations correlate with those 
included in the SHEA/IDSA Compendium of Strategies to Prevent Healthcare-
Associated Infections in Acute Care Hospitals. 
 
Note that topics such as that of hand hygiene, healthcare personnel- and patient-
vaccinations, such as those recommended in the guideline for prevention of 
influenza, and similar overarching requirements are not included below in order to 
focus on specific recommendations for prevention of each infection type. 
 
A. Prevention of Catheter-Associated Urinary Tract Infections 
 
The CDC Guideline for Prevention of Catheter-Associated Urinary Tract Infections 
(CAUTI) is being updated in 2008 to expand upon the previous guideline published in 
1981. The updated guideline is more concise than previous guidelines and includes new, 
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In addition, the guideline contains an implementation and audit section. Because of this 
updated methodology this guideline provides the greatest implementation and auditing 
detail among the four guidelines. 
 
For prioritization of clinical practices for the prevention of CAUTI, Category 1A, 1B, and 
1C recommendations were considered. Category 1C recommendations are required by 
state or federal regulation, or represent an established association standard, regardless of 
the quality of scientific evidence used to support the recommendation. 
 
Priority Module 1 – Recommendations for Appropriate Urinary Catheter Use  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Insert catheters only for appropriate indications, and leave in 
place only as long as needed (Category 1A) 
 HICPAC Rec.: Do not use urinary catheters in patients and nursing home 
residents for management of incontinence (Category 1B) 
 HICPAC Rec.: For operative patients, who have an indication for an indwelling 
catheter; remove the catheter as soon as possible post-operatively, preferably 
within 24 hours (Category 1B) 
 
Priority Module 2 – Recommendations for Aseptic Insertion of Urinary Catheters  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Ensure that only properly trained persons (e.g., hospital 
personnel, family members, or patients themselves) who know the correct 
technique of aseptic catheter insertion and maintenance are given this 
responsibility (Category 1C) 
 HICPAC Rec.: Insert catheters using aseptic technique and sterile equipment 
(except as stated in other recommendations where clean technique is appropriate 
for intermittent catheterization) (Category 1C) 
 
Priority Module 3 – Recommendations for Proper Urinary Catheter Maintenance  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Maintain a sterile, continuously closed drainage system 
(Category 1C) 
 HICPAC Rec.: Do not disconnect the catheter and urinary drainage system 
unless the catheter must be irrigated (Category 1B) 
 
B. Prevention of Intravascular Catheter-Associated Infections 
 
The CDC guidelines for Prevention of Intravascular Catheter-Related Infections were 
published in 2002. Among the infections associated with intravascular catheter use, 
bloodstream infections (BSI) have severe consequences for patients and are therefore the 
focus of these prioritized recommendations. However, adhering to recommendations for 
prevention of BSI will reduce superficial catheter-site infections as well. Due to the 
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number of recommendations in this guideline, only Category 1A recommendations were 
considered for prioritization. 
 
Priority Module 1 – Recommendations for Aseptic Insertion of Vascular Catheters  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Maintain aseptic technique during insertion and care of 
intravascular catheters (Category 1A) 
 HICPAC Rec.: Use aseptic technique including the use of a cap, mask, sterile 
gown, sterile gloves, and a large sterile drape, for the insertion of central venous 
catheters (CVC),including for peripherally inserted central catheters (PICC) and 
guide wire exchange (Category 1A) 
 HICPAC Rec.: Apply an appropriate antiseptic to the insertion site on the skin 
before catheter insertion and during dressing changes (Category 1A) 
 HICPAC Rec.: Although a 2% chlorhexidine-based preparation is preferred, 
tincture of iodine, an iodophor, or 70% alcohol can be used (Category 1A) 
 HICPAC Rec.: Select the catheter, insertion technique, and insertion site with the 
lowest risk for complications (infectious and noninfectious) for the anticipated 
type and duration of IV therapy (Category 1A) 
 HICPAC Rec.: Use a subclavian site (rather than a jugular or a femoral site) in 
adult patients to minimize infection risk for non-tunneled CVC placement 
(Category 1A) 
 HICPAC Rec.: Weigh the risk and benefits of placing a device at a 
recommended site to reduce infectious complications against the risk for 
mechanical complications (e.g., pneumothorax, subclavian artery puncture, 
subclavian vein laceration, subclavian vein stenosis, hemothorax, thrombosis, air 
embolism, and catheter misplacement) (Category 1A) 
 
Priority Module 2 – Recommendations for Appropriate Maintenance of Vascular 
Catheters 
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Use either sterile gauze or sterile, transparent, semipermeable 
dressing to cover the catheter site (Category 1A) 
 HICPAC Rec.: Promptly remove any intravascular catheter that is no longer 
essential (Category 1A) 
 HICPAC Rec.: Replace the catheter-site dressing when it becomes damp, 
loosened, or soiled or when inspection of the site is necessary (Category 1A) 
 
C. Prevention of Surgical Site Infections 
 
The CDC guideline for Prevention of Surgical Site Infection (SSI) was published in 1999. 
As such, recent research on SSI is not captured in the guideline. However the 
recommendations in the 1999 guideline remain important. Recent evidence was reviewed 
and recommendations that have been called into question based on research published 
after 1999 were excluded from consideration. Both Category 1A and 1B 
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recommendations were considered for prioritization due to the limited number of 1A 
recommendations for this topic. 
 
Priority Module 1 – Recommendations for Appropriate Pre-Operative Measures  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Whenever possible, identify and treat all infections remote to the 
surgical site before elective operation and postpone elective operations on patients 
with remote site infections until the infection has resolved (Category 1A) 
 HICPAC Rec.: Do not remove hair preoperatively unless the hair at or around 
the incision site will interfere with the operation (Category 1A) 
 HICPAC Rec. : If hair is removed, remove immediately before the operation, 
preferably with electric clippers (Category 1A) 
 HICPAC Rec.: Administer a prophylactic antimicrobial agent only when 
indicated, and select it based on its efficacy against the most common pathogens 
causing SSI for a specific operation and published recommendations (Category 
1A) 
 HICPAC Rec.: Administer by the intravenous route the initial dose of 
prophylactic antimicrobial agent, timed such that a bactericidal concentration of 
the drug is established in serum and tissues when the incision is made (Category 
1A) 
 HICPAC Rec.: Maintain therapeutic levels of the agent in serum and tissues 
throughout the operation and until, at most, a few hours after the incision is closed 
in the operating room (Category 1A) 
 HICPAC Rec.: Before elective colorectal operations, mechanically prepare the 
colon by use of enemas and cathartic agents; Administer nonabsorbable oral 
antimicrobial agents in divided doses on the day before the operation (Category 
1A) 
 HICPAC Rec.: Use an appropriate antiseptic agent for skin preparation 
(Category 1B) 
 
Priority Module 2 – Recommendations for Appropriate Intra-Operative Measures  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Adequately control serum blood glucose levels in all diabetic 
patients and avoid perioperative hyperglycemia (Category 1B) 
 HICPAC Rec.: Keep operating room doors closed during surgery except as 
needed for passage of equipment, personnel, and the patient (Category 1B) 
 
Priority Module 3 - Recommendations for Appropriate Post-Operative Measures  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Protect primary-closure incisions with a sterile dressing for 24 to 
48 hours postoperatively (Category 1B) 
 
D. Prevention of Ventilator-Associated Pneumonia 
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Due to marked severity and high mortality of VAP, this prioritization focuses on the 
subset of VAP-relevant recommendations within the broader category of healthcare-
associated pneumonia prevention. The CDC Guideline for Preventing Healthcare 
Associated Pneumonia was published in 2003. Additional recommendations included in 
Module 1 of this prioritization are derived from the 2008 SHEA/IDSA Compendium of 
Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals and 
therefore do not carry HICPAC evidence ratings. 
 
Priority Module 1 – Recommendations for Routine Care of Patients Requiring 
Mechanical Ventilation 
Related Recommendations from 2008 SHEA/IDSA Compendium of Strategies 
 
 Use non-invasive ventilation whenever possible 
 Use orotracheal rather than nasotracheal intubation when possible 
 Minimize the duration of ventilation; Perform daily assessments of readiness to 
wean from ventilation 
 Prevent aspiration by maintaining patients in a semi-recumbent position (30-45 
degree elevation of head of bed) unless otherwise contraindicated 
 Use a cuffed endotracheal tube with an endotracheal cuff pressure of at least 
20cm H2O and in-line or subglottic suctioning 
 Perform regular oral care with an antiseptic solution 
 
Priority Module 2 – Recommendations for Appropriate Cleaning, Disinfection, and 
Sterilization of Ventilator Equipment 
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Thoroughly clean all equipment and devices to be sterilized or 
disinfected (Category 1A) 
a.  Whenever possible, use steam sterilization (by autoclaving) or high-level 
disinfection by wet heat pasteurization at >158°F (>70°C) for 30 minutes for 
reprocessing semi-critical equipment or devices (i.e., items that come into 
direct or indirect contact with mucous membranes of the lower respiratory 
tract) that are not sensitive to heat and moisture (Category 1A) 
b. Use low-temperature sterilization methods (as approved by the Office of 
Device Evaluation, Center for Devices and Radiologic Health, Food and 
Drug Administration [FDA]) for equipment or devices that are heat- or 
moisture-sensitive (Category 1A) 
c. After disinfection, proceed with appropriate rinsing, drying, and packaging, 
taking care not to contaminate the disinfected items in the process (Category 
1A) 
 HICPAC Rec.: Preferentially use sterile water for rinsing reusable semi-critical 
respiratory equipment and devices when rinsing is needed after they have been 
chemically disinfected; If this is not feasible, rinse the device with filtered water 
(i.e., water that has been through a 0.2µ filter) or tap water, and then rinse with 
isopropyl alcohol and dry with forced air or in a drying cabinet (Category 1B) 
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 HICPAC Rec.: Between uses on different patients, clean reusable components of 
the breathing system or patient circuit (e.g., tracheal tube or face mask) 
inspiratory and expiratory breathing tubing, y-piece, reservoir bag, humidifier, 
and tubing, and then sterilize or subject them to high-level liquid chemical 
disinfection or pasteurization in accordance with the device manufacturers' 
instructions (Category 1B) 
 HICPAC Rec.: Between treatments on the same patient clean, disinfect, rinse 
with sterile water (if rinsing is needed), or dry small-volume in-line or hand-held 
medication nebulizers (Category 1B) 
 HICPAC Rec.: Between their uses on different patients, sterilize or subject to 
high-level disinfection portable respirometers and ventilator thermometers 
(Category 1B) 
 
Priority Module 3 – Recommendations for Appropriate Maintenance of Ventilator 
Circuit and Associated Devices  
Related HICPAC Recommendations: 
 
 HICPAC Rec.: Drain and discard any condensate that collects in the tubing of a 
mechanical ventilator, taking precautions not to allow condensate to drain toward 
the patient (Category 1B) 
 HICPAC Rec.: Use only sterile fluid for nebulization and dispense the fluid into 
the nebulizer aseptically (Category 1A) 
 HICPAC Rec. : Use only sterile (not distilled, nonsterile) water to fill reservoirs 





The HHS effort currently underway offers a coordinated strategy that makes the best use 
of currently available technologic and procedural capacities and drives toward future 
needs. The focus on measurable progress toward specific national target metrics is both 
practical and efficient. 
 
In order to achieve those targets, we have provided prioritized modules for 
implementation at the bedside, realizing that priorities will change and be updated as 
adherence targets are met and new areas for attention are identified. Although current 
emphasis is being placed on priorities for implementation, safe and effective healthcare 
still requires correct adherence to all recommended practices for every episode of care. 
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A broad, comprehensive research agenda to support a national effort to prevent 
healthcare-associated infections (HAIs) needs to address the issue from a number of 
aspects. Increased understanding of the basic science underlying HAIs and their 
associated pathogens will be critical for informing prevention efforts. A coordinated 
research agenda needs to be developed in order to strengthen the scientific understanding 
of these infections. Research into the epidemiology of HAIs needs to be broadened. Gaps 
in the existing epidemiologic knowledge base should be identified with corresponding 
research projects targeted to fill those gaps. 
 
To build upon an expanded understanding of the basic science and epidemiology of 
HAIs, the effectiveness of current infection control practices in hospitals should also be 
evaluated. New techniques to prevent HAIs need to be identified. Better implementation 
of existing practices is needed where the scientific basis for these practices already exists. 
Interventions that utilize technology to promote HAI prevention and provide clinical 
decision support, as well as the human and organizational factors affecting adoption of 
effective interventions in hospitals, need to be studied. Additionally, training grants for 
clinical HAI researchers could augment the resources addressing these issues. 
 
Specific projects for enhancing the implementation and impact of existing, evidence-
based practices can then be identified, prioritized, and executed. Lastly, and perhaps most 
importantly, completely new and innovative approaches will be needed to combat current 
and emerging challenges related to these infections. 
 
Thus, the two broad goals of the research portion of the initiative were to: 1) identify 
gaps in the existing knowledge base of current infection control practices in hospitals 
and, 2) develop a coordinated research agenda to strengthen the science for infection 
control prevention in hospitals. 
 
 
II. Current State of the Art and Identified Gaps in Knowledge and Practice 
 
A. Cross Cutting Issues 
In preparation for identifying specific research areas, the working group identified gaps 
in the existing knowledge base of current infection control practices in hospitals. Several 
cross-cutting issues emerged: 
 
1) Adherence to Current Prevention Recommendations Has Been Suboptimal 
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Adherence to current prevention recommendations in healthcare settings has 
been generally suboptimal, even when knowledge of recommended practices 
is sufficient. Several lines of evidence suggest that merely increasing 
adherence to currently recommended practices can result in a dramatic 
reduction in infection rates, at least for some infection types. 
 
A better understanding of the barriers to adherence, and strategies to 
overcome those barriers, are needed to promote improvements such as the 
following: 
 
a. The use of technology to improve adherence 
b. Better understanding of human and organizational factors that affect 
adoption and implementation of effective strategies 
c. Standardized methods (i.e., performance methods) that are feasible, 
valid, and reliable for measuring and reporting compliance with broad-
based HAI prevention practices that must be practiced consistently by 
a large number of healthcare personnel (e.g., compliance hand 
hygiene, isolation precautions, environmental cleaning practices) in 
order to prevent infections 
 
2) Demonstrating Preventability through Multicenter Demonstration Projects 
Has Proven to Be an Effective Strategy for Influencing the Widespread 
Adoption of Recommended Practices 
 
Preventability is defined for this purpose as the proportion of all cases of a 
certain HAI that can be demonstrated as possible to prevent through the 
careful and concerted implementation of current or existing recommendations 
and/or guidance. 
 
Recent multicenter demonstration projects involving large numbers of 
healthcare facilities working collaboratively to decrease HAIs by 
simultaneously implementing a multifaceted prevention program have been 
able to demonstrate, through standardized data collection, deep reductions in 
central-line associated bloodstream infections (CLABSIs) in ICUs.  
 
These projects have answered important questions regarding the preventability 
of this particular infection type, and have likely directly influenced practice 
across the United States by setting new expectations for prevention. 
Additional prevention demonstration projects involving other targeted 
infections, such as surgical site infection, Clostridium difficile infection, and 
methicillin-resistant Staphylococcus aureus, would be helpful. 
 
3) Limitations in Current Surveillance Strategies Exist and There is a Need to 
Use Electronic Data in Measuring Processes and Outcomes 
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A critical component of an effective prevention program is use of 
standardized process and outcome data as a means to inform those responsible 
for implementing the program and evaluate its impact. Unfortunately, many of 
the current healthcare-associated infection surveillance strategies are labor 
intensive and subject to limitations as a result of poor inter-rater reliability in 
applying standard definitions and variable implementation of case-finding 
strategies.  
 
In addition, current case-finding strategies are largely focused on identifying 
infections that are manifested during an inpatient stay or as a result of specific 
surgical procedures. Such strategies may not capture an important and 
potentially large proportion of healthcare-associated infections that, although 
the direct result of care delivered during an inpatient stay or in the ambulatory 
care setting, have their onset in the community. 
 
Strategies that make use of existing electronic data sources for creating 
process and outcome measures may have a number of important potential 
advantages, including decreasing the burden of data collection, reducing error 
introduced by poor inter-rater reliability, and providing the ability to track 
adverse events longitudinally over the spectrum of a particular patient’s 
healthcare delivery. More research on the use of electronic data for 
surveillance of healthcare-associated infections is needed. 
 
4) Multicenter Collaborative Trials to Establish the Efficacy of Preventive 
Interventions are Needed 
 
In addition to multicenter demonstration projects designed to document 
preventability using current or existing prevention recommendations, there is 
a need for additional multicenter collaborative trials that are carefully 
designed and conducted to establish the efficacy of new preventive 
interventions and further enhance our understanding of the efficacy of existing 
interventions. 
 
5) Additional Research is Necessary to Strengthen the Scientific Basis for the 
Acquisition of Healthcare-Associated Pathogens 
 
The scientific basis for the acquisition (including basic pathogenesis, 
transmission, and colonization) of numerous healthcare-associated pathogens 
is poorly understood. Many current practices are based on empiric 
observation. More biologically plausible preventive measures may be derived 
from additional basic, epidemiological, and translational research. 
 
 
B. Issues Regarding the Specific Tier 1 Procedures and Organisms 
The current state of the art and specific gaps in knowledge and practice across three 
areas: 
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1) Basic and/or Laboratory Science; 
2) Epidemiology; and 
3) Prevention Practices are presented for the following healthcare-associated 
infections: 
 
a. Central Line-Associated Bloodstream Infections 
b. Surgical Site Infections 
c. Clostridium difficile Infections 
d. Catheter-Associated Urinary Tract Infections 
e. Ventilator-Associated Pneumonia 
f. Methicillin-resistant Staphylococcus aureus 
 
1) Central Line-Associated Bloodstream Infections (CLABSIs) 
 
Current State of the Art Practice 
Detailed recommendations on the prevention of CLABSIs have been developed by 
the Centers for Disease Control and Prevention (CDC) and Healthcare Infection 
Control Practices Advisory Committee (HICPAC).1 Recent investigations have 
demonstrated that adherence to recommended catheter insertion practices are usually 
followed by a dramatic reduction in infection rates, suggesting that the preventable 
fraction of CLABSIs is large. 
 
Efforts to implement “bundles” of catheter insertion practices have been quite popular 
in the intensive care setting, and although the rates of adherence are largely unknown, 
data from the National Healthcare Safety Network (NHSN) suggests that the rate of 
CLABSIs has been decreasing annually across all ICU types reporting data to that 
system. Although data suggest that the vast majority of CLABSIs occur outside of the 
ICU, precise data about catheter use and CLABSI rates in this setting, including 
among non-hospitalized patient populations, is sparse. 
 
Current Gaps in Knowledge and Practice 
 Basic and/or Laboratory Science 
o Biofilms and their relationship to the pathogenesis of device-associated 
infections 
o The prevention of biofilm formation or disruption/removal of biofilms in 
situ 
o Effective strategies and/or techniques for the early detection of CLABSI 
and for the differentiation of CLABSI from other bacteremias 
 Epidemiology 
o A better understanding of CLABSIs occurring outside the intensive care 
unit is needed 
o Improved methods for surveillance that allow capture of adverse events 
associated with catheters regardless of patient location are needed 
 Prevention Practices 
 
1 http://www.cdc.gov/ncidod/dhqp/gl_intravascular.html 
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o What strategies could be developed to inhibit or destroy biofilms as a 
means of preventing device-associated infections? 
o Use of antibiotic lock solutions: Are they effective? Are there unintended 
consequences (e.g., antimicrobial resistance)? Are there certain patient 
populations that should be targeted for this practice? 
o What is the impact of daily chlorhexidine bathing on CLABSI rates, and 
does this practice lead to a shift in pathogens causing CLABSI by 
selecting for certain gram negative organisms that have intrinsic tolerance 
or antimicrobial resistance? 
o What is the impact of chlorhexidine-impregnated sponge dressings? 
o How should antimicrobial-impregnated catheters be optimally utilized? 
o How do we optimize post-insertion catheter care? 
o How do we assure that catheters are promptly removed when no longer 
clinically necessary? 
o How do we optimize catheter care in non-hospitalized patients? 
 
2) Surgical Site Infections (SSIs) 
 
Current State of the Art Practice 
Detailed recommendations on the prevention of SSIs have been developed by CDC 
and HICPAC.2 Overall SSI rates have been relatively stable over recent years, 
although for some procedures, there has been a shift in pathogens for many cardiac 
and orthopedic procedures SSI [Staphylococcus aureus being the major pathogen, 
with an increasing proportion caused by Methicillin-resistant Staphylococcus aureus 
(MRSA)]. Adherence to current recommendations on the use of peri-operative 
antimicrobial prophylaxis is generally suboptimal.3 
 
Current Gaps in Knowledge and Practice 
 Basic and/or Laboratory Science 
o Biofilms and their relationship to the pathogenesis of infections following 
procedures involving implantation of devices 
o The prevention of biofilm formation or disruption/removal of biofilms in 
situ 
o The role of Nitric Oxide, innate adaptive immune response, cytokines, and 
endotoxemia in the pathogenesis of SSI 
 Epidemiology 
o Surgical care has been shifting to the outpatient setting in recent decades 
and post-operative inpatient stays are becoming shorter. These trends raise 
challenges in detecting SSIs, as no standardized methods for post-
discharge and outpatient SSI surveillance exist, and common approaches 
to case finding may be inadequate. There is data suggesting that SSI rates 
reported to the NHSN may be underestimated. More standardized methods 
 
2 http://www.cdc.gov/ncidod/dhqp/gl_surgicalsite.html 
3 Bratzler D, Houck P, Richards C, Steele L, Dellinger EP, Fry DE, Wright C, Ma A, Carr K, and Red L. Utilization of Antimicrobial 
Prophylaxis for Major Surgery: Baseline Results from the National Surgical Infection Prevention Project. Archives of Surgery 2005; 
140:174-182. 
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for SSI case finding are needed, including those that are exportable 
beyond acute care to ambulatory care centers. 
o There are limitations in current risk-adjustment strategies for comparing 
inter-facility surgical site infection rates. Better risk adjustment strategies 
are needed. 
o Most of the current prevention recommendations focus on pre- and intra-
operative practices. Some recent data suggest that post-operative care may 
be important in determining whether or not a surgical incision becomes 
infected. A better understanding of post-operative risk factors for SSI 
might lead to an important new approach for SSI prevention. 
 Prevention Practices 
o There is uncertainty as to how the trend towards increasing resistance 
among staphylococcal infections in cardiac and orthopedic procedures 
should influence optimal antimicrobial prophylaxis practices (e.g., when 
should vancomycin be included? Should other agents be used?) 
o The effectiveness of certain pre-operative prevention practices requires 
further study: 
 Pre-operative bathing with antiseptics; 
 Pre-operative screening for staphylococcal colonization and/or 
routine attempts to decolonize patients with antimicrobial agents 
prior to surgery; 
 Role of maintaining intra-and peri-operative normothermia; 
 Role of supplemental oxygenation during surgery; 
 Antimicrobial dosing in obese patients; and, 
 Determining whether antimicrobial strategies are different for 
surgery as compared with device implantation. 
 
3) Clostridium difficile Infection (CDI) 
 
Current State of the Art 
As identified by CDC, CDI infection rates have been increasing in recent years, 
mostly due to transmission of a single, fluoroquinolone-resistant epidemic strain with 
enhanced virulence characteristics. Prevention strategies primarily focus on 
optimizing antimicrobial use, and in preventing transmission using basic infection 
control precautions. Since Clostridium difficile spores can persist on environmental 
surfaces, the role of environmental cleaning is likely to be important. 
 
Current Gaps in Knowledge and Practice 
 Basic and/or Laboratory Science 
o Role of immunity in preventing CDI and the most effective vaccine 
strategies 
o Evaluate for the presence of metronidazole resistance in C. difficile 
isolates 
o Role of the gut flora, precisely what component of the gut flora, is 
protective 
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o Changes in the ecology of gut flora in the setting of cancer chemotherapy 
and antimicrobial therapy 
o Role of proctitis and/or nontoxigenic C. difficile in reestablishing gut flora 
ecology 
o Basic biology of the sporulation and germination of C. difficile 
o Development of valid animal models of C. difficile-associated diarrhea 
(CDAD) 
o Roles of Toxin B and binary toxin in pathogenesis 
 Epidemiology 
o Better assessments of incidence/burden of CDI in the United States, 
including setting of onset and in relation to healthcare exposures 
o Methodology for measuring transmission and burden of CDI in non-acute 
care settings (e.g., long term care facilities) 
o Better understanding of the epidemiology of antimicrobial use in inpatient 
settings 
o Role of asymptomatic carriers in healthcare transmission is unknown 
o Role of C. difficile in neonatal/infant diarrhea 
o  Better understanding of the incubation period before CDI develops after 
C. difficile acquisition 
o Relative importance of different sources of C. difficile transmission in the 
healthcare setting (e.g., environment versus healthcare workers) and in 
relation to CDI burden 
o Better understanding of CDI in the community 
 Prevention Practices 
o Develop and assess the impact of a C. difficile environmental cleaning 
bundle, role of sporicidal agents (e.g., bleach) 
o Determine the role of extending duration of contact precautions beyond 
duration of symptoms in reducing transmission of C. difficile in healthcare 
facilities 
o Define optimal measures to reduce unnecessary antimicrobial use 
o Role of gastric acid suppression 
 
4) Catheter-Associated Urinary Tract Infection (CAUTI) 
 
Current State of the Art 
Detailed recommendations on the prevention of UTIs have been developed by CDC 
and HICPAC.4 Between 15% to 25% of hospitalized patients may receive short-term 
indwelling urinary catheters. In many cases, catheters are placed for inappropriate 
indications, and healthcare providers are often unaware that their patients have 
catheters, leading to prolonged, unnecessary use. 
 
An estimate of annual incidence of HAIs and mortality in 2002, based on a broad 
survey of U.S. hospitals, found that urinary tract infections made up the highest 
number of infections (> 560,000) compared to other HAIs. Although morbidity and 
mortality from CAUTI is considered to be relatively low compared to other HAIs, the 
 
4 http://www.cdc.gov/ncidod/dhqp/gl_catheter_assoc.html 
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high prevalence of urinary catheter use leads to a large cumulative burden of 
infections with resulting infectious complications and deaths. In addition, bacteriuria 
frequently leads to unnecessary antimicrobial use, and urinary drainage systems may 
serve as reservoirs for multi-drug-resistant bacteria and a source of transmission to 
other patients. 
 
Current Gaps in Knowledge and Practice 
 Basic and/or Laboratory Science 
o Biofilms and their relationship to the pathogenesis of urinary catheter-
associated infections  
o The prevention of biofilm formation or disruption/removal of biofilms in 
situ 
o Effective strategies and/or techniques for the early detection of CAUTI 
 Epidemiology 
o Quantification of the contribution of urinary tract infection and bacteruria 
to antimicrobial use 
o Role of urinary catheter systems as a reservoir for antimicrobial resistant 
bacteria and how different types of catheters affect the reservoir 
composition 
o Quantification of unnecessary urinary catheter use 
 Prevention Practices 
o Role of newer catheter materials and technology in prevention of CAUTI 
o Appropriate catheter use in incontinent patients 
 Risks and benefits of periodic use of condom catheters in 
incontinent male patients 
 Risk of local complications (e.g., skin maceration, phimosis) with 
the use of condom catheters 
 Appropriate use of urinary catheters to manage skin breakdown in 
incontinent patients or nursing home residents  
o Role of antiseptics in preventing CAUTI (periurethral cleaning, 
methanamine) 
o Alternatives to indwelling urethral catheters and bag drainage (suprapubic 
catheters, urethral stent in bladder outlet obstruction, catheter valves) 
o Optimal methods for preventing encrustation in long-term catheterized 
patients who have frequent obstruction (catheter materials, irrigation, oral 
urease inhibitors, methanamine) 
o Use of portable ultrasound in patients with low-urine output to reduce 
unnecessary catheter insertions or irrigations (in catheterized patients) 
o Use of new prevention strategies in patients requiring chronic 
catheterization such as bacterial interference 
 
5) Ventilator-Associated Pneumonia (VAP) 
 
Current State of the Art 
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Detailed recommendations on the prevention of VAP have been developed by CDC 
and HICPAC.5 The National Nosocomial Infections Study (NNIS) database from 
1992 to 1997 demonstrated that VAP accounted for 27% of ICU infections in the 112 
participating ICUs. By 2008, VAP had become the most common nosocomial 
infection seen in the intensive care unit in several studies and is one of the major 
causes of severe healthcare-associated morbidity and mortality among ICU patients.  
 
Unlike most other ICU infection syndromes that have relatively low mortality rates, 
the mortality rate for ventilator-associated pneumonia ranges in most studies between 
20% to 50%. For patients hospitalized in the critical care unit, VAP contributes 
disproportionately both to poor outcomes as well as to substantially higher costs of 
care. Current approaches to preventing VAP rely on evidence-based strategies that 
minimize intubation, minimize the duration of mechanical ventilation, as well as 
minimizing the risk of aspiration of oropharyngeal pathogens. 
 
Multiple resistant microorganisms are playing an increasingly important role in the 
pathogenesis of VAP, particularly among infections occurring after the first week in 
the ICU. These pathogens contribute significantly to the increased costs, morbidity, 
and mortality seen with this syndrome. 
 
Current Gaps in Knowledge and Practice 
 Basic and/or Laboratory Science 
o Gaps in knowledge about the pathogenesis of VAP lead to inconsistency 
of both definition as well as diagnosis of the syndrome 
o Biofilms and their relationship to the pathogenesis of ventilator-associated 
pneumonia  
o The prevention of biofilm formation or disruption/removal of biofilms in 
situ  
o Better understanding of the contribution of endotracheal tube composition 
to infection pathogenesis 
o Poor understanding of the role of various host factors in the defense 
against VAP 
o Evaluation of the effects of mucosal and pulmonary immunity on the 
prevention of VAP 
o The effect of inflammatory lung injury on the susceptibility to VAP 
 Epidemiology 
o Lack of a clear understanding of the relative contributions of the large 
number of complex and confounding variables/risk factors that influence 
the development of VAP 
o Need a better understanding of the role of broad-spectrum antimicrobials 
in the development of VAP caused by multiple-resistant pathogens 
o Relationship of endotracheal tube-induced bacterial sinusitis to VAP 
o Understanding the natural tension between the need for adequate nutrition 
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o Identify and evaluate proxy measures for VAP (i.e., acute lung injury) for 
inter-facility comparisons that do not require stringent diagnostic 
approaches 
 Diagnosis 
o No “gold-standard” diagnostic technique 
o Role of diagnostic bronchoscopy with culture 
o Role of various microbiological culturing techniques, including 
quantitative cultures 
 Prevention Practices 
o Role of oral decontamination 
o Role of gastric decontamination 
o Secretion management/role of subglottic suction 
o Role of H-2 blockers and sucralfate 
o Role of positioning the patient 
o Degree to which less-invasive ventilatory support (e.g., CPAP, high 
oxygen therapy, even iron lung) could reduce the need for positive 
pressure ventilation via endotrachael tube or tracheostomy and whether 
this could improve overall outcomes 
o Role of antimicrobial impregnated endotrachael tubes 
o Impact of internal ventilator filters and ventilator breathing circuit filters 
on the risk of VAP 
 Implementation 
o Impact of bundles for improving adherence 
 
6) Methicillin-Resistant Staphylococcus aureus (MRSA) 
 
Current State of the Art 
Methicillin-resistant Staphylococcus aureus (MRSA) remains an important cause of 
healthcare-associated infections, and is endemic in most US hospitals. In addition to 
adding to the total burden of S. aureus infection, healthcare-associated MRSA 
infections are associated with increased morbidity and mortality when compared to 
infections caused by methicillin-susceptible strains. MRSA has also emerged as an 
important cause of infection in the community. 59% of all purulent skin infections 
evaluated in U.S. emergency departments are caused by MRSA. MRSA infections, 
both healthcare- and community-associated, are generally caused by a very limited 
number of strains, suggesting that most cases result from direct or indirect person-to-
person transmission of MRSA. 
 
It is widely held that the major reservoir for transmission in the healthcare setting is 
infected or colonized patients, and that patient-to-patient transmission occurs 
indirectly via transient carriage by healthcare personnel or through contaminated 
shared equipment. In 2005, there were an estimated 94,000 invasive MRSA infections 
in the United States. These were associated with nearly 18,000 deaths. Of these 
invasive infections, 86% were associated with healthcare delivery, and two-thirds of 
the healthcare-associated infections had their onset outside the hospital setting. 
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Although the optimal strategy for prevention and control of healthcare-associated 
MRSA has not been fully determined, it seems likely that successful control requires 
a multifaceted approach that may vary according to individual characteristics of a 
healthcare facility, as outlined in the CDC guidance document “Management of 
Multidrug-resistant Organisms in Healthcare Facilities, 2006.”6 
 
Current Gaps in Knowledge and Practice 
 Basic and/or Laboratory Science 
o Effective vaccine target antigens 
o Determinants of colonization/carriage (host, organism, environment) 
o Host determinants in the development of invasive versus soft tissue 
disease 
o Virulence facts associated with MRSA HAI 
 Epidemiology 
o Better understanding of colonization and transmission dynamics within the 
healthcare setting 
 Are there patient characteristics that influence their risk of serving 
as a reservoir of transmission? 
 Are there patient characteristics that influence the risk of acquiring 
MRSA carriage? 
o Better understanding of the inter-relationship of healthcare facilities within 
a region or system in sustaining transmission 
o Better understanding of the impact of community MRSA emergence on 
healthcare-associated MRSA infection 
o Preventability of endemic MRSA colonization/infection 
o Better understanding of the epidemiology of healthcare-associated MRSA 
infections that have their onset outside of hospitals 
o Role of fomites in the healthcare-associated transmission of MRSA HAI 
 Prevention Practices 
o What is the impact (both intended and unintended) of suppressing or 
eradicating colonization for the purpose of either preventing infection in 
colonized individuals or preventing transmission to others? 
o What is the optimal role for active surveillance for detecting asymptomatic 
carriage? 
o How can transmission be measured? (i.e., how does a healthcare facility 
know when it is effectively preventing transmission?) 
 Implementation 
o Optimal approach to antibiotic-use controls 
 
 
III. Criteria for Setting Research Priorities 
 
A criterion-based approach was used to identify a set of research projects that should be 
given high priority in the near term.  Four major criteria were applied when evaluating 
proposed projects: 
                                                 
6 http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf 
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1) Contribution to Understanding 
 Will the project fill a knowledge gap? 
Prevalence or Epidemiology: Known/Unknown 
Severity: Known/Unknown 
Mechanism of Disease or Infection: Known/Unknown 
Effectiveness of Present Intervention: Known/Unknown 
 What level of evidence will the project yield? Will the evidence likely 
change behavior? 
 
      –  Evidence     Weak 
         Strong     Compliance 
           Non-compliance  Barriers to compliance 
 
 Will the project impact be long- or short-term? 
 
      –  Demonstrated impact  Short-term 
               Long-term 
 
 Will the evidence be generalizable? 




 Are resources (human, technologic, technical, etc.) available to 
perform the project? 
 Is there an ability to leverage resources? 
 Will the proposed research intervention be scalable to other 
environments? 




 Are the costs of the project justifiable for the potential health impact? 
 
4) Impact on Public Health 
 Are the project results easily understood and of value to policy-
makers? 
 Are the impacts of projects on the general public easily 
understandable? 




IV. Proposed Initial Priority Research Projects  
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In order to develop a list of the research projects that should be given the highest priority 
for possible initial investment, the gaps in knowledge and practice outlined in Section II 
were each considered in the context of the criteria for setting research priorities discussed 
in Section III. 
 
The following list of high priority research projects emerged from that process and 
represents a research portfolio that addresses gaps in basic science, epidemiology, 
practice, as well as each of the priority infection types identified by the HHS Steering 
Committee for the Prevention of Healthcare-Associated Infections. These initial priority 
projects should not be construed as sufficient to adequately address all HAI prevention 
research needs, but rather an initial step in what should be an ongoing, long-term 
approach to research that enables continuous learning of HAI prevention. 
 
The scientific understanding of HAI prevention is rapidly evolving, and therefore the next 
steps in HHS-supported research should be determined after consideration of information 
and knowledge gained from these initial projects and other ongoing research efforts. 
These determinations should be made on a rolling basis by an interagency group (see 
Section V). 
 
Recommendations on Projects: 
 
 Projects that Address Specific Knowledge Gaps (Basic Science, Epidemiology, 
and Practices) 
 
a. Basic Science 
i. Design and implement broad-based studies that define and clearly 
delineate the pathogenesis of device-associated infection 
ii. Develop strategies for preventing and/or eliminating biofilms 
associated with medical devices 
 
b. Epidemiology 
i. Perform studies of the epidemiology of bloodstream infections that 
occur outside of the hospital, including those related to 
hospitalization. These studies would include an assessment of 
patient characteristics and risk factors for bloodstream infection 
that could lead to new prevention strategies. 
 
ii. Establish preventability 
1. Establish preventability of CDI through a regional hospital 
collaborative intervention to reduce endemic rates through 
employment of tiered evidence-based recommendations 
(e.g., transmission reduction and risk reduction through 
antimicrobial stewardship), peer-to-peer learning, and 
standardized electronic collection and feedback of CDI rate 
data using the NHSN to assess impact 
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2. Establish preventability of unnecessary antimicrobial use 
through a multi-center collaborative intervention. These 
efforts could include coordinated development and 
implementation of clinical diagnosis and antimicrobial use 
paradigms in the treatment of CAUTI and VAP, as well as 
in the prevention of SSI (i.e., surgical antimicrobial 
prophylaxis) with the aim of reducing overall antimicrobial 
use. 
3. Establish preventability of SSI through a multi-center 
collaborative intervention to reduce rates. These efforts 
could include coordinated development and 
implementation of strategies to implement existing 
evidence-based recommendations, peer-to-peer learning, 
and standardized electronic collection and feedback of SSI 
rate data using the NHSN to assess impact. 
 
c. Practices 
i. Perform a large, cluster-randomized study to assess whether ICU-
wide application of a MRSA decolonization strategy is effective at 
reducing healthcare-associated infection and mortality compared to 
targeted decolonization strategy guided by active surveillance for 
MRSA colonization 
 
 Projects Designed to Enhance the Implementation and Impact of Existing, 
Evidence-Based Infection Control Practices 
 
d. Multidisciplinary investigation of the human cultural and organizational 
barriers at the unit and institutional level that inhibit the successful 
implementation of prevention measures 
 
e. Improving measurement to support and evaluate prevention practices 
i. Perform studies to develop and evaluate novel and potentially 
automatable strategies for measuring healthcare-associated 
infections, transmission of epidemiologically important pathogens, 
and related processes of care using electronic data sources 
routinely captured during the course of patient care 
ii. Evaluation and validation of standardized post-discharge 
surveillance methodology that can be used in both inpatient and 
ambulatory care settings 
iii. Identify and evaluate proxy measures for VAP (i.e., acute lung 
injury) for inter-facility comparisons that do not require stringent 
diagnostic approaches 
iv. Develop standardized methods (i.e., performance methods) that are 
feasible, valid, and reliable for measuring and reporting 
compliance with broad-based HAI prevention practices that need 
to be practiced consistently by a large number of healthcare 
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V. Long Term Prioritization, Coordination, and Evaluation of Research Efforts  
 
Highlights of the broad areas of current HAI-related responsibilities for the HHS 
components involved in the Plan’s development are illustrated in Appendix C. 
 
Addressing the longer term research needs for healthcare-associated infections for the 
nation will require a coordinated effort across the Department and with external 
stakeholders. Many agencies within the Department such as the Agency for 
Healthcare Research and Quality (AHRQ), CDC, Centers for Medicare and Medicaid 
Services (CMS), and National Institutes of Health (NIH) have funded research to address 
healthcare-associated infections and their underlying causes. However, no mechanism 
currently exists to coordinate these efforts. 
 
Research on the basic science, epidemiology including risk factors, testing of prevention 
methods and implementation of evidence-based practices, and effects of payment and 
coverage policy should be linked, so findings from each area can inform and build upon 
findings in the other areas. For example, if CDC finds a potential population or setting a 
risk factor for a healthcare-associated infection, this information could help establish 
potential priorities for AHRQ-funded research on prevention or implementation of 
evidence-based practices. Synergies will also emerge, i.e., AHRQ could fund research 
assessing the effect of a CMS change in payment policy or NIH findings could point 
toward a potential CDC-funded prevention strategy. This coordination will reduce 
potential duplication and enhance the impact of each agency’s work. 
 
Specifically the following mechanism for coordination is proposed: 
 
The Healthcare-Associated Infections Research Working Group is chartered and meets 
quarterly. This group would have at least two representatives from AHRQ, CDC, CMS, 
and NIH and representatives from other HHS Operating and Staff Divisions or federal 
agencies, as needed. The committee would have three main objectives: 
 
1) Coordinate and prioritize research efforts to reduce healthcare-
associated infections nationwide 
 
2) Design a plan and metrics for evaluating progress within the research 
domain to address healthcare-associated infections 
 
3) Serve as a contact point to communicate to external stakeholders on 
this issue so HHS’s efforts are coordinated and linked to a broader 
national coalition 
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The proposed Healthcare-Associated Infections Research Working Group should set up 
criteria and a plan for evaluation of the HHS research program to address healthcare-
associated infections. The evaluation should assess the research program and the projects 
it has specifically funded. Additionally, the Working Group is committed to the ongoing 
documentation of HAI research gaps. Metrics of accomplishment could include 
documented improvements in care, published articles, dissemination of findings through 
conferences or other means, or other research products. 
 
It is important to note that successful research may demonstrate negative results or bring 
up more questions as well as demonstrate effective interventions. The Research Working 
Group will set up a priori criteria to evaluate the Department’s research program on HAIs 
and a plan for the timing of evaluation, such as annually. The evaluation of the program 
should lead to adjustments to the program in subsequent years. 
 
 
VI. Conclusion and Vision for the Future: Creating a Learning Healthcare System 
in the United States 
 
The large knowledge gaps that exist in HAI prevention are, in part, the result of barriers 
to new generation of knowledge that currently exit in U.S. healthcare. In a background 
paper developed and presented at an Institute of Medicine workshop sponsored 
Roundtable on Evidence Based Medicine and entitled, “Leadership Commitments to 
Improve Value in Health Care,” Platt and colleagues argue that evidence generation, i.e., 
learning what works and what does not, should be established as a normal part of health 
care in the U.S. 
 
The authors outline major challenges confronting the development of knowledge to 
support the learning healthcare system. These include: 1) Limited investment for research 
and development towards understanding how well various strategies work in practice, or 
how to assure that the right preventive or therapeutic regimen is offered to individuals 
who need it; 2) Difficulty in using much of the existing data, even when it exists in 
electronic form, because of fragmentation among organizations that control the data, 
variation in the way different organizations interpret the Health Insurance Portability and 
Accountability Act (HIPAA) Privacy Rule, Institutional Review Boards’ varying 
interpretations of regulations governing the use of these data for research, and proprietary 
concerns of data holders; 3) Important limitations in the quality and generalizability of 
the existing data; and 4) Lack of a full understanding of the strengths and weaknesses of 
the different research methods, ways in which to strengthen them, and the situations in 
which they are best applied. 
 
While knowledge gaps do exist, there is much that has been accomplished. The research 
plans proposed in this section have begun to identify the gaps in the existing knowledge 
base of current infection control practices in hospitals, a necessary first step in the 
process to develop a coordinated research agenda that will strengthen the science for 
infection control prevention practices in hospitals. It is critical that we understand why 
adherence to current HAI prevention recommendations has been suboptimal, that we 
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fully understand the specific limitations that exist in current surveillance strategies, and 
that we have explored how electronic data can be used to measure process and outcomes. 
 
The proposed research projects address the gaps identified in the basic sciences, 
epidemiology, practices, and the priority infection types identified in the first phase of the 
initiative. They lay the foundation for further steps that will be informed by the results of 
the initial projects and other ongoing research. An ongoing challenge will be the 
identification of projects that will enhance the implementation and impact of existing 
evidence-based infection control practices. The Department is committed to collaborating 
within HHS and with external stakeholders to assess current research methods, funding 
levels, information technology use, and researcher training and to present solutions to 
facilitate and accelerate knowledge generation. The overall goal is to support the research 
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HHS Action Plan to Prevent Healthcare-Associated Infections: 





Mounting clinical and public health concerns about healthcare-associated infections 
(HAIs) compel the healthcare community at large to reexamine the approaches to 
addressing the prevention of HAIs. Advances in information technology, harmonization 
of disparate data standards, and capabilities to connect with and integrate multiple data 
types and sources all create new opportunities for the Department of Health and Human 
Services (HHS) and other federal agencies to re-think and refine strategies to better focus 
on improving the national capacity to monitor, measure, and prevent the occurrence of 
HAIs. HHS and other federal agencies share goals with state agencies, hospitals and other 
healthcare organizations, healthcare practitioners, accrediting and professional 
organizations, and the public to take action addressing the prevention of HAIs. 
 
Some such common goals that could be addressed through leveraging advances in state-
of-the-art information systems and technology might include: 
 
1) Achieve more rapid and more complete detection of HAIs by increasing 
capabilities to exploit current and future data sources. Efforts would initially use 
available laboratory data sources and computer-based detection algorithms, but 
actively work toward the inclusion of data from the clinical record of care. This 
will be possible only when standard terms for HAIs are used routinely and when 
automated, intelligent systems are applied to identify HAI indicators among a 
constellation of clinical findings within electronic data resources. 
 
2) Increase the rate of dissemination of reporting data to external HAI surveillance 
activities performed by quality improvement organization and public health 
monitoring efforts. This will permit rapid detection of patterns and trends for 
predetermined or ad hoc sets of demographics, thus creating the opportunity to 
formulate appropriately targeted tactics and execute early prevention and 
intervention techniques. 
 
3) Provide more comprehensive and timely data to focus prevention efforts and 
measure their effectiveness at the national level at reducing surgical site 
infections, central line-associated bloodstream infections, catheter-associated 
urinary tract infections, ventilator-associated pneumonia, methicillin-resistant 
Staphylococcus aureus infections, and Clostridium difficile infections. 
 
4) Make available the HAI data for an entire episode of care, e.g., both surgical 
process-of-care data recorded at the healthcare facility where the patient had 
his/her operation as well as surgical site infection data recorded at another 
healthcare facility, such as another hospital or a physician’s office, when the 
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patient seeks care there. Spur the nationwide adoption of electronic health record 
(EHR) systems that can exchange data interoperably with other systems which 
will yield enormous benefits, including new capacity for episode-of-care data 
collection and more complete measurement and analysis of HAIs. 
 
5) Create an “early warning” mechanism that is context-sensitive to HAI prevention 
reminders or clinical guidelines, either of which might be triggered automatically 
by findings or clinical plans or actions that are entered into EHR systems, 
resulting in point-of-care availability of relevant information that can help guide 
patient care decisions and documentation, such as decisions about contact 
precautions designed to prevent transmission of HAIs. 
 
Improvements in national-level HAI data collection, analysis, and reporting are integral 
to what HHS and other federal agencies seek to accomplish in a broad-based, national 
HAI prevention effort. The Department recognizes that there are some issues with the 
current systems, despite notable efforts in this arena by federal agencies. 
 
Previous efforts to pursue integration of federal systems for adverse events reporting have 
produced mixed results because of the challenges of trying to integrate already-existing 
data and systems. A proactive strategy to integrate data where it originates, in addition to 
retrospective integration of different federal systems of reporting, would go beyond 
addressing data “control and fragmentation” issues in clinical care and begin to capitalize 
on prevention opportunities in the clinical workflow. 
 
Programs at multiple agencies currently collect and report HAI and HAI-related data in 
separate systems and databases that function, in effect, as “silos” perpetuating singular 
and isolated paths of information used for making decisions. In some cases, the lack of an 
integrated stream of information creates disconnects and results in loss of potentially 
important information. In other cases, the databases serve such fundamentally different 
purposes that productive integration efforts may be virtually impossible. 
 
Promoting the linking or sharing of HAI data across systems in a more integrated fashion 
offers myriad opportunities to yield important benefits for comprehensive analysis and 
action, provided safeguards are in place to assure that the merged data are used 
exclusively for authorized public health purposes and are scrupulously protected from 
unauthorized access. For example, combining patient-level surgical process-of-care data 
from one system with surgical site infection data from another system, with appropriate 
protections of personally identifiable health data, could provide new insights into near-
term opportunities for prevention and quality-of-care improvement. 
 
In other situations, a longer-term strategy to achieve integration will be needed to enable 
interoperable data exchanges between separate systems and to leverage the standards-
based, electronic record keeping and data sharing that have entered the mainstream of 
U.S. healthcare. Achieving these longer-term strategies should provide HAI data to 
multiple agencies with greater efficiency, economy, timeliness, comprehensiveness, and 
reliability than is currently possible. 
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II. Establishing the Foundation for HAI Data Integration and Interoperability 
 
Critical precursors to achieving HAI data integration and interoperability within HHS and 
across federal agencies should include: 
 
 Increased visibility and priority given to the measurement and prevention of 
HAIs, so agency heads will incorporate this as a key objective and important 
priority into their respective strategic plans. The proposed goal is the execution of 
these strategies in an integrated fashion with federal and external partners. 
 
 Careful planning and close coordination across federal agencies towards gradual 
and intentional implementation of system and process changes that utilize 
common data, information, and knowledge models. This should be done to 
support the prevention of HAIs and all quality-of-care initiatives sharing common 
strategic healthcare improvement goals. 
 
 Close collaboration with private and other public entities that promote, manage, 
and implement widely adopted healthcare data and technology standards and the 
Interoperability Standards that have been recognized by the HHS Secretary to 
ensure that the business case for prevention of HAIs is included in the 
development and ongoing maintenance of standards, including efforts to 
harmonize multiple domains of data. 
 
 Proactive participation in large-scale strategies and other federal initiatives, 
similar to those which have been advanced by the American Health Information 
Community (AHIC), the Healthcare Information Technology Standards Panel 
(HITSP), and the HHS Office of the National Coordinator for Health IT (ONC). 
This will help shape the development and implementation of an HAI Information 
Architecture that works in conjunction with the Nationwide Health Information 
Network (NHIN) and the Federal Health Information Sharing Environment 
(FHISE) initiatives. 
 
To the fullest extent possible, efforts to improve HAI data integration and interoperability 
should be aligned with the NHIN and FHISE initiatives. The Nationwide Health 
Information Network is a collective set of health information exchanges (HIEs), 
including providers and several federal agencies that are working together as the NHIN 
Cooperative to securely exchange healthcare data. 
 
The purpose of the NHIN is to provide a secure, nationwide, interoperable health 
information infrastructure that will connect providers, consumers, and others involved in 
supporting health and healthcare. The connection of HIEs is a key step in building a 
“network of networks,” the NHIN. The Federal Health Information Sharing Environment 
(FHISE) is a framework to help agencies map their business priorities to information-
sharing products and identify what interoperable solutions are currently available and in 
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future planning. The FHISE framework will help agencies to sift through the enormous 
amount of information available to identify exactly the information, products, and 
services needed to address problems. 
 
 
III. Coordination of Efforts: Interagency Working Group 
 
To meet the information technology needs of a national HAI prevention effort, a well-
coordinated effort will be required of the Department. Various agencies across HHS 
house systems and databases containing HAI-related information. These agencies will 
need to collaborate to find system integration solutions in order to obtain reliable national 
estimates of HAIs and a more accurate view of the overall issue. 
 
Thoughtful development and successful implementation of specific interagency projects 
will be essential to improve national-level HAI monitoring and measurement. A 
coordinated effort will involve enhanced and consistent communication across the 
Department. This will allow for problems to be approached in a more holistic fashion 
rather than in its disparate parts. 
 
Programs in existence or development within one or more agencies should be identified 
and leveraged to aid in the overall prevention strategy. Also, a coordinated effort will 
potentially reduce duplication of work and enhance the impact of each agency’s 
contribution to the program. 
 
Specifically, the mechanism proposed to accomplish a coordinated effort would be the 
establishment of an Interagency Working Group. Implementation of this task will serve 
as the foundation for accomplishing the remaining tasks outlined in the Action Plan. The 
Interagency Working Group (or “Healthcare-Associated Infections Information Systems 
and Technology Working Group”) should be chartered and will initially be comprised of 
at least one representative each from the Agency for Healthcare Research and Quality 
(AHRQ), Centers for Disease Control and Prevention (CDC), Centers for Medicare and 
Medicaid Services (CMS), Food and Drug Administration (FDA), and ONC, plus 
representatives from other agencies as designated. The representatives should have an 
overarching understanding of their respective agency’s HAI-related systems and 
databases as well as the inter-relationships between these systems. They should also have 
an in-depth knowledge of gaps in HAI data. Project managers of specific systems within 
these agencies will serve as technical consultants to the Interagency Working Group. In 
order to facilitate regular communication, the group will meet monthly. 
 
The Interagency Working Group should focus its attention on specific projects that can 
be completed with a time horizon of one to two years. The highest priority will be placed 
on projects that combine data from existing systems to improve capacity at the national 
level to benchmark progress in reducing HAIs. Near-term efforts to link or share data 
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Processes should be established for reconciling differences that would otherwise impede 
progress in completing high-priority projects. For example, selecting common patient 
identifiers for use in separate databases may be necessary to link patient-level data that 
provide a more comprehensive measure of HAIs than is available in any single system. 
 
 
IV. Work Group Goals, Tasks, and Operational Charter 
 
The goals and tasks for the Interagency Work Group are: 
 
Goal A: Establish definitional alignment and identify standardized data elements that are 
needed to measure HAIs across HHS agencies and encourage existing federal 
participation with Standards Development Organizations to ensure that gaps in the 
available standards are addressed. 
 
Tasks: 
1) Develop a comprehensive inventory of existing HAI databases in HHS agencies, 
including information about data collection, data uses, and data validation. 
2) Broker agreement on the terms that need to be defined and the set of data 
elements that needs to be specified to measure HAIs. 
3) Document term definitions, value sets, and data elements included in HAI 
databases in HHS agencies, specifically those needed to measure HAIs. 
4) Establish definitional alignment and data element standardization across HHS 
agencies, with special emphasis on standardizing healthcare data already available 
in electronic form. 
5) Identify and analyze policy and legal issues and limitations relevant to 
exchanging data among agencies. 
 
Goal B: Provide guidance to enable integration of HAI data from multiple HHS databases 
for the purpose of benchmarking progress in reducing HAIs. 
 
Tasks: 
1) Reach agreement on what data are needed to benchmark progress. 
2) Identify HHS databases that are candidates for integration, with emphasis on the 
strategic opportunities. 
3) Complete a business analysis of the integration opportunities that are identified. 
 
Goal C: Mobilize health information systems to help reinforce appropriate patient safety 
recommended clinical practices. 
 
Tasks: 
1) Compile an inventory of health information system functional components, e.g., 
clinical decision support. This can be used to reinforce recommended clinical 
practices. 
2) Develop a plan for HHS actions that can help move functional components into 
wider clinical use at an accelerated pace. 
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Goal D: Seek strategic opportunities to make varied HHS data systems interoperable to 
enhance understanding of HAIs. 
 
Tasks: 
1) Express strategic opportunities for integration as use cases that describe data 
flows and what is required to support them. 
 
To accomplish these goals and tasks, the Interagency Working Group should be guided 
by an operational charter that describes the Working Group’s purpose, scope, authority, 
participants, roles and responsibilities, and stakeholders. 
 
The operational charter should organize the Working Group’s efforts around four major 
objectives: 
 
1) Establish and use an information technology strategy 
 
a. Develop an overall information technology strategy to support near-term 
and long-term HAI data integration while safeguarding data from 
unauthorized access and use. 
b. Make decisions regarding specific projects and the scope and boundaries 
of projects incorporated within a coordinated strategy. 
c. Establish priorities and provide oversight for interagency system 
integration projects. 
 
2) Communicate with stakeholders 
 
a. Formulate a communication strategy to be used both within and external 
to HHS to ensure the highest degree of understanding of priorities. 
b. Serve as a point of contact for communication to external stakeholders so 
HHS efforts are coordinated and linked to a broader national coalition. 
c. Provide status reports and updates to the overall HHS Steering Committee. 
d. Identify and serve as a conduit to appropriate points of contact within 
agencies for data/database information. 
 
3) Maintain accountability for the work effort 
 
a. Design a set of process measures to monitor progress on achieving goals 
within the information technology strategy. 
b. Assist related groups (e.g., the Interagency Healthcare-Associated 
Infections Research Working Group) with the design of a set of measures 
and a plan to improve the measures over time to monitor the nation’s 
performance on reducing healthcare-associated infections. 
 
4) Minimize reporting burden and maximize information output 
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a. Formulate a related strategy to streamline and reduce redundancy in HAI 
reporting from healthcare facilities and limit additional data collection to 
ease the reporting burden on stakeholders, specifically hospitals. 
b. Use small pilot studies to determine the effectiveness of information 
technology solutions for minimizing burden and maximizing output before 
solutions are disseminated and deployed. 
c. Leverage the availability of healthcare data in electronic form, such as 
microbiology results data, to automate case detection and enable electronic 
reporting of HAI data wherever possible.    
d. Establish consistent standards and coordinated data collection 
methodologies for how stakeholders should submit HAI data to various 
HHS systems. 
e. Develop strategies to ensure that end users (i.e., the institutions and 
individuals entering the data) have adequate access to information 
technology resources and help desk functions to support end users in a 
manner that simultaneously reduces their burden and improves the 
accuracy of data input (e.g., integrated help functions, error-reporting 
mechanisms, etc.). As part of these strategies, develop tools for user data 
entry which span a broad range of technical capabilities and work flows 




V. HAI Data and Data Inventory 
 
An inaugural project for the Interagency Working Group would be an inventory of HAI 
data and database resources to guide preliminary analysis and decision-making for near-
term and long-term data integration projects. Specifically, an HAI data inventory will 
establish the extent of definitional alignment and data element standardization needed to 
link or share HAI data across agencies. It also will provide operational guidance on the 
steps needed to achieve integration and semantic interoperability of HAI data from 
multiple databases. The inventory should cover HAI databases regardless of whether 
integration would involve manual integration with other databases or integration through 
information exchange. Such an inventory is necessary for and will be used to mobilize 
health information systems to help reinforce appropriate patient safety recommended 
clinical practices and to seek strategic opportunities to make varied HHS data systems 
interoperable to enhance understanding of HAIs. 
 
A comprehensive and consistent set of information about different HAI databases is 
needed to assess definitions of key concepts across databases, the extent of data element 
standardization, opportunities to combine data from different HAI databases to provide a 
unified view for benchmarking purposes, and the prospects for interoperable data 
communications between HHS systems that can serve to improve understanding of HAIs 
in terms of risk factors, morbidity, mortality, cost, and prevention. In addition, the 
inventory should provide the conceptual components of and inform the structural 
framework for an overarching conceptual model to represent knowledge about HAI. 
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The information that should be included in the HAI data inventory is broad and complex. 
It should include data specifications that are already compiled and stored in existing 
databases and groupings of data based on a set of relationships, and it also will involve 
access to documents and other information sources that will require special effort to 
analyze and interpret the metadata. Thus, a well designed and carefully planned project 
should be done with a commitment of qualified project staff and executive sponsorship 
with allocation of sufficient resources and the concerted efforts and resourcefulness of 
HHS personnel who serve as programmatic stewards for HAI databases. 
 
The HAI data inventory should be a systematic collection of information about HAI-
specific and HAI-related data currently collected and housed in different databases 
maintained by HHS and other federal agencies that provide national-level data about risk 
factors, morbidity, mortality, cost, or prevention of HAIs. Specific information about 
each database should be tabulated and the results summarized in a report that is 
sufficiently comprehensive and detailed to guide assessments and decisions about 
definitional and data element harmonization across multiple databases and domains, to 
identify opportunities for data integration, and to determine the level of readiness of the 
organization hosting the needed HAI data sources to engage in interoperable data 
exchanges. 
 
   The HAI databases to be inventoried should include, but are not necessarily limited to the 
following: 
 
 Agency for Healthcare Research and Quality (AHRQ) 
 Healthcare Cost and Utilization Project (HCUP) database, nationwide 
inpatient sample 
 Network of Patient Safety Databases (NPSD) 
 
 Centers for Disease Controls and Prevention (CDC) 
 Active Bacterial Core surveillance (ABCs) database 
 National Healthcare Safety Network (NHSN) database 
 National Hospital Discharge Survey (NHDS) database 
 National Inpatient Sample 
 Mortality data files   
 
 Centers for Medicare and Medicaid Services (CMS) 
 Annual Payment Update (APU) database 
 Healthcare Cost Report Information System (HCRIS) database 
 Medicare Beneficiary Database 
 Medicare Patient Safety Monitoring System (MPSMS) database 
 Medicare Provider Analysis and Review (MEDPAR) database 
 
 Food and Drug Administration (FDA) 
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 MedWatch 
 Manufacturer and User Facility Device Experience (MAUDE) database 
 
Attributes of each database to be inventoried should include, but are not limited to: 
 
 - Purpose(s)    - File format 
 
 - Reporting incentive(s)    - Documentation 
 
 - Geographic coverage   - Privacy protection 
 
 - Temporal coverage   - Dissemination 
 
 - Data sources    - Access 
 
 - Frequency of data collection  - Requirements for use 
 
 - Definition of key concepts  - Data Use Agreement 
 
 - Data elements 
    
A detailed plan and timetable should identify all phases, activities, and tasks needed to 
complete the inventory. It is anticipated that the HAI data inventory would be completed 
within six months of project kick-off. The objectives of this project should be to deliver a 
comprehensive and well-characterized inventory of HAI data and source databases in a 




VI. Integrating Sources of Data 
 
Based on the database inventory and deliberations by the Interagency Work Group, 
decisions should be made about which near-term data integration activities are of the 
highest priority. These decisions should be guided by the understanding of the original 
business purposes of the data or data groupings and the metadata information available 
from the HAI data inventory. Caution should be applied when re-purposing data while 
also focusing attention on filling the most important gaps in HAI data coverage. 
 
One example of leveraging current capacity would be to provide a means to share data 
between CMS’s Surgical Care Improvement Program (SCIP) and CDC’s National 
Healthcare Safety Network (NHSN); specifically, surgical process-of-care data from 
SCIP can be combined on the facility and patient levels with surgical site infection data 
from NHSN. In the current environment, fundamental differences in purpose, data 
requirements, and methods among some systems reduce the prospects for meaningful 
data linkage or sharing. For example, combining HAI incidence data collected by hospital 
infection control professionals with HAI incidence data collected from coded hospital 
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discharge records would have only limited value owing to fundamental methodological 
differences in case detection. Discrepancies between these two methods of HAI case 
finding preclude meaningful data mergers: One method involves use of information 
beyond what is documented in medical records, while the other uses only the coded 
discharge abstract of medical records. 
  
A sustained and well-coordinated effort will be needed by AHRQ, CDC, CMS, and other 
federal agencies to develop and implement a long-term action plan for systems 
integration. Longer-term opportunities exist to create a formal information architecture 
supporting HAI prevention. This work should be guided and informed by the FHISE and 
NHIN and should take full advantage of the healthcare technology and data standards that 
are entering the mainstream of electronic clinical record keeping and reporting. 
 
Using these standards and interoperability specifications to develop, enhance, or modify 
federal systems would enable data integration and should connect federal systems to the 
standards-based electronic health record systems (EHRs) that are rapidly emerging. 
Thorough and ongoing use of standards-based solutions should be developed to reduce or 
obviate the need for abstracting clinical observations from healthcare records in order to 
report HAI data to federal agencies. Ideally, clinical data entries describing HAIs will 
automatically populate HAI reports generated from EHRs. 
 
While this scenario of electronic HAI reporting remains visionary, HHS and other federal 
agencies are well positioned strategically to help catalyze and coordinate the technical 
advances needed to make this vision a reality. 
 
 
VII. Challenges and Opportunities 
 
The Interagency Working Group will face many challenges in its efforts to create a 
successful environment for sharing of HAI information among federal agencies. 
 
HAI data owners from a variety of sectors (including state, local, and private) should 
consider investing in the development and deployment of a common reporting format, as 
well as the infrastructure needed to share the information nationally. Minimizing HAI 
data reporting burdens on healthcare facilities is a priority, as is close collaboration with 
accrediting organizations and healthcare professional organizations. Duplication and 
other data quality issues must be minimized or eliminated when data are aggregated at the 
national level. Finally, aggregating data from multiple sources will require agreement on 
common semantics for the data. 
 
An HAI solution must be requirements driven. An early focus on the data required for 
specific usages should enable better decisions about information systems and technology. 
Usage scenarios must be developed for the data. It is anticipated that an informatics 
solution would be developed in iterative phases. The integration of data from disparate 
sources might initially target simple collation of data, in which reports would be retrieved 
from existing HAI databases “as is,” and made available through a shared repository. 
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A subsequent aggregation phase should involve developing common definitions and 
formats that all HAI databases would use to generate electronic information feeds to the 
information sharing environment. An HAI database of the future could be built and 
maintained using a data model that is harmonized with clinical and administrative 
domains, maintaining strong linkages to HAI data of interest that are captured by various 
healthcare systems of origin. 
 
An HAI database of the future should contain metadata and support a standard metadata 
registry, and would also support a knowledgebase used for developing training, guidance, 
and adjustments to public health policies with respect to prevention of infections. This 
future database would ideally capitalize on interoperability between federal systems that 
enables aggregation and reuse of data from disparate systems, each of which serves a 






A well-organized and effective Interagency Working Group, informed in its deliberations 
and decision-making by a systematic inventory of HAI data and databases and a common 
information model, can complete the fact finding and analytic work needed to refine 
plans and define resource requirements for integration of HAI data across existing federal 
systems. Highest priority should be given to near- and long-term integration projects that 
will yield new capacity to measure national-level progress in HAI prevention. 
 
The Department is strategically positioned to catalyze multi-agency integration efforts 
and foster close collaboration with other public entities and private sector organizations 
that have a stake in HAI data or that have lead roles in standard-setting for healthcare 
data and information technology. To the fullest extent possible, efforts to enhance return 
on investment in federal sources of HAI data should be aligned with the NHIN and 
FHISE initiatives. Integrating data from HAI database sources at multiple agencies will 
require sustained commitment and careful project planning and execution. Successful 
project outcomes can establish new programmatic collaborations across federal agencies 
and yield benefits for analysis and action in a broad-based, national effort to prevent 
HAIs. 
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The Department of Health and Human Services (HHS), specifically the Centers for 
Medicare and Medicaid Services (CMS), has a variety of tools within its statutory and 
regulatory authority to encourage the prevention of healthcare-associated infections 
(HAIs). These tools can be broadly classified as regulatory oversight, financial 
incentives, transparency and associated incentives, or some combination of these. CMS 
also has a number of initiatives within each of these broad categories to combat 
healthcare-associated infections, and the following describes the various ways in which 
these tools and initiatives support the nation’s efforts to prevent infections. 
 
 




The Conditions of Participation (CoPs) are the federal health and safety requirements 
that hospitals and other providers must meet to participate in the Medicare and 
Medicaid programs. The CoPs are intended to ensure that high quality care is 
provided to all patients. Compliance with the CoPs is determined by State Survey 
Agencies (SAs) or Accreditation Organizations (AOs). The SAs survey hospitals to 
assess compliance with the CoPs. Hospitals are deemed to have met the requirements 
in the CoPs if they are accredited by national accreditation programs approved by 
CMS.  All Medicare- and Medicaid-participating hospitals are required to be in 
compliance with CMS’ CoPs regardless of their accreditation status. 
 
B. Conditions of Participation 
 
The Medicare CoPs are intended to be the minimum health and safety standards 
required for the protection of patients, and revisions to the CoPs require an extensive, 
(and, at times, lengthy) rulemaking process by CMS. When revisions are made to 
these requirements, particular attention must be paid to the ever-evolving nature of 
medicine and patient care. Moreover, a certain degree of latitude must be left in the 
requirements to allow for innovations in medical practice that improve the quality of 
care and move toward the reduction of medical errors and patient harm. These 
innovations in patient care, if supported by well-documented research evidence, most 
often lead to the issuance of guidelines and recommendations (sometimes referred to 
as “best practices”). These guidelines and recommendations come from federal 
agencies, such as the Agency for Healthcare Research and Quality (AHRQ), Centers 
for Disease Control and Prevention (CDC), and the Occupational Safety and Health 
Administrations (OSHA) within the Department of Labor, as well as from other 
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nationally recognized organizations. Historically, these national federal and private 
entities have been able to disseminate and update these best practices more quickly 
than CMS has been able to through its regulatory rulemaking process. 
 
The hospital infection control CoP directly addresses the reduction of HAIs. Rather 
than continually revising the infection control requirements in the CoPs to meet 
emerging needs, the CoP is most effective serving used as a baseline requirement for 
hospitals. This COP baseline should be used by health systems to integrate nationally-
recognized infection control standards and best practices into their individual 
infection control programs and to change their policies and procedures if, and when, 
the guidelines change. 
 
Additionally, the CMS survey and certification interpretive guidelines for the 
Infection Control CoP (discussed in detail in Section II.D), provide a regulatory 
vehicle for a more specific discussion of best practices in infection control for 
hospitals. The current Infection Control interpretive guidelines contain references to 
the recommendations of organizations such as the CDC, OSHA, and the Association 
for Professionals in Infection Control and Epidemiology, the Society for Healthcare 
Epidemiology of America, and the Association of Peri-Operative Registered Nurses.  
The guidelines specifically address special challenges to a hospital’s infection control 
program, including multi-drug resistant organisms, communicable disease outbreaks, 
and bioterrorism, and directly refer to current and nationally accepted sources of 




As mentioned above, accreditation by a nationally-recognized accreditation program 
can substitute for an ongoing State review. If a provider entity demonstrates through 
accreditation by an approved national Accreditation Organization (AO) that all 
applicable Medicare conditions are met or exceeded, CMS may "deem" those 
provider entities as having met the Medicare requirements. Accreditation by an AO is 
voluntary and is not required for Medicare participation. The use of private 
accreditation for ensuring provider compliance with Medicare requirements began in 
1965 when Congress granted statutory deemed status for hospitals accredited by The 
Joint Commission. The statute was later amended to permit deeming for accreditation 
by national organizations other than The Joint Commission and for categories of 
providers beyond hospitals. A national AO applying for approval of deeming 
authority must provide CMS with a reasonable assurance that the AO requires 
accredited provider entities to meet requirements that are at least as stringent as the 
Medicare CoPs. 
 
In addition to The Joint Commission's hospital program, hospitals currently have two 
other accreditation options. CMS has granted hospital deeming authority to the 
American Osteopathic Association (AOA) and Det Norske Veritas Healthcare 
(DNVHC). Specifics on each include: 
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1) AOA has had CMS approved hospital deeming authority since 1966 and is 
approved through September 25, 2009. CMS recently approved DNVHC's 
application for recognition as a national accreditation program for hospitals, 
effective September 26, 2008 through September 26, 2012. 
 
2) DNVHC's hospital accreditation program is unique in that it integrates the 
ISO 9001 standards (international quality standards that define minimum 
requirements for a quality management system) and the Medicare CoPs. In 
addition, the program conducts annual, rather than triennial, surveys to ensure 
ongoing compliance. 
 
Currently, there are approximately 4,072 Joint Commission-accredited hospitals, 
which is 83 percent of all hospitals (4,921) participating in the Medicare program.  
There are approximately 157 AOA-accredited hospitals; approximately half of these 
hospitals are dually-accredited by the Joint Commission and AOA. In total, over 84% 
(4,146) of all Medicare-participating hospitals are deemed by these AOs. Hospitals 
accredited by CMS-recognized AOs, are not subject to routine Medicare surveys by 
SAs. However, these hospitals are subject to validation surveys conducted by SAs on 
behalf of CMS in response to allegations of significant deficiencies which, if 
substantiated, would adversely affect the health and safety of patients. 
 
Recently, Section 125 of the Medicare Improvement for Patients and Providers Act of 
2008 (MIPPA) removed The Joint Commission’s statutorily-guaranteed accreditation 
authority for hospitals, to be effective July 15, 2010. At that time, The Joint 
Commission’s hospital accreditation program will be subject to CMS requirements 
for AOs seeking deeming authority. To avoid a lapse in deeming authority, The Joint 
Commission must submit an application for hospital deeming authority consistent 
with these requirements and within a time frame that will enable CMS to review and 
evaluate their submission. 
 
D. Survey and Certification 
 
The survey and certification program is designed to ensure that providers and 
suppliers comply with CoPs. CMS works with the SAs to conduct on site facility 
inspections for the vast majority of facilities that seek Medicare participation. Only 
certified providers, suppliers, and laboratories are eligible for Medicare or Medicaid 
payments. Currently, the CMS Survey & Certification Group oversees compliance 
with Medicare health and safety standards for more than 271,000 medical facilities of 
different types, including hospitals, laboratories, nursing homes, home health 
agencies, hospices, and end stage renal disease facilities. There are approximately 
7,200 active SA surveyors nationwide (about 6,500 full-time equivalents), with 
roughly 500 dedicated to hospital surveys. 
 
In FY 2008, CMS successfully trained more than 70% of the hospital surveyors on 
the new revised hospital interpretive guidelines for infection control (revised 
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November 21, 2007.1 The interpretive guidelines are sub-regulatory, or a manual 
version of how CMS, through the SA surveyors, enforces regulatory requirements, 
including those associated with infection control. This November 2007 revision to the 
hospital interpretive guidelines for infection control was updated to reflect changing 
infectious and communicable disease threats as well as current and nationally-
recognized infection control guidelines, best practices, and other resources for 
hospitals. 
 
When deficiency findings, such as deficient infection control practices, are identified 
through a hospital or other setting survey, the information is captured in a database.  
In FY 2007, an infection control deficiency was cited 1% of the time on average. The 
database has several deficiency identifiers or tags that are related to infection control.  
With the use of specific tag identifiers for the deficient practice(s), CMS can later 
analyze the findings for greater insight into problem areas. For example, CMS is able 
to breakdown the CoP for infection control into subparta to specifically capture in our 
database whether the hospital is in compliance with having the required designated 
infection control officer (which “crosswalks” directly in CMS’s database to A-748). 
 
Hospital complaints have typically been the second highest volume of complaints 
CMS receives among all the Medicare provider types certified. When the top 
allegations for complaints are examined, infection control issues are consistently in 
the top 12 (see Appendix D). 
 
E. Recommendations and Action Plans 
 
Conditions of Participation 
The Medicare Hospital Infection Control CoP was first published over 20 years ago.  
Since then, infections such as HIV/AIDS, SARS, West Nile virus, avian influenza, 
and MRSA (to name but a few) have emerged and have been quickly followed by 
infection control guidelines. These tend to be specific to each emerging infection and 
are issued by nationally recognized organizations. The national organizations have 
typically revised the guidelines as needed to keep pace with new developments and as 
a way to help hospitals continue to track, monitor, and prevent such diseases. 
 
However, as new sources of infection and communicable disease present new 
challenges to patient care, Medicare infection control requirements need to remain 
flexible and broad enough in their scope so that hospitals are able to incorporate the 
most current infection prevention and control guidelines into their programs. Shifting 
toward a more prescriptive regulatory approach (i.e., one that would focus on the 
prevention and control of specific infections and communicable diseases as would 
need to be designated in the regulatory text) would be a move backward to a more 
rigid and process-oriented regulatory structure. It would also be a move away from 
the more flexible and evidence-based approach that continues to prove a more 
successful model for reducing harm and improving outcomes for patients. Currently, 
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the Infection Control interpretive guidelines make direct reference to the evidence-
based infection control guidelines and recommendations established by nationally-
recognized organizations. 
 
The following recommendations would further strengthen the commitment to quality 
in the prevention of HAIs: 
 
 Require that a hospital ensure that their infection control program follows 
currently recognized standards of practice as established by national 
organizations. 
 
 Require that the infection control program be an integral part of the hospital’s 
quality assessment and performance improvement (QAPI) program. While the 
current Infection Control CoP does require that the hospital-wide quality 
assurance program address the problems identified by the infection control 
officer, this revision would more directly link the Infection Control CoP with the 
equally important QAPI CoP and would require hospitals to pursue a more 




In July 2004, the Government Accountability Office (GAO) made several 
recommendations to improve CMS oversight of the hospital accreditation program.2  
The recommendations included modifying the method used to calculate the disparity 
rate, identifying additional indicators of The Joint Commission’s performance, and 
increasing the validation sample size. CMS’ current and planned actions to enhance 
oversight of hospital accreditation are described below: 
 
 Methodological Changes to Improve Oversight – CMS is assessing differing 
approaches to refining and improving the current method of measuring AO 
performance in assuring compliance with the CoPs. CMS secured the services of 
a contractor in FY 2006 to assist in this endeavor, which is expected to be 
expanded to address all AOs and all deemed programs. However, a revised 
approach to performance assessment may also require regulatory revisions. 
 
 Analysis of Complaint Data – CMS is investigating cost-effective approaches to 
enhancing hospital survey activities, including integration into our overall 
assessment of the AO’s performance, as a result of complaint investigations 
conducted in hospitals. CMS continues to work with a contractor to explore the 
utility of the complaint data as a means to assess the performance of the AOs. 
 
Survey and Certification 
In the survey and certification area, CMS and experts have identified a number of 
future enhancements for regulatory oversight of hospitals as recommendations: 
 
                                                 
2 GAO-04-850, CMS Needs Additional Authority to Adequately Oversee Patient Safety in Hospitals 
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 Increase hospital surveyor training on recent revisions of hospital interpretative 
guidelines to ensure that 100% of dedicated hospital surveyors have the 
opportunity to be trained on the revised guidelines. 
 
 Incorporate enhancements, which arise from collaborative activities with the 
CDC, into the surveyor training program as a means of providing surveyors with 
illustrative examples of best infection control practices in hospitals. 
 
 Conduct a pilot of a surveyor tool. Piloting of a modified version of a CDC-
developed surveyor tool for comprehensively assessing infection control practices 
in ambulatory surgical centers has begun. Depending on the assessment of the 
pilot experience, CMS may develop another version of the tool that could be 
employed in the hospital setting. This would require partnership with CDC for 
applicability to hospital setting. 
 
 Consider instructing surveyors to assess compliance with infection control 
practices on every hospital complaint survey, in addition to assessing compliance 
with requirements related to the complaint allegation. 
 
 Consider requiring AOs to also make assessment of infection control a priority 
focus. 
 
 Partner with the AOs on sharing complaints or survey findings where infectious 
disease findings occurred. 
 
 Consider joint educational intervention, such as a conference, with the AOs on the 
subject of infection control compliance. (Note this might be subject to privacy 
provisions and not be easily implemented.) 
 
 Consider strengthening the relevant sections of the CoPs related to infection 
control and quality assurance/performance improvement. 
 
 Consider adding a performance/evaluative metric related to hospital acquired 
infections. This could be accomplished in collaboration with CDC and AHRQ and 
using systems such as CDC’s National Healthcare Safety Network (NHSN). 
 
 




CMS is applying the tools within its statutory authority to enhance the quality and 
efficiency of services provided to Medicare beneficiaries through value-based 
purchasing (VBP) and related initiatives. These include measurement and payment 
incentives to encourage beneficial interventions and outcomes to improve 
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performance. Using these resources, CMS is working to transform Medicare from a 
“passive payer” to a more active purchaser of higher value health care services. 
 
The Preventable Hospital-acquired Conditions (HAC) Provision, and Present on 
Admission Indicator Reporting, and Hospital Pay-for-Reporting are three hospital-
related initiatives that CMS is using to promote increased quality and efficiency of 
care. 
 
In addition, CMS is studying the application of measurement and payment incentives 
to hospitals through various demonstration projects, and CMS has presented an 
approach to transition from pay-for-reporting to performance-based payment in the 
Hospital Value-Based Purchasing Plan Report to Congress. Each of these initiatives is 
discussed in turn below. 
 




The HAC provision is one approach that CMS is using to combat healthcare-
associated complications, including infections, in the hospital setting. The Medicare 
statute requires CMS to select conditions that will no longer trigger higher payment 
when they are acquired during hospitalization. 
 
CMS selected conditions must be: (1) high cost, high volume, or both; (2) assigned to 
a higher paying Medicare-severity diagnosis-related group (MS-DRG) when present 
as a secondary diagnosis; and (3) could reasonably have been prevented through the 
application of evidence-based guidelines. 
 
Beginning October 1, 2008, Medicare can no longer assign an inpatient hospital 
discharge to a higher paying MS-DRG if a selected condition is listed on the claim 
and was not present on admission. That is, the case will be paid as though the 
condition were not present. Medicare will continue to assign a discharge to a higher 
paying MS-DRG if the selected condition is present on admission. However, if any 
non-selected complicating condition appears on the claim, the claim will continue to 
be paid at the higher MS-DRG rate. 
 
CMS has also begun collecting a present on admission (POA) indicator to determine 
whether diagnoses were present on admission or acquired during hospitalization. On 
October 1, 2007, CMS began requiring hospitals to submit this information on 
Medicare claims. The POA indicator is necessary to identify which conditions are 
HACs for payment purposes, and this information is also potentially valuable for the 
broader public health uses of Medicare data. 
 
Inpatient Proposed Payment System Payment Incentives   
Medicare’s Inpatient Proposed Payment System (IPPS) encourages hospitals to treat 
patients efficiently. Hospitals generally receive the same payment for stays that vary 
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in the patient’s length of stay and in the intensity of the services provided, which 
gives hospitals an incentive to avoid unnecessary costs in the delivery of care. In 
some cases, complications, including infections, acquired in the hospital do not 
generate higher payments than the hospitals would otherwise receive for 
uncomplicated cases paid under the same DRG. To this extent, the IPPS encourages 
hospitals to avoid complications, including infections. 
 
However, complications acquired in the hospital can generate higher Medicare 
payments. For instance, under the MS-DRGs that took effect for hospital payment in 
FY 2008, there are currently 258 sets of MS-DRGs that split into two or three 
subgroups based on the presence or absence of a complicating condition (CC) or 
major complicating condition (MCC). 
 
If a condition is one of the conditions on the CC or MCC list, the hospital receives a 
higher MS-DRG payment, unless CMS selected the condition as an HAC and the 
condition was not present on admission. Medicare continues to assign a discharge to a 
higher paying MS-DRG if the selected condition is present on admission. 
 
The following table demonstrates how payments are made on average depending on 




(Examples for a single  secondary diagnosis) 






Principal Diagnosis:  MS-DRG 066 
 Stroke without CC/MCC  
-- $5,347.98 
Principal Diagnosis:  MS-DRG 065 
 Stroke with CC 
Example Secondary Diagnosis: 





Principal Diagnosis:  MS-DRG 066 
 Stroke with CC 
Example Secondary Diagnosis: 





Principal Diagnosis:  MS-DRG 064 
 Stroke with MCC 
Example Secondary Diagnosis: 






Principal Diagnosis:  MS-DRG 066 
 Stroke with MCC 
Example Secondary Diagnosis: 
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This example illustrates the different MS-DRG payments that result when selected 
HACs are present on the claim. These scenarios are for a single secondary diagnosis 
only, which is atypical for a hospitalized Medicare beneficiary. The presence of at 
least one non-HAC CC/MCC on the claim will continue to trigger the higher paying 
MS-DRG. 
 
Collaboration and Public Input in HAC Selection 
CMS clinical quality experts have worked closely with public health and infectious 
disease experts from the CDC to identify the candidate preventable HACs, review 
comments, and select HACs. CMS and CDC staff also collaborated on the process for 
hospitals to submit a POA indicator for each diagnosis listed on inpatient Medicare 
claims and on defining the payment implications of the various POA reporting 
options. 
 
On December 17, 2007, CMS and CDC hosted a jointly-sponsored HAC and POA 
Listening Session to receive individual input from the over 500 interested 
organizations and individuals who participated. CMS and CDC received verbal 
comments during the listening session and subsequently received numerous written 
comments. CMS has also sought public comment during FY 2007, FY 2008, and FY 
2009 IPPS rulemaking. CMS noted that it will be considering additional HAC 
candidates, including additional infectious conditions, in future rulemaking. CMS 
expects to continue its collaboration with the CDC, other federal agencies, and 
stakeholders in the refinement and expansion of the HAC payment provision. As a 
next step, CMS and CDC intend to jointly sponsor a second HAC and POA Listening 
Session in December 2008. 
 
HAC Selection Criteria 
In selecting proposed candidate conditions and finalizing conditions as HACs, CMS 
and CDC staff evaluated each condition against the statutory criteria. These criteria 
limit which conditions can be selected for the HAC payment provision. The first 
criterion requires that a selected condition is high cost, high volume, or both. The 
second criterion requires that a selected condition trigger a higher Medicare payment.  
To do so, a condition must be represented by an ICD-9-CM diagnosis code that 
clearly identifies that condition, is designated as a CC or an MCC, and results in the 
assignment of the case to a higher paying MS-DRG when the code is reported as a 
secondary diagnosis. That is, a selected condition must be a CC or MCC diagnosis 
code that would, in the absence of the HAC payment provision, result in the 
assignment of a higher paying DRG. 
 
The third criterion requires that a selected condition must be considered reasonably 
preventable through the application of evidence-based guidelines. 
 
Guidelines developed by entities such as the HHS Secretary’ s Healthcare Infection 
Control Practices Advisory Committee (HICPAC), professional organizations, and 
academic institutions were reviewed to evaluate whether guidelines are available that 
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hospitals should follow to prevent conditions from occurring in hospitals. The 
absence of prevention guidelines for many potential candidate conditions, including 
certain infectious conditions, limits the universe of candidate conditions. 
 
In addition, the third criterion requires that a selected condition be considered 
reasonably preventable when the interventions in the guidelines are followed. The 
absence of evidence quantifying the extent to which application of evidence-based 
guidelines results in the prevention of certain conditions, including infectious 
conditions, also limits the universe of candidate conditions. 
 
Selected HACs for 2009 
After evaluating proposed candidate conditions against the statutory criteria and 
considering public comments received during FY 2007, FY 2008, and FY 2009 IPPS 
rulemaking, CMS and CDC experts selected 10 categories of conditions to which the 
HAC payment provision will apply beginning October 1, 2008. The HACs are more 
precisely defined by specific diagnosis codes (see Appendix E for specific codes). 
 
 
HACs - 10 Categories of Conditions 
1.  Foreign Object Retained After Surgery  
2.  Air Embolism 
3.  Blood Incompatibility 
4.  Pressure Ulcer Stages III & IV 
5.  Falls and Trauma: 
  - Fracture 
  - Dislocation 
  - Intracranial Injury 
  - Crushing Injury 
  - Burn 
  - Electric Shock 
6.  Catheter-Associated Urinary Tract Infection (UTI) 
7.  Vascular Catheter-Associated Infection 
8.  Manifestations of Poor Glycemic Control 
9a.  Surgical Site Infection, Mediastinitis Following 
Coronary Artery Bypass Graft (CABG) 
9b.  Surgical Site Infection Following Certain 
Orthopedic Procedures 
9c.  Surgical Site Infection Following Bariatric 
Surgery for Obesity 
10.  Deep Vein Thrombosis and Pulmonary Embolism 
Following Certain Orthopedic Procedures 
 
Enhancements and Future Issues 
Each year through IPPS rulemaking, CMS will consider refinements to the HAC list 
and potential candidate conditions. This might include the consideration of additional 
categories of conditions, expansion of existing categories, and reconsideration of 
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conditions that had previously been proposed but not selected. For example, 
stakeholders have suggested that water-borne pathogens be considered, that the 
surgical site infection category be expanded, and that ventilator-associated pneumonia 
and Staphylococcus aureus septicemia be reconsidered. The ability to select 
additional conditions will depend on the development of evidence-based guidelines 
such that when those guidelines are followed, the conditions can be considered 
reasonably preventable. In addition, having the POA indicator as a part of the 
Medicare claims data will help facilitate identification of additional candidate HACs. 
 
Consumer groups and the media have suggested that methicillin-resistant 
Staphylococcus aureus (MRSA) and Clostridium difficile should be selected as HACs 
for the payment provision. Importantly, these infectious agents are directly addressed 
in part by the infectious conditions currently selected as HACs. For example, MRSA 
could be the etiologic agent for a vascular catheter-associated infection. However, the 
current coding for MRSA and C. difficile does not differentiate colonization from 
infection. As the diagnosis coding is refined, the ability to differentiate community 
from hospital-acquired infections improves, and evidence-based guidelines for the 
prevention of infectious agents are defined and enhanced, these infectious agents may 
be reconsidered as candidates for the HAC payment provision in future rounds of 
IPPS rulemaking. 
 
Several means to make the HAC payment policy more precise could be considered in 
the future, including risk adjustment, implementation of a more sophisticated VBP 
model based on occurrence rates for conditions over time, and adoption of ICD-10. 
Rather than not paying any additional amount when a selected HAC occurs during 
hospitalization, payment reductions could be made proportional to the patient’s or 
patient population’s risk – the relative likelihood of acquiring a particular condition 
during hospitalization. This approach may recognize that medical history, co-
morbidities, and severity of illness, among other factors, affect the expected 
occurrence of complications. 
 
The application of a performance-based payment model that incorporates 
complication rates over time may be a more meaningful, actionable, and fair way to 
adjust a hospital’s payments up or down based on the incidence of HACs (see 
discussion below in Section III.D.2, entitled, “Hospital Value-Based Purchasing Plan 
Report to Congress”). 
 
The adoption of ICD-10 would provide a better infrastructure for the HAC payment 
policy. Having more specific coding information would facilitate more precise 
identification of HACs. The adoption of ICD-10 has been proposed through 
rulemaking. 
 
Collection of the POA indicator will provide important information, not only for 
Medicare payment, but also for enhancing public health. Researchers should be able 
to use POA data for risk adjustment of quality measurement data and to gain insights 
into the incidence of conditions in the community and in hospitals. The POA data can 
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be analyzed for only Medicare beneficiaries or can be combined with private sector or 
state POA data to support broader conclusions. In addition, POA data, including POA 
data about hospital-acquired infections, could inform publicly reported information to 
support better health care decision making by consumers and professionals. 
 
C. Hospital Pay-for-Reporting 
 
Another approach CMS has adopted as it transforms the Medicare program from a 
passive payer towards the goal of being an active purchaser of higher quality, more 
efficient health care is hospital pay-for-reporting. 
 
This initiative is intended to equip consumers with quality of care information to 
make more informed decisions about their health care, while encouraging hospitals 
and clinicians to improve the quality of inpatient care provided to all patients. In 
December 2002, the HHS Secretary announced a partnership with several 
collaborators intended to promote hospital quality improvement and public reporting 
of hospital quality information. These collaborators included the American Hospital 
Association (AHA), the Federation of American Hospitals (FAH), the Association of 
American Medical Colleges (AAMC), the Joint Commission on Accreditation of 
Healthcare Organizations (now called The Joint Commission), the National Quality 
Forum (NQF), the American Medical Association (AMA), the Consumer-Purchaser 
Disclosure Project, the American Association of Retired Persons (AARP), the 
American Federation of Labor-Congress of Industrial Organizations (AFL-CIO), 
AHRQ, as well as CMS and others. In July 2003, CMS began the National Voluntary 
Hospital Reporting Initiative. This initiative is now known as the Hospital Quality 
Alliance (HQA): Improving Care through Information. 
 
CMS established a “starter set” of 10 quality measures, used to gauge how well an 
entity provides care to its patients. Measures are based on scientific evidence and can 
reflect guidelines, standards of care, or practice parameters. A quality measure 
converts medical information from patient records into a rate or percentage that 
allows facilities to assess their performance. 
 
This set includes measures addressing acute myocardial infarction, heart failure, and 
pneumonia, for voluntary reporting as of November 1, 2003. The 10 quality measures 
were endorsed by the NQF, a voluntary consensus standard-setting organization 
established to standardize health care quality measurement and reporting. In addition, 
this starter set is a subset of measures currently collected for The Joint Commission as 
part of its hospital inpatient certification program. CMS chose these 10 quality 
measures to collect data that would: (1) provide useful and valid information about 
hospital quality to the public; (2) provide hospitals with a sense of predictability 
about public reporting expectations; (3) begin to standardize data and data collection 
mechanisms; and (4) foster hospital quality improvement. 
 
Hospitals submit quality data through the secure portion of the QualityNet Web site 
(formerly known as QualityNet Exchange) (www.QualityNet.org). Data from this 
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initiative are used to populate the Hospital Compare Website (see discussion in 
Section IV.B below). 
 
Hospitals that did not submit data received a reduction of 0.4 percentage points to 
their update percentage increase (also known as the market basket update) for each of 
FYs 2005 through 2007, establishing an incentive for Inpatient Proposed Payment 
System (IPPS) hospitals to submit data on the specified 10 quality measures. The 
reduction to the update has subsequently increased from 0.4 to 2.0 percentage points 
for FY 2007 and beyond. For FY 2008, CMS required that hospitals submit data 
regarding 27 quality measures. The quality data collected includes a number of 
infection-related measures and encompasses the following conditions: acute 
myocardial infarction, heart failure, pneumonia, surgical care improvement, 30-day 
mortality rates for acute myocardial infarction and heart failure patients, and patients’ 
experience of care through the HCAHPS patient survey. 
 
CMS will collect a total of 42 quality measures for FY 2010, including: (1) Nine 
CMS-calculated AHRQ Patient Safety Indicators (PSIs) and Inpatient Quality 
Indicators (IQIs) that have been endorsed by the NQF; (2) another NQF endorsed 
measure, Participation in a Systematic Database for Cardiac Surgery; and (3) a heart 
failure readmission measure. 
 
Specific infection-related measures include: 
 
 Timing of receipt of initial antibiotic following hospital arrival 
 Blood culture performed before first antibiotic received in hospital 
 Appropriate initial antibiotic selection 
 Prophylactic antibiotic received within one hour prior to surgical incision 
 Prophylactic antibiotics discontinued within 24 hours after surgery end time 
 Surgical Care Improvement Project (SCIP) Infection 2: Prophylactic antibiotic 
selection for surgical patients 
 SCIP Infection 4: Cardiac surgery patients with controlled 6AM postoperative 
serum glucose 
 SCIP Infection 6: Surgery patients with appropriate hair removal 
 
CMS anticipates adopting additional readmission measures as discussed in the FY 
2009 IPPS final rule, pending endorsement by the NQF. 
 
The maintenance of measure specifications occurs through publication of the 
Specifications Manual. Thus, measure selection occurs through the rulemaking 
process; whereas the maintenance of the technical specifications for the selected 
measures occurs through a sub-regulatory process so as to best maintain the 
specifications consistent with current science and consensus. The data submission 
requirements, Specifications Manual, and submission deadlines are posted on the 
QualityNet web site at www.QualityNet.org. 
 
D. Demonstration Projects 
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The Medicare Program has a long and successful history of developing program 
initiatives through its demonstration authority. At any given time, CMS has over 
three-dozen demonstrations in its portfolio, including demonstrations under 
development, demonstrations in operation, and demonstrations that are in a close-out 
phase. The development and implementation of these demonstrations frequently 
provide the agency practical lessons on policy tradeoffs and objectives, details related 
to operations of a specific pilot program, and unanticipated issues related to how to 
recruit and engage demonstration participants. 
 
In addition to these practical design and implementation issues, formal evaluations 
play a critical part of any demonstration. CMS’ Office of Research, Development, 
and Implementation conducts full evaluations of each demonstration project with help 
from experts from the research community. Evaluations are carefully developed, 
often using randomly-assigned control groups and other sophisticated evaluation 
techniques, to report the results of the demonstrations to CMS and other executive 
branch leadership, the Congress, and the public. 
 
CMS currently has several demonstration projects that are designed to test methods to 
improve the value of healthcare. One of the most important of these is the Premier 
Hospital Quality Incentive Demonstration, which includes 250 hospitals in 38 states 
in collaboration with Premier, Inc., which operates a large quality measurement and 
improvement operation. That demonstration started in October 2003, and has 
documented substantial improvements in the quality of inpatient care. The 
demonstration is measuring and providing bonus incentives for improving quality of 
care in five clinical areas: acute myocardial infarction, pneumonia, heart failure, 
coronary artery bypass graft, and hip and knee replacement. In the initial three years 
of operations, the demonstration hospitals have improved their quality of care in five 
clinical areas by an average of 16 percentage points. 
 
CMS has extended the demonstration for a second three-year period. CMS added new 
quality measures for testing, including all of the Surgical Care Improvement Project 
(SCIP) measures. These measures have just recently been added to the demonstration, 
so it is too early to determine the extent to which these new measures have shown 
improvement. 
  
In developing demonstrations, CMS uses the most recent available quality measures 
wherever applicable, including the SCIP measures, which are included in the two 
related gainsharing demonstrations. These demonstrations are designed to study 
whether incentives for collaborative arrangements between hospitals and physicians 
can improve the quality and efficiency of care provided to Medicare beneficiaries. 
The demonstrations are intended to provide for parallel incentives for hospitals and 
physicians, thus improving coordination and quality. Efficiencies will be measured in 
internal hospital costs, and if the hospitals are successful in reducing their costs, they 
may share savings with physicians and with clinical staff. Examples of greater 
efficiencies include providing diagnoses faster and thus reducing length of stay, 
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improving the turnaround in operating rooms, reducing the use of redundant tests, and 
the use of innovative products to improve treatment efficiency. CMS is carefully 
tracking quality of care in participating hospitals to assure that the demonstration 
results in improved care, and not in any reduced quality. Among the measures of 
quality are SCIP measures including the use of prophylactic antibiotics before 
surgical incisions, the proper selection of antibiotics, proper surgical preparation to 
avoid infections, and discontinuation of the antibiotics on schedule to reduce 
antibiotic resistant bacteria strains. 
 
The SCIP measures are also included in a key demonstration that is intended to 
improve inpatient quality of care, the Acute Care Episode (ACE) Demonstration. In 
this demonstration, scheduled for implementation in early 2009, Medicare will pay up 
to 15 hospitals in Texas, Oklahoma, Colorado, and New Mexico a “global fee” for 
cardiac and orthopedic procedures. The global fee is a bundled payment for both 
hospital and physician costs, including the surgeon, any consultants, radiologists, 
anesthesiologists, or other physicians included in the care of the patient. 
 
The participating hospitals and physicians will be permitted to use gain-sharing to 
improve incentives for collaboration. This demonstration is intended to improve 
internal hospital cost efficiency and quality of care, reduce costs for Medicare, and 
improve transparency of information for beneficiaries. Quality will be measured 
through a series of reported process and outcome measures, including several that 
focus on surgical infections such as selection and administration of antibiotics and 
deep sternal wound infection rate. 
 
Thus, in three important Medicare demonstrations that involve inpatient costs and 
efficiency, CMS has measured the quality of care using available quality measures, 
and that these measures will be monitored on a regular basis to track progress toward 
improving quality. If any demonstration hospital were found to be unable to maintain 
high levels of quality, that participating hospital could be removed from the 
applicable demonstration. The measurement and evaluation of hospital-acquired 
infections are an important part of this evaluation, and the Medicare demonstrations 
program will continue to include HAI measures, as they are developed, standardized, 
and available for use in the demonstration projects. 
 
E. Hospital Value-Based Purchasing Plan Report to Congress 
 
Introduction 
On November 21, 2007, CMS submitted a Report to Congress: Plan to Implement a 
Medicare Hospital Value-Based Purchasing Program (the Plan).3 The Plan would 
build on the current hospital pay-for-reporting program discussed above and 
establishes performance-based Medicare hospital payment. Under value-based 
purchasing (VBP), a portion of hospital payment would be contingent on actual 
performance, rather than simply on a hospital’s reporting of measurement data. The 
VBP performance measures would include infection rates. 
                                                 
3 www.cms.hhs.gov/AcuteInpatientPPS/downloads/HospitalVBPPlanRTCFINALSUBMITTED2007.pdf 
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Hospital VBP would provide powerful incentives – both financial and non-financial – 
for discouraging hospital-associated infections. Payments to higher performing 
hospitals would be larger than those for lower performing hospitals, providing 
financial incentives to drive improvement. Public reporting of performance on 
Medicare’s Hospital Compare website, (discussed below in Section IV) would 
provide non-financial incentives to encourage hospital performance improvement. 
 
Extensive public input was sought during each phase of plan development. Two 
Listening Sessions to receive individual input from organizations and individuals 
were held: the first to discuss the key issues in hospital performance-based payment 
and a second to discuss design options for the Plan. The Listening Sessions elicited 
over 100 comments. Comments were also sought during FY 2007, FY 2008, and FY 
2009 IPPS rulemaking. In addition, on several occasions, CMS leaders met with 
leaders from national hospital organizations to discuss issues related to Plan 
development. 
 
Hospital VBP Performance Assessment Model and Incentive Payments 
The performance assessment model is the methodology that would be used for 
scoring hospital performance on specific measures. Those aggregate scores would 
then be used to determine an incentive payment. The model evaluates a hospital’s 
performance on each measure based on the highest of either an attainment score or an 
improvement score. The improvement score would be determined by comparing the 
hospital’s current score with its baseline performance. 
 
A hospital’s performance on individual measures would be summed within each 
measurement domain – such as process of care, outcomes, or patient experience – and 
then the domains would be weighted and summed to yield the hospital’s total 
performance score. Using an exchange function, the hospital’s total performance 
score would be translated into an incentive payment. The source of the incentive 
payment would be a percentage of the hospital’s base operating DRG payments. 
Essentially, hospitals would have to earn back a portion of their Medicare payments 
by performing at a high level or improving their performance. 
 
Hospital VBP Measures 
Measures are the foundation of performance-based payment. To qualify for the 
incentive payment under the Plan, a hospital must report on all measures relevant to 
its service mix. Measures of various aspects of healthcare quality, such as patient 
safety, process of care, outcomes, patient experience, efficiency, and care 
coordination, would be added over time. A subset of the current hospital pay-for-
reporting measures would be used for initial implementation, including the current 
infectious-condition measures related to pneumonia and surgical infection prevention. 
As measures related to infectious conditions emerge from development and testing, 
they would be adopted for the VBP financial incentives and public reporting. 
 
Other Issues in the Hospital VBP Plan 
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The Hospital VBP Plan addresses a number of other issues related to the design and 
implementation of hospital performance-based payment. The current infrastructure 
for reporting hospital data would be improved through streamlining the submission 
process, allowing resubmissions, improving feedback reports, enhancing user support, 
and strengthening data validation. The Hospital Compare website could continue to 
serve as the platform for public display of performance results. Given the relative 
newness of performance-based payment, mechanisms for real-time monitoring and 
in-depth evaluation would be necessary for timely corrective action of unintended 
consequences and future enhancements. 
 
Enhancements and Future Issues 
CMS continues to refine the Hospital VBP Plan and to test the financial impact that 
the Plan would have on various types of hospitals if it were implemented. Preliminary 
tests show that the Plan would reward hospitals that achieve high levels of attainment 
or improvement, without unintended re-distributional effects. 
 
In implementing the Hospital VBP Plan, the measures for the financial incentive and 
public reporting would continue to evolve. A patient safety domain of measurement 
could be expanded over time to include measures addressing the priority infections 
identified. 
 
F. Recommendations and Action Plan 
 
CMS currently has the statutory authority to adjust hospital MS-DRG payments for 
selected conditions under the HAC payment provision. CMS has selected catheter-
associated urinary tract infection, vascular-catheter associated infection, and certain 
surgical site infections for non-payment under the HAC provision when those 
infections are acquired during hospitalization. 
 
Other infections, like ventilator-associated infections, methicillin-resistant 
Staphylococcus aureus (MRSA), Clostridium difficile, and other surgical site 
infections may be reconsidered as candidates for the HAC payment policy during 
future rounds of rulemaking; however, the ability to select additional conditions will 
depend on the development of evidence-based guidelines and on published literature 
supporting the conclusion that when the guidelines are followed, the conditions can 
be considered reasonably preventable. 
 
CMS also currently has the statutory authority to collect and publicly report hospital 
quality data under the RHQDAPU program. The RHQDAPU program measures 
compliance with an increasing number of infection prevention and control best 
practices, including measures developed by the Surgical Care Improvement Project. 
 
Adoption of additional measures occurs through rulemaking, which occurs annually 
with a proposed rule published in the Federal Register in the spring and a final rule 
published by August. 
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CMS has used the experience gained through implementing the HAC payment 
provision, through the RHQDAPU measurement and public reporting program, and 
through the various performance-based payment demonstration projects, to inform the 
development of the Hospital VBP Plan. CMS believes that the Hospital VBP Plan, if 
the agency had that statutory authority to implement, would be a more sophisticated 
approach to value-based purchasing than the current HAC and pay-for-reporting 
approaches. Risk-adjusted rates of infection prevention interventions and outcomes 
over time for infections like ventilator-associated pneumonia, MRSA, or C. difficile 
could be included to enhance a patient safety domain of measurement, which would 
count toward determination of a hospital’s VBP incentive payment for all DRGs. 
 
Thus, the infection prevention and outcomes measures in the patient safety domain 
could become a subset of the “rollup measure” or total performance score of the 
hospital VBP performance assessment model. Scores for the individual infection 
prevention and outcomes measures, for aggregated infection measures, and for the 
patient safety domain could be posted on the Hospital Compare website, along with 
the scores for the other domains and the total performance score, and could serve as 
one type of “scorecard” for infection prevention and outcomes. 
 
Recommendations on how the Hospital VBP Plan methodology could incorporate 
measures of infection prevention and outcomes: 
 
 Individual measures of infection prevention and outcomes, specified elsewhere in 
this report, could be scored for hospitals as part of performance assessment. 
 
 Individual infection measure scores could be aggregated into a rollup infection 
measure for hospitals. 
 
 Individual infection measure scores or a rollup infection measure could be 
aggregated into a roll up patient safety domain, which could be included in 
hospitals’ total performance scores. Thus, hospitals’ financial incentives would 
depend, in part, on their performance on measures of infection prevention and 
outcomes. 
 
 Scores for individual measures, roll up infection measures, and the roll up patient 
safety domain could be reported on Hospital Compare as an infection scorecard 
for hospitals. 
 
However, even if the Hospital VBP Plan were implemented, elements of the HAC 
provision and the RHQDAPU program would ideally be retained to serve specific 
purposes. For example, the HAC payment provision could be better suited for 
conditions with a very low incidence that cannot be accurately and reliably measured 
by rates, and the RHQDAPU program’s pay-for-reporting approach could be useful 
for collecting data on measures that are being tested for VBP or that are topped out 
and no longer provide meaningful differentiation in performance for VBP payment 
incentives. 
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The President’s FY 2009 Budget proposed the Hospital VBP Plan as a way to 
enhance the quality and value of Medicare services. In the interim, CMS will 
continue to consider candidate HACs through rulemaking and will pursue evaluation 
of promising value-based purchasing strategies through demonstration projects. 
 
 




Transparency is a broad-scale initiative intended to equip consumers with quality of 
care information to make informed decisions about their health care, while 
encouraging institutions and clinicians to improve the quality of care provided to all 
patients. Transparency in healthcare facilitates improvement of performance, 
efficiency, and quality by providing facilities and physicians with the additional 
information necessary for benchmarking. 
 
Public reporting enhances accountability in healthcare by increasing the transparency 
of quality data. Public reporting is designed to create both “indirect” financial and 
non-financial incentives to improve quality of care. Indirect financial incentives result 
when public reporting drives patients’ choices and, therefore, market share. Non-
financial incentives include publicizing performance, reputation, competition, 
motivation, accountability, and public recognition. Providing reliable quality and cost 
information empowers not only patients’ choices, but also the choices of stakeholders 
within local and regional communities, as well as nationally. Professionals are more 
likely to want to join the staffs of high performing hospitals. Choice leads to 
incentives at all levels and motivates the entire system; improvements take place as 
providers compete. 
 
B. Hospital Compare 
 
Hospital Compare (www.hospitalcompare.hhs.gov) is a consumer-oriented website 
that provides information on how well hospitals provide care to their patients with 
certain medical conditions, including care related to the prevention of infections. 
Hospital Compare publicly reports hospital performance data in a consistent, unified 
manner to ensure public availability of credible information about the care delivered 
in the nation's hospitals. 
 
The effort to publicly report various processes of care and outcome measures furthers 
the goal to improve the quality and transparency of hospital care by giving the public 
and healthcare professionals better access to important hospital data. These quality 
measures are meant to be one way to see how well a hospital is caring for its patients. 
 
By making this information available, CMS is meeting two of the Secretary’ s four 
cornerstones for Value-Driven Health Care – to measure and publish quality and price 
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information. Hospital Compare allows consumers to see how hospitals are delivering 
care to their patients through nationally standardized process of care and outcome 
measures and cost information for individual hospitals. This information helps 
educate consumers who are selecting a hospital. 
 
CMS launched the Hospital Compare tool on March 31, 2005. The measures 
currently reported on Hospital Compare include 10 starter measures and additional 
measures that many hospitals also voluntarily report to receive their full payment 
updates (see Appendix F). These measures represent agreement among CMS, the 
hospital industry, and public sector stakeholders such as The Joint Commission, NQF, 
and AHRQ. A number of the measures are related to infections: there are three 
measures related to the prevention of surgical infections, seven measures related to 
pneumonia care, and one measure related to pneumonia outcomes. 
 
Recently, ten measures from a standardized survey of patient perspectives of their 
hospital care, known as Hospital Consumer Assessment of Healthcare Providers and 
Systems (HCAHPS), have also been added to the Hospital Compare site. Public 
reporting of standardized measures on patients’ perspectives of the quality of hospital 
care encourages consumers and their physicians to discuss and make more informed 
decisions on how to get the best hospital care, as well as increases the public 
accountability of hospitals. 
 
The transparency provided by the Hospital Compare tool provides incentives for the 
entire hospital system. The tool is not only a valuable information resource for 
patients but also could enhance a hospital’s reputation in the community. A hospital 
performing well on the Hospital Compare site could provide a community reputation 
that attracts patients, physicians, and staff. 
 
C. Recommendations and Action Plan 
 
Each year, CMS will continue adding additional measures to Hospital Compare. 
These enhancements are part of HHS’ ongoing commitment to increased healthcare 
transparency. CMS is adding 13 new measures for the FY 2010 program, and retiring 
one existing measure. The inclusion of these additional measures will encourage 
hospitals to take steps to make care safer for patients. 
 
As measures are developed for hospital-associated infections related to catheter-
associated urinary tract infections, vascular-catheter associated infections, ventilator-
associated pneumonia, surgical site infections, methicillin-resistant Staphylococcus 
aureus, and Clostridium difficile, they may be added to the Hospital Compare 
website. 
 
The addition of hospital-associated infection measures to Hospital Compare could 
increase awareness and educate consumers as well as continue to hold hospitals and 
other providers accountable for providing better more efficient care. 
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CMS has undertaken a number of other Medicare and Medicaid initiatives to combat 
healthcare-associated infections. Within the Medicare program, the Quality 
Improvement Organizations (QIOs) provide direct provider support for reducing 
infections. Medicare Part C is applying the Part A hospital-acquired conditions 
payment policy to Medicare Advantage organizations, which also have quality 
improvement program requirements that include the prevention and control of 
infections. The Medicaid program is encouraging States to adopt the Medicare 
hospital-acquired conditions payment policy and is funding Transformation Grants 
that include addressing central line infections for premature infants in the Neonatal 
Intensive Care Unit (NICU). 
 
B. Quality Improvement Organizations 
 
Introduction 
The statutory mission of the Quality Improvement Organization (QIO) program is to 
improve the effectiveness, efficiency, economy, and quality of services delivered to 
Medicare beneficiaries. The QIO Program is a network of organizations staffed with 
physicians, nurses, technicians, and statisticians – experts in healthcare quality – with 
each QIO responsible for a U.S. state, territory, or the District of Columbia. Each of 
the 53 QIOs is governed by a performance-based cost reimbursement contract. The 
current contract, (the 9th Scope of Work (SOW), which continues for three years 
beginning August 2008) focuses on four themes: Beneficiary Protection, Care 
Transitions, Patient Safety, and Prevention. There are also three cross-cutting themes: 
Reducing Health Care Disparities, Promoting Use of Health Information Technology, 
and Value-Driven Health Care and a comprehensive set of tasks, roles and 
responsibilities, progress measures, and an evaluation design. 
 
The following discussion expands on the Patient Safety and Prevention themes, which 
are more relevant to the healthcare-associated infections focus of this report. 
 
Patient Safety 
Patient Safety efforts will reduce patient harm using proven interventions in areas 
with a record of QIO success in helping to improve safety. This work will define 
improvement in patient safety as the reduction or elimination of patient harm that is 
more likely a result of the patient’s interaction with the healthcare system than an 
attendant disease process. Work toward these goals will by definition increase the 
value of healthcare services as it produces higher quality care for Medicare 
beneficiaries. 
 
QIO activities for the Patient Safety Theme will focus on five topics: improving 
inpatient surgical safety, heart failure, reducing rates of nosocomial MRSA 
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infections, improving drug safety, and reducing rates of pressure ulcers and physical 
restraints in nursing homes as well as pressure ulcers in hospitals. Additionally, 
nursing homes that have difficulty meeting the CMS survey and certification 
requirements will be given the opportunity to work with QIOs to assess the areas for 
improvement and to work on their pressure ulcer and physical restraint rates. QIOs 
will work with providers to achieve the following: 23,610 fewer restraints, 43,303 
fewer patients with pressure ulcers in nursing homes and hospitals, 7,875 fewer 
MRSA infections, and 14,252 fewer postoperative deaths due to surgical site 
infection, venous thromboembolic events, or perioperative myocardial infarction. 
 
In CMS’ efforts to improve quality and avoid unnecessary costs to the Medicare Trust 
Fund, the Office of Clinical Standards and Quality (OCSQ), as part of the QIO 9th 
SOW’s Patient Safety Theme, has formed an interagency collaboration with CDC and 
AHRQ to combat hospital-acquired MRSA. Over the past several decades, the 
incidence of MRSA infections has grown exponentially. In 1974, MRSA infections 
accounted for only two percent of the total number of staphylococcus infections; in 
1995 it was 22%; in 2004 it was 63%. This rate comes with a mean per patient cost of 
$35,367 that is directly attributable to MRSA infections. 
 
The new 9th SOW contract, which began on August 1, 2008, creates an opportunity 
for hospitals to choose to report on MRSA under the CDC’s NHSN Multidrug-
Resistant Organism (MDRO) Module and to work with QIOs to reduce infection and 
transmission rates attributable to MRSA. CDC oversees the NHSN and will soon be 
launching the MDRO Module, which tracks MRSA infections. All hospitals are 
encouraged to consider reporting through the MDRO module. Hospitals choosing to 
participate in the MDRO module will undergo on-line training provided by CDC for 
the NHSN and the MDRO Module. Hospitals working with the QIOs will receive 
additional training based on proven effective practices for reducing healthcare-
associated MRSA infections and TeamSTEPPS. TeamSTEPPS is a teamwork system 
which offers a powerful solution to improving collaboration and communications 
within institutions. Teamwork has been found to be one of the key initiatives within 
patient safety that can transform the culture within healthcare. 
 
Prevention 
Prevention efforts will emphasize evidence-based and cost-effective care proven to 
prevent and/or slow the progression of disease. Work toward these goals will affect 
healthcare programs, products, policies, practices, community norms, and linkages 
and will produce higher quality of care for Medicare beneficiaries and significant cost 
savings. Over time, as disease is mitigated and its progression slowed through 
preventive measures such as early testing, immunization, and effective and timely 
intervention, the nation will see a healthier Medicare population emerge. This 
downstream impact will be most evident in the reduction of chronic kidney disease 
(CKD) and decrease in the rate of progression to kidney failure. 
 
C. Medicare Advantage Efforts 
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New Reporting Requirements for Medicare Advantage Organizations 
As part of the proposed Medicare Part C reporting requirements effective January 1, 
2009, CMS will collect a set of measures that involve hospital-acquired conditions. 
Some of these measures involve infections, including: vascular catheter-associated 
infection; catheter-associated urinary tract infection (UTI); surgical site infection, 
mediastinitis, after coronary artery bypass graft (CABG); surgical site infection 
following certain orthopedic procedures; and surgical site infection following 
bariatric surgery for obesity. These data will be used in developing and reporting 
performance metrics for Medicare Advantage (MA) organizations. 
 
CMS will be issuing guidance to MA consistent with original Medicare rules 
effective October 1, 2008 to not cover specified preventable medical errors that occur 
at non-contracting hospitals (see discussion in Section III.B above). CMS will also be 
updating the "MA Payment Guide for Out of Network Payments" to reflect this 
information for all MA plans. 
 
Medicare Advantage Quality of Care Requirements 
 
The MA quality framework, including quality improvement programs (QIPs), are 
described in the MA regulations, which currently require MA coordinated care plans 
to: 
 
1) Have QIPs. 
2) Initiate annual QI projects and report results to CMS on these projects when 
they submit materials for their routine CMS audits. 
3) Have a chronic care improvement program. 
4) Report on annual activity of their Chronic Care Improvement Program when 
they submit materials for their routine CMS audits; and 
5) Report standardized performance measures specified by CMS annually. These 
standardized performance measures include: HEDIS, CAHPS, and HOS. 
HEDIS covers measures related to effectiveness of care, access/availability of 
care, and use of services; CAHPS measures experiences with the care received 
through the health plan; and HOS measures changes in physical and mental 
health status. 
 
Under the MA provider selection and credentialing requirements, MA plans are 
required to contract with providers who meet the credentialing requirements specified 
in the MA regulations. Included is a requirement that providers must be State licensed 
and in compliance with all applicable state and federal requirements. 
 
Under the recent Medicare Improvements for Patients and Providers Act of 2008 
(MIPPA), beginning in 2011, each MA Private Fee-for-Service (PFFS) and Medicare 
Savings Account (MSA) plan must have an ongoing QIP that meets the regulatory 
requirements. CMS is currently developing regulations to implement these new 
MIPAA quality requirements for PFFS and MSA plans. For 2010, MSA and PFFS 
plan QI reporting will only apply with respect to administrative claims data. 
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D. State Medicaid Program Efforts 
 
The implementation of Medicare’s hospital-acquired conditions (HACs) payment 
policy (see discussion in Section III.B above) left many State Medicaid Agencies 
wondering whether healthcare providers serving dually-eligible Medicaid and 
Medicare patients would simply attempt to pass through unpaid Medicare bills to 
Medicaid as a secondary payer. Such action would effectively shift costs to States 
and, even more seriously, undermine any deterrent effect that the Medicare HAC 
payment policy would otherwise have. 
 
Consequently, on July 31, 2008, CMS issued a State Medicaid Directors’ Letter 
(SMD). The SMD (#08-004) invited States to submit State Plan Amendments (SPAs) 
to CMS to conform State Medicaid payment policy to the Medicare HAC payment 
policy. The letter offered States the option to do nothing, to conform Medicaid 
payment policy to the Medicare HAC non-payment policy, or to establish a more 
ambitious “never events” policy that might add any of the 28 “never events” defined 
by the NQF or other health organization (e.g., CDC) to the Medicare HACs. Some of 
the “never events” are related to infections, like death or disability associated with the 
use of contaminated drugs, devices, or biologics; severe pressure ulcers; and burns.  
The letter encouraged States to consider the entire Medicaid population (not just dual 
eligibles) in formulating this State payment policy, to clearly link payment with 
performance. 
 
About 20 of the States had already expressed interest in a “never event” policy and 
most had expected to use all or some of the 28 NQF “never events” as the basis for 
their Medicaid payment policies. With the issuance of the new SMD, CMS expects 
that the majority of States will move to align their Medicaid payment policies with 
the Medicare HAC policy. Given that many of the HACs deal with hospital-acquired 
infections, this alignment of Medicare and Medicaid payment policy will send a 
strong, consistent message to hospitals that federal and state payers expect them to 
strengthen their infection control programs and prevent all avoidable hospital-
acquired infections. 
 
The Neonatal Outcomes Project is another Medicaid infection prevention project that 
involves the creation and testing of a Protocol for the Prevention and Handling of 
Premature Births. The project commenced in 2006 and, among other interventions, 
addresses proper infection control practices in the NICU. At this point, three states 
have been selected for CMS Transformation Grants to pilot certain of the 
interventions. These interventions are evidence-based and have been shown to be 
effective, and the Grants are intended to spread the promising practices into the wider 
neonatal community to reduce variability in outcomes and improve overall mortality 
and morbidity statistics for prematurity throughout the nation. 
 
Ohio, which has the first operational Transformation Grant, has as one of its two 
objectives the infection control intervention, which addresses central line infections in 
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the NICU. Central line infections are a significant issue in NICUs in Ohio and across 
the nation, but there is an established protocol to reduce these infections to a fraction 
of their present level. This protocol was first tested for adults by the Institute for 
Healthcare Improvement (IHI) in its successful 100,000 Lives campaign. 
Subsequently, the Perinatal Quality Improvement Panel of California modified the 
protocol for neonates and, in 2004, published its results (Wirtschafter, NeoReviews, 
2004). These results indicated that the neonatal protocol, when properly applied, 
reduced central line infections to less than half of the previous rate before use of the 
protocol. 
 
It is expected that the results of these Transformation Grants will demonstrate the 
effectiveness of these improved infection control techniques for premature infants in 
the NICU and justify a national effort to introduce these evidence-based methods into 





CMS, working with other HHS agencies and various national and local partners, has a 
number of initiatives and programs to regulate and track HAI infections; and compliance 
with these regulations and promotion of the quality based improvement practices used by 
CMS in concert with its partners, will improve the public’s health. Increasingly, these 
efforts also include more direct sources of information for providers and patients that 
should influence choices that help diminish and prevent healthcare-associated infections. 
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HHS Action Plan to Prevent Healthcare-Associated Infections: 





As noted in earlier sections, healthcare-associated infections (HAIs) are a significant 
cause of mortality and morbidity each year in the U.S. To address this important public 
health and patient safety issue, the Department of Health and Human Services (HHS) will 
encourage pro-active efforts on behalf of all facets of the healthcare system, as well as 
consumers, to take important preventive steps. 
 
To this end, HHS will engage in state of the art methods of communication with 
stakeholders that include providers, purchasers, professional associations, governmental 
agencies, academia, and the public to raise awareness to the key prevention actions 
outlined within the plan on or around January 2009. 
 
Communications methods using various channels of communications and state of the art 
best practices using risk communication and social marketing will include: 
 
1) Raising awareness to the importance of addressing HAIs; 
2) Empowering consumers with tools and knowledge to be effective patient 
advocates for prevention; 
3) Helping healthcare professionals focus their attention on preventive steps that will 
yield the greatest benefits; and 
4) Sharing the overall progress of the nation in reducing national rates of HAIs. 
 
 
II. Primary Objective of the Communications Campaign 
 
Reduce healthcare-associated infections by formulating goals and interim benchmarks 
that aim to: 
  
 Increase dissemination of key messages about practices to prevent healthcare-
associated infections to target audiences. 
 Increase knowledge and awareness of key prevention practices to reduce 




III. HHS Secretary’s Goal on the Prevention and Elimination of HAIs 
 
The HHS Secretary has issued a call to action to reduce healthcare-associated infections.  
To do this he has established a plan that the government, the healthcare industry, and 
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consumers can stand behind to achieve this common goal. Furthermore, HHS aims to 
empower consumers with information to help to prevent HAIs.    
 
The communication campaign will focus on these mutual goals and the primary 
objectives outlined above. Some details about the campaign are found below: 
 
A. Proposed Date 
January, 2009 HHS Action Plan Released  
 
B. Proposed Theme 
Reducing, preventing, and working towards the eventual elimination of the great 
majority of healthcare-associated infections 
 
C. Target Audiences Include 
 
1) Healthcare Provider Groups 
 CEO/ Management/Leadership in the Hospitals 
 Healthcare Workers – Practicing doctors, nurses, etc. 
 Infection Preventionists (IPs) – IPs set hospital policy and are responsible 
for taking the information to staff in service 
 Hospitalists 
 Allied Health Professionals  
 Janitorial and maintenance workers who could be at risk for acquiring an 
HAI 
 Quality Improvement Organizations (QIOs). (For additional information, 
see “Incentives and Oversight” The Centers for Medicare and Medicaid 
Services (CMS) has just launched a new three-year QIO contract cycle, 
whereby QIOs will be focusing on infection control in the hospital 
setting. Their particular focus will be on Methicillin-resistant 
Staphylococcus aureus (MRSA) prevention. {HHS plans to coordinate the 
communication messaging with the QIOs as part of their inpatient staph-
infection prevention/reduction efforts. As background, the QIOs are 
partnering with specific hospitals in each state, so their reach would be 
more towards providers than consumers. Each QIO will be able to devise 
localized methods for communication, in coordination with CMS/HHS’ 
National Patient Safety Initiative and this campaign.} 
 
2) Consumer Groups 
 Patients 
 Caregivers (Including family and friends) 
 Patient Advocacy Groups 
 
3) Public Health Community 
 Public health agencies and organizations at the local, state, regional, and 
federal levels 
 Graduate schools of public health 
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 Other professional and allied health schools 
 Public health laboratories and associations 
 
4) Academia 
 Healthcare institutions 
 Healthcare instructors 
 Curriculum developers 
 
 
IV. Partnership Development 
 
Recognizing that reducing HAIs nationally is a shared responsibility of government and 
the healthcare industry, HHS must develop a strong partnership network to amplify 
prevention messages, promote implementation of recommended practices, and monitor 
progress at the national, regional, and local level.  In addition, consumers can play an 
important role in advocating for their and other’s safe health care. Many of the outreach 
and messaging activities is currently happening within the various operating and/or staff 
divisions of HHS. As such, the key focus will be to coordinate and leverage existing 
agency efforts.   
 
Pivotal to the success of the HAI campaign strategy will be the ability to personalize 
prevention messages in a way that it can be embraced by all segments of society so as to 
bring about a shift in prevailing social norms. Some recommendations on the messaging 
strategy: 
 
 Messages should be tailored appropriately to the audiences that are being 
targeted (e.g., healthcare professionals and consumers), keeping unique 
populations and subgroups in mind. 
 The messaging should be focused and consistent. 
 The messaging should consider the impacts and/or benefits to the target 
audience, i.e., why they should care, and why it is important they have and 
use this information. 
 
A. Potential Partners 
 
Partners representing all sectors are encouraged to participate in the HHS Campaign.  
First tier partners will primarily be those organizations who have been active and/or 
have synergistic efforts currently underway with their constituencies. Partners should 
include professional associations for healthcare providers, large hospital systems, 
associations that deal with infection control and patient safety, health officials (public 
sector organizations), consumer groups, health care institutions, and other public 
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B. Benefits of Partnering with HHS 
 
Partner assistance and support will help the nation achieve and sustain long-term 
success in preventing and reducing HAIs. Partnering with HHS offers many benefits, 
including: 
 
 Public recognition as an HHS partner; 
 Scientific expertise of HHS; 
 Sharing information and resources with the broad representation of HHS 
Operating and Staff Divisions; 
 Use of HHS educational and promotional materials; 
 Use of HHS national media campaign products; 
 Improved health and welfare of all Americans; 
 Improved quality of patient care; and 
 Reduction of unnecessary healthcare costs. 
 
There are many opportunities for partners to get actively involved with the initiative 
campaign. Suggested recommended actions include: 
 
 Messages should be provided to healthcare consumers/patients. 
 HHS and its partners should display posters and other materials in high 
visibility areas. 
 It is important to distribute to healthcare providers detailing sheets 
reviewing appropriate prevention guidelines. 
 Local communities and partners should develop local level appropriate 
HAI prevention campaigns, including educational products. 
 HHS, in conjunction with its regional offices and partnering with state 
health agencies, should provide assistance to local level campaigns in 
producing educational materials or sponsoring events. 
 It will be critical to deliver presentations on prevention to interested 
parties. HHS and its partners should actively share information with local 




V. Messaging  
 
The messaging for the overall campaign should be appropriate to the level of the 
audience and use the principles of risk communication and social marketing. If used by 
HHS, all messages should have the appropriate level of agency clearance. 
Other messaging should be developed by HHS and be part of the public domain for 
shared used by professional groups and audiences. 
 
 
A. Top Ten Messages for Outreach Strategy 
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HHS along with its partners should disseminate the following priority messages: 
 
 Many healthcare-associated infections are preventable. 
 A systemic approach to reducing the transmission of disease can be more 
effective than disease-specific approaches. 
 Developing and supporting the conduct of basic and translational studies to 
address the gaps in the science in this field will allow generation of additional 
strategies that can be used to reduce the risks of HAI transmission. 
 It will take a strong partnership between federal and local/state governments 
and communities to truly help prevent HAIs. HHS is committed to this 
partnership and many of its agencies are and will be involved. 
 The education of best practices for providers and other healthcare personnel is 
critical to prevent HAIs. 
 Specific metrics and national targets have been developed by HHS in concert 
with national experts on controlling infections. 
 Educating patients on HAIs and how to prevent them will be a critical part of 
the national effort. 
 An informed media can help promote the education of the American public 
about the need to prevent HAIs and what HHS and its partners are doing. 
 Preventive steps to control and prevent HAIs are cost-effective and will save 
many lives and reduce disability for Americans. 
 The time to act on HAIs is now, and HHS and its partners are committed to 
working closely with providers, health systems, community leaders, and 
governments to help prevent HAIs. 
 
B. Top 5 Campaign Messages 
 
The HICPAC, in partnership with HHS, has developed the top five messages for a 
healthcare worker and consumer awareness campaign.  These messages are consistent 
with important areas of prevention focus currently identified for HAI.  Detailed 
examples of the following overarching messages can be found under Education and 
Training Tools at http://www.cdc.gov/ncidod/dhqp/index.html.  
 
1. Hand hygiene 
2. Healthcare personnel vaccination 
3. Patient vaccination 
4. Prompt removal of catheters and other devices 
5. Antimicrobial stewardship 
 
C. Promotional Activities 
 
The Department will organize national and regional activities to foster 
implementation of the Action Plan and educate partners about the Campaign’s key 
messages at different levels. HHS will also promote its message through the ten 
Regional Offices for distribution to states, territories, and communities in their 
jurisdictions. 
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1) National 
Initial efforts to educate and create partnerships at the national level include: 
 
 HHS participation in national conferences and meetings, 
 National Roundtable Discussions with key stakeholders, the media, and 
national organizations to discuss contributions and support for the Action 
Plan, 
 Dedicated website housing key prevention information (pending 
resources), and  
 The use of social networking sites, Web casts and blogs to disseminate 
information.  
 
2) Regional  
Educational stakeholder meetings plus additional training sessions for providers 
will be planned and hosted by HHS Regional Offices throughout the country and 
hosted by Regional Health Administrators. 
 
The purpose of these initial meetings should be to communicate to providers and 
consumer organizations, and local healthcare providers to garner and advance support 
for reducing HAIs across the country and will: 
 
 Share and promote the objectives of the Action Plan and campaign, 
 Assess any concerns regarding implementation of the plan and campaign, 
 Assess levels of acceptance, 
 Assess any additional support providers would like to receive, and, 
 Provide feedback on a media outreach campaign. 
 
As the effort advances towards implementation, Regional Health Administrators 
should plan to provide training sessions targeted towards healthcare providers and 
administrators regarding the recommendations outlined and expressed in the Action 
Plan. These training sessions will augment any existing prevention activities already 
occurring at the local level, which were not generated by the Action Plan. 
 
The training sessions will: 
 
 Garner further support in advancing prevention, and  
 Translate specific application of the guidelines into practical application. 
 
 
VI. HHS Assets to Coordinate External Outreach 
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These agency-specific efforts should share information on the HHS Action Plan, share 
updated prevention information with key audiences, and help improve coordination 
among the many partners. 
 
Various assets are available across the Department. A preliminary list of available 
resources for use in the near-term includes: 
 
A. Healthy People 2010 and Healthy People 2020 (in development).  
Healthy People 2010 provides a framework for prevention for the Nation. It is a 
statement of national health objectives designed to identify the most significant 
preventable threats to health and to establish national goals to reduce these threats.  
B. Newsletters and Listservs 
 
1) Agency for Healthcare Research and Quality (AHRQ) 
 Agency's Electronic Newsletter (over 31,000 subscribers): 
www.ahrq.gov/news/enewsix.htm 
 Agency's Patient Safety and Health Information Technology E-Newsletter 
(over 15,000 subscribers): www.ahrq.gov/news/ptsnews.htm 
 Agency's "Research Activities" newsletter (27,000 subscribers): 
www.ahrq.gov/research/resact.htm 
 
2) Centers for Disease Control and Prevention (CDC) 
 Clinician Outreach and Communication Activity (COCA) Listserv with 
Newsletter: www.bt.cdc.gov/coca 
 CDC E-mail Blast to CDC Partners (newsletter): www.cdc.gov/Partners 
 Rapid Notification System (RNS): 
www2.cdc.gov/ncidod/hip/rns/hip_rns_subscribe.html 
 CDC E-cards: www2a.cdc.gov/eCards (Note: Personal e-cards can be sent 
to different audiences (consumers and healthcare providers) with a 
message about healthcare-associated infections.) 
 
3) Centers for Medicare and Medicaid Services (CMS) 
 Provider Partnership Listserv: Representatives from 124 national provider 
associations sign up to this listserv after a face-to-face meeting with the 
Division Director for Division of Provider Information Planning and 
Development. 
 All Medicare FFS provider types listserv (123,104 subscribers) 
 Additional listservs that target the following groups/topics: Allied health, 
employers, quality, value based purchasing list (includes The Leapfrog 
Group and others), health plans, hospitals, cancer, consumer, disability, 
discharge planners, disease, long term care, pharmaceutical companies, 
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Websites that currently address issues related to or about healthcare-associated 
infections that will be utilized: 
 
1) Agency for Healthcare Research and Quality (AHRQ) 
 Notice on patient safety and medical errors site: 
www.ahrq.gov/qual/errorsix.htm 
 
2) Centers for Disease Control and Prevention (CDC) 
 HAI Website: www.cdc.gov/ncidod/dhqp/healthdis.html 
 Morbidity and Mortality Weekly Report (MMWR) Website: 
www.cdc.gov/mmwr/weekcvol.html (To reach health professionals and 
health departments, include a “Notice to Readers” about HAIs) 
 CDC Web Features: www.cdc.gov/Features/PediatricColdMeds (Could 
write a feature and link to other HHS sources of info on HAIs) 
 Emerging Infectious Diseases (EID) Journal: 
www.cdc.gov/ncidod/EID/announc.htm (Could post announcement and 
links to reports or meetings on the EID website) 
 
3) Centers for Medicare and Medicaid Services (CMS) 
 Technical information about Hospital Acquired Conditions and Present on 




1) Agency for Healthcare Research and Quality (AHRQ) 
 Radiocasts/podcasts via AHRQ's Healthcare411: 
http://healthcare411.ahrq.gov/ 
 
2) Centers for Disease Control and Prevention (CDC) 
 Website: www2a.cdc.gov/podcasts/player.asp?f=7953 (Can create a 
podcast and link to other HHS sources of info on HAIs) 
 
E. Meetings/Conference Calls/Conferences 
 
1) Centers for Disease Control and Prevention (CDC) 
 Clinician Outreach and Communication Activity (COCA): 
www.bt.cdc.gov/coca (Conference calls that offer free CME to 
participants) 
 Healthcare Infection Control Practices Advisory Committee (HICPAC): 
www.cdc.gov/ncidod/dhqp/hicpac.html (Liaisons representing American 
College of Occupational and Environmental Medicine, American Hospital 
Association, American Healthcare Association, Advisory Council for the 
Elimination of Tuberculosis, Association of Perioperative Registered 
Nurses, Association of Professionals of Infection Control and 
Epidemiology, Consumer’s Union, Council of State and Territorial 
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Epidemiologists, Joint Commission, and Society for Healthcare 
Epidemiology of America) 
 
F. Media Listservs 
 
HHS will utilize a Media listserv to email “news” updates to reporters, regionally and 
nationally, and will include usage of the following: 
 AHRQ's Media /Reporters listserv 
 CDC Division of Media Relations: www.cdc.gov/media/archives.htm 
(DMR has a broad listserv of reporters as well as list of reporters who 
cover CDC and some specific for HAIs) 
 Office of Public Health and Science (OPHS) 
 
G. HHS Products 
Operating Divisions, including AHRQ, CDC, and CMS, have already produced 
materials which should be added to the Website. 
 
 AHRQ: Table containing AHRQ products  
 CDC: Table containing CDC products 
 CMS: Two different fact sheets listed under CMS Website 
 
H. HHS Products in Development 
 
 Consumer brochure 
 Posters for healthcare providers 
 Buttons for healthcare providers 
 Provider fact sheet 
 “Top Ten Bill of Rights” laminated cards for consumers 
 HHS Website on HAI, hosting information, linking to products, materials, 
conferences etc. 
 CMS fact sheets which contain an overview description of Hospital 
Acquired Conditions and Present on Admission (currently being updated 
and should be available shortly) 
 
 
VII. General Timelines for Projected Late Winter/Early Spring 2010 Launch 
 
 Pre-Event Media Advisory/Press Release: Issue in advance of the event 
 Post-Event News Release: Issue news release summarizing the event after the 
event  
 Media Roundtables: To continue the momentum across the country and engage 
the media, consumers and other stakeholders 
 News Conference: To announce the launch of the media campaign  
 On-site Media Room/Media Avail: Depending on details of the event, establish 
on-the-ground media support (media room or media availabilities) 
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The Department is committed to disseminating the Action Plan widely and will be 
working with its Regional Offices and many partners in broadcasting state of the art 
messaging that will help prevent and eliminate (to the greatest extent possible) 
healthcare-associated infections. 
 
HHS will continue to focus its efforts on developing an effective strategy for building 
strong nationwide support for the plan to reduce the incidence of HAI. Utilizing a two 
tier, regional and national approach, the messages will be developed targeting both 
healthcare providers and consumer groups. 
 
Messages will be disseminated via HHS resources including list servs, websites, and 
conference calls, as well as through the vehicles of communication provided through the 
partnership organizations.  
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HHS Action Plan to Prevent Healthcare-Associated Infections: 
COORDINATION, EVALUATION, AND CONCLUSION 
 
 
Coordination of Efforts 
 
The success of a national healthcare-associated infection (HAI) prevention effort will 
require effective coordination within the Department of Health and Human Services 
(HHS) and between the Department and external stakeholders. A synchronized effort will 
involve consistent communication between all the agencies involved in the initiative. 
This enhanced communication will allow for problems to be approached in a more 
holistic fashion rather than in its disparate parts. Initiatives in existence or development 
within one agency can be identified, targeted, and leveraged to aid in the overall 
prevention of these infections. 
 
Various agencies within HHS currently fund efforts related to prevention, research, 
information technology infrastructure, communication, and incentives to prevent HAIs. 
However, there has been no official mechanism to lead and align these efforts in a 
cohesive manner, reduce duplication, and capitalize on potential synergies to increase 
overall impact. As specific examples of potential coordination, the Centers for Medicare 
and Medicaid Services (CMS) could plan to introduce incentives into the payment system 
and could coordinate research on the effects of implementing payment policies with the 
Agency for Healthcare Research and Quality (AHRQ) and/or Centers for Disease Control 
and Prevention (CDC) or research projects could be aligned between the National 
Institutes of Health (NIH), CDC, and AHRQ. 
 
The mechanism proposed to institutionalize this coordinated effort is the establishment of 
an Interagency Steering Committee or “Steering Committee for the Prevention of 
Healthcare-Associated Infections.” The formation of the Steering Committee will enable 
implementation of the Action Plan and provide a context for measuring progress in 
achieving the Action Plan’s goals. 
 
Effective partnership with other segments of the federal government and private sector 
stakeholders will be essential to the success of the initiative. The Steering Committee will 
seek to leverage the resources within and external to HHS to successfully implement the 
Action Plan. 
 
At a minimum, objectives of the Steering Committee will include: 
 
1) Coordination of efforts across prevention, research, information technology 
infrastructure, incentives and oversight, and public messaging and outreach to 
reduce HAIs nationwide. 
 
2) Establish criteria and develop a plan to evaluate the Department’s progress in 
reducing HAIs nationwide. As part of evaluating the effort, designate a set of 
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primary measures to track HAIs and formulate a plan to further develop these 
measures over time. 
 
3) Serve as a contact point to communicate to external stakeholders on this issue 
so the Department’s efforts are harmonized and linked to a broader national 
coalition. 
 
The following structure is proposed: 
 
1) The Steering Committee will be chaired by the Principal Deputy Assistant 
Secretary for Health. It will initially be comprised of at least one member 
from AHRQ, CDC, CMS, the Food and Drug Administration (FDA), NIH, the 
Office of the Assistant Secretary for Public Affairs (ASPA), the Office of the 
Assistant Secretary for Planning and Evaluation (ASPE), the Office of the 
National Coordinator for Health Information Technology (ONC), and the 
Office of Public Health and Science (OPHS). 
 
2) The Steering Committee will meet at least quarterly. 
 
3) The Steering Committee Chairmanship and membership will be reassessed 
annually starting in 2010. 
 
The Steering Committee may elect to form working groups to address specific topics or 
implement project plans as determined. The work of these groups will be overseen and 
coordinated by the Steering Committee. The working groups may be convened at any 





The proposed “Steering Committee for the Prevention of Healthcare-Associated 
Infections” will establish criteria and formulate a plan for evaluation of the national 
prevention effort. The evaluation criteria may include national measures of infection rates 
as well as assessment of specific programs and projects initiated by the Department and 
coordinated by the Steering Committee. 
 
Input from and partnership with external stakeholders will be valuable to the accurate 
measurement of the nation’s progress in preventing HAIs. Measures and measurement 
plans in use or development by other segments of the nation will be harmonized with 
those of the Steering Committee. 
 
The Steering Committee will evaluate progress towards the national prevention of these 
infections annually. Regular updates will be requested from Steering Committee 
members and key external stakeholders regarding current and planned activities related to 
HAI prevention. These inventories will be used for ongoing monitoring, coordination, 
and evaluation of efforts. Results from the regular assessments of the initiative will lead 
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The Department has a long and proud history in steadily and substantially improving the 
health and welfare of Americans. Despite this progress, HAIs continue to take a 
significant toll on human life. As shared in the introduction, it is estimated that there are 
1.7 million HAIs in hospitals each year, which result in approximately 99,000 deaths and 
an estimated $28 to $33 billion in additional healthcare costs. The good news is that 
many of these deaths can be prevented through increased awareness and implementation 
of recommended infection control practices. For these reasons, the prevention of HAIs is 
a top priority for the Department. 
 
The Steering Committee for the Prevention of HAIs focused its efforts on the 
development of an Action Plan. This endeavor provided an unprecedented opportunity to 
gather the various HHS Offices and Operating Divisions to bring the Department’s 
extensive resources to bear on this critical patient safety issue. In addition, the 
opportunity to collaborate with external stakeholders has helped us all achieve significant 
and sustainable success. The work is not complete, but will continue to require the 
concerted and focused effort of all involved, for the end result of helping to create a 
healthier America. 
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National 5-Year Prevention 
Target 
1. CLABSI 1 CLABSIs per 1,000 device 





CLABSIs per 1,000 device 
days by ICU and other 
locations below present 
NHSN 25th percentile by 
location type (75% reduction 
in SIR) 
2. CLABSI 2 Laboratory detected 




50% reduction in laboratory 
detected bacteremia per 
1,000 patient days 





50% reduction in CLABSIs 
per 100 patient months 





100% compliance with 
central line bundle (non-
emergent insertions) 
5. C diff 1 Case rate per patient days and 
administrative/discharge data 
for ICD9 coded Clostridium 





30% reduction in the case 
rate per patient days and 
administrative / discharge 




NOTE: Preventability of 
endemic CDI is unknown; 
therefore, the experts 
suggested that HHS revisit 
this target in 2 years as 
prevention research findings 
may become available 
6. C diff 2 Contact precautions NHSN MDRO 
module 
100% compliance with 
contact precautions 




100% compliance with 
appropriate hand hygiene 
practices 
8. CAUTI 1 Rate of BSI secondary to UTI / 
1,000 patient days 
NHSN 50-75% reduction in the rate 
of BSI secondary to UTI / 
1,000 patient days 
9. CAUTI 2 # of symptomatic UTI / 1,000 





25% reduction in the 
number of symptomatic UTI 
/ 1,000 urinary catheter days 
                                                 
1 Any source that would provide nationally representative hospital discharge coding (i.e., ICD9 or, in the future, ICD10) data, 
including such sources as the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project, the CDC 
National Center for Health Statistics or National Hospital Discharge Survey, and those in the Centers for Medicare and Medicaid 
Services (CMS). 
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[Number of UTIs (ICD9+not 
present on admission) / (# 







25% reduction in the 
[Number of UTIs (ICD9+not 
present on admission) / (# 
major surgery ICD9+ 
urinary catheter ICD9)]*100 
discharges2 
10. CAUTI 3 (Urinary catheter days / 
patient days)*100 
NHSN 50% reduction in (urinary 
catheter days / patient 
days)*100 
11. MRSA 1 Incidence rate (number per 
100,000 persons) of invasive 
MRSA infections  
CDC EIP/ABCs 50% reduction in incidence 
rate of all healthcare-
associated invasive MRSA 
infections 
12. MRSA 2 Incidence rate (number per 
1,000 patient days) of hospital-




50% reduction in incidence 
rate of hospital-onset MRSA 
bacteremia (hospital wide) 
13. MRSA 3 Number of hospitalizations 





Number of hospitalizations 
with non-present on admission 





25% reduction in 
hospitalizations with non-
present on admission MRSA 
not otherwise specified 
(NOS)/pneumonia/sepsis 
 
90% of facilities with fewer 
“hospitalizations” with non-
present on admission MRSA 
not otherwise specified 
(NOS)/pneumonia/sepsis 
than predicted (i.e. model 
prediction) 
14. SSI 1 Deep incision and organ space 
infection rates using NHSN 
definitions (SCIP procedures) 
NHSN Median deep incision and 
organ space infection rate 
for each procedure/risk 
group will be at or below the 
current NHSN 25th 
percentile 
15. SSI 2 Adherence to SCIP/NQF 
infection process measures 
(perioperative antibiotics, hair 
removal, postoperative glucose 
control, normothermia) 
CMS SCIP 95% adherence rates to each 
SCIP/NQF infection process 
measure 
16. VAP 1 VAP rate, ventilator utilization 
(vent days), intermediate 
outcome – duration of 
ventilation 
NHSN definitions Track performance, no 
national target 
17. VAP 2 VAP process bundle: 
Continuous assessment of head 
of bed elevation; Daily oral 
care and daily assessment of 




100% compliance with each 
metric in the VAP process 
bundle within 2 years 
 
                                                                                                                                                 
2 Zhan C, et.al. Medical Care (in press) 
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NQF Measures3 Compendium 
Measures4 
1. CLABSI 1 CLABSIs per 
1000 device 






































































with cleaning of 
catheter hubs and 
injection ports 
before they are 
accessed. 
4. Compliance 
with avoiding the 
femoral vein site 
for CVC insertion 
in adult patients. 












in the case rate 




for ICD9 coded 
 CDI rates should 
be calculated 





                                                 
3 NQF Endorsed Measures for Healthcare-Associated Infections (http://www.qualityforum.org/pdf/reports/HAI%20Report.pdf) 
4 SHEA/IDSA “Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals” 
(http://www.cdc.gov/ncidod/dhqp/HAI_shea_idsa.html) 
5 Any source that would provide nationally representative hospital discharge coding (i.e., ICD9 or, in the future, ICD10) data, 
including such sources as the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project, the CDC 
National Center for Health Statistics or National Hospital Discharge Survey, and those in the Centers for Medicare and Medicaid 
Services (CMS). 
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HHS revisit this 

















4. CAUTI 2 # of 
symptomatic 































catheter days  
 
25% reduction 




















by risk factors 
(age, sex, ward, 
indication, and 
catheter-days) 







CDC EIP/ABCs 50% reduction 
in incidence 

























group will be at 




and organ space 
infections as a 





                                                 
6 Zhan C, et.al. Medical Care (in press) 
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Appendix C – Current HHS HAI-Related Research Responsibilities (AHRQ, CDC, CMS, and NIH) 
 
 AHRQ CDC CMS NIH 
Basic Discovery  Biofilms, resistance 
mechanisms 
 Vaccines, biofilms, studies 
of pathogenesis (intramural 
and extramural) 
Surveillance At a population level, using 
hospital inpatient and 
outpatient administrative 
databases 
National Healthcare Safety 
Network (NHSN), Active 
Bacterial Core Surveillance, 
new measure development 
and validation, e-
surveillance, electronic 
medical record capture 
 Electronic healthcare 
epidemiology surveillance 
system currently being 





population risk associations) 
Outbreak response, 
molecular epidemiology, 
other epidemiologic studies 
(burden estimates, risk 
factors, etc.) 
 Intramural studies in a 
unique clinical research 
hospital setting 
Etiology  Identification of emerging 
pathogens through 
surveillance and outbreak 
response 
 Funding for clinical studies, 
basic studies characterizing 




 Prevention demonstration 
projects, intervention studies, 
investigation of novel/ 
innovative prevention 
strategies 






systems of care, institutions, 






Through quality reporting, 
payment incentives, and 
special Quality Improvement 
Organization (QIO) 
programs 
Clinical studies, including 
comparative trials 
(intramural and extramural) 
Guidelines Generate the evidence base 
for further guideline 
development 




guidelines and related 
guidance; Maintain 
consistent case definitions in 
guidelines and NHSN 
 Research contributions to 
inform Public Health Service 
guidelines, society-
sponsored guidelines, etc. 
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 AH RQ CDC CMS NIH 
Treatment 
 Comparative Effectiveness 
  
  
 Implementation  
 




systems of care, institutions, 
primary care networks 
 




through information from 




(intramural and extramural) 
Quality/Safety of 
Healthcare 
Patient Safety Organizations, 
measurement tools for 
baseline and evaluation and 
quality improvement, 
training, data collection 
NHSN as a system to track 
infections; Develop baseline 
through measurement, 
training, and data collection; 
NHSN as a quality 
improvement tool 
Through quality reporting, 
payment incentives, and 
special QIO programs 
Developed and implemented 
electronic occurrence 




improvement program at the 
NIH/Clinical Center 
Efficiency and Costs Improved quality and 
reduced costs, avoidable 
admissions and re-
admissions (HAIs) 
Cost estimate studies, assess 
impact, assess unintended 
consequences of prevention 
initiatives and policies 
related to HAI prevention 
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Top 5 Hospital Allegations for Complaints & Incidents, CY2005 to CY2008 
 
 
TOP 5 HOSPITAL  ALLEGATIONS FOR 
COMPLAINTS & INCIDENTS 
   
Ranking Allegation # Allegations 
   
 CY2008 to date (01012008-08182008) 
   
1 Quality of Care/Treatment 2426
2 Restrain/Seclusion - Death 2074
3 Resident/Patient/Client Rights 1205
4 Nursing Services 832
5 EMTALA 826
   
13 Infection Control 216
   
      
 CFY2007  
   
1 Quality of Care/Treatment 4103
2 Resident/Patient/Client Rights 2225
3 EMTALA 1346
4 Nursing Services 1157
5 Resident/Patient/Client Abuse 631
   
11 Infection Control 405
   
      
 CY2006  
   
1 Quality of Care/Treatment 3677
2 Resident/Patient/Client Rights 2101
3 EMTALA 1517
4 Nursing Services 1105
5 Resident/Patient/Client Abuse 608
   
12 Infection Control 314
   
      
 CY2005  
   
1 Quality of Care/Treatment 3872
2 Resident/Patient/Client Rights 3240
3 EMTALA 1483
4 Nursing Services 1139
5 Resident/Patient/Client Neglect 705
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12 Infection Control 384
   
   
Source:  QIES Workbench 8/21/2008; ACTS; Pennsylvania    
Complaints and incidents are combined for this report 
Note:  Includes data for the State of Pennsylvania    
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Hospital Acquired Conditions, Including Codes, Selected for October 1, 2008 
 
HAC CC/MCC  
(ICD-9-CM Codes) 
1.  Foreign Object Retained After Surgery  998.4 (CC)
998.7 (CC)
2.  Air Embolism 999.1 (MCC)
3.  Blood Incompatibility 999.6 (CC)
4.  Pressure Ulcer Stages III & IV 707.23 (MCC)
707.24 (MCC)
5.  Falls and Trauma: 
  - Fracture 
  - Dislocation 
  - Intracranial Injury 
  - Crushing Injury 
  - Burn 
  - Electric Shock 
 









6.  Catheter-Associated Urinary Tract Infection (UTI) 996.64 (CC)
Also excludes the following 











7.  Vascular Catheter-Associated Infection 999.31 (CC)





9a.  Surgical Site Infection, Mediastinitis Following 
Coronary Artery Bypass Graft (CABG) 
519.2 (MCC)
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HAC CC/MCC  
(ICD-9-CM Codes) 




And one of the following 
procedure codes:  81.01-81.08, 
81.23-81.24, 81.31-81.38, 
81.83, 81.85
9c.  Surgical Site Infection Following Bariatric 
Surgery for Obesity 
Principal Diagnosis – 278.01
998.59 (CC)
And one of the following 
procedure codes:  44.38, 44.39, 
or  44.95
10.  Deep Vein Thrombosis and Pulmonary Embolism 




And one of the following 
procedure codes: 00.85-00.87, 
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Hospital Compare Measures as of October 1, 2008  
 
Aspirin at Arrival  
Aspirin Prescribed at Discharge  
ACE Inhibitor or Angiotensin Receptor Blocker  
(ARB) for Left Ventricular Systolic Dysfunction  
Adult Smoking Cessation Advice/Counseling  
Beta-Blocker Prescribed at Discharge  
Beta-Blocker at Arrival  
Fibrinolytic Therapy Received within 30 Minutes of 
Hospital Arrival  
Primary Percutaneous Coronary Intervention (PCI) 
within 90 Minutes of Hospital Arrival  
Acute Myocardial Infarction 
(AMI) – Heart Attack  
AMI 30-day Mortality  
Discharge Instructions  
Evaluation of Left Ventricular Systolic Function  
ACE Inhibitor or Angiotensin Receptor Blocker  
(ARB) for Left Ventricular Systolic Dysfunction  
Adult Smoking Cessation Advice/Counseling  
Heart Failure (HF)  
HF 30-day Mortality  
Oxygenation Assessment  
Pneumococcal Vaccination  
Blood Culture Performed in the Emergency  
Department Prior to Initial Antibiotic Received in 
the Hospital  
Adult Smoking Cessation Advice/Counseling  
Initial Antibiotic Received within 6 Hours of  
Hospital Arrival  
Appropriate Initial Antibiotic Selection  
Influenza Vaccination  
Pneumonia (PN)  
PN 30-day Mortality  
Prophylactic Antibiotic Received One Hour Prior to 
Surgical Incision  
Prophylactic Antibiotic Selection for Surgical 
Patients  
Prophylactic Antibiotics Discontinued within 24 
Hours After Surgery End Time  
Surgical Care Improvement 
Project (SCIP)  
Surgery Patients with Recommended Venous 
Thromboembolism (VTE) Prophylaxis Ordered  
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Surgery Patients Who Received Recommended 
Venous Thromboembolism (VTE) Prophylaxis 
Within 24 Hours Prior to Surgery to 24 Hours After 
Surgery  
Communication with nurses  
Communication with doctors  
Responsiveness of hospital staff  
Pain management  
Communication about medicines  
Discharge information  
Cleanliness of hospital environment  
Quietness of hospital environment  
Overall rating of hospital  
Hospital Consumer Assessment of 
Healthcare Providers and  
Systems (HCAHPS)  
Willingness to recommend hospital  
Use of relievers for inpatient asthma  Children’s Asthma Care  
Use of systemic corticosteroids for inpatient asthma  
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Appendix G – Stakeholder Feedback and Revisions to the Original Draft Metrics and Targets 
 
Comments on the initial draft metrics published as part of the HHS Action Plan to Prevent Healthcare-Associated Infections in January 2009 
were solicited and reviewed. While comments ranged from high level strategic observations to technical measurement details, overall 
commenters encouraged established baselines, both at the national and local level, use of standardized definitions and methods, engagement 
with the National Quality Forum (NQF), raised concerns regarding the use of national targets for payment or accreditation purposes and of the 
validity of proposed measures, and would like to have both a target rate and a percent reduction for all metrics. Commenters varied on the 
aggressiveness of the national targets, with some expressing concern that these targets were overly ambitious while others were concerned 
that the targets were not ambitious enough. Furthermore, commenters emphasized the need for flexibility in the metrics, to accommodate 
advances in electronic reporting and information technology and for advances in prevention of healthcare-associated infections (HAIs), in 
particular ventilator-associated pneumonia. Finally, some commenters expressed concern that the proposed process measures included in the 
HAI metrics do not have demonstrated correlation with reduced HAIs. 
 
To address comments received on the Action Plan Metrics and Targets, proposed metrics have been updated to include the proposed source of 
metric data, baselines, and which agency would coordinate the measure. To respond to the requests for percentage reduction in HAIs in 
addition to HAI rates, a new type of metric, the standardized infection ratio (SIR), is being proposed. Although metrics using infection rates 
are NQF endorsed, the Department of Health and Human Services (HHS) staff will work with NQF to address future consideration by NQF 
of the SIR for endorsement. Below is a detailed technical description of the SIR. 
 
To address concerns regarding validity, HHS is providing funding, utilizing Recovery Act of 2009 funds, to the Centers for Disease Control 
and Prevention (CDC) to support states in validating National Healthcare Safety Network (NHSN)-related measures and to support reporting 
on HHS metrics through NHSN. Also, most of the reporting metrics outlined here have already been endorsed by NQF and for population-
based national measures on methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. Work to develop hospital level 
measures will be conducted in the next year utilizing support to CDC through funds available in the Recovery Act. 
 
Finally, to address concerns regarding flexibility in accommodating new measures, reviewing progress on current measures, and 
incorporating new sources of measure data (e.g., electronic data, administrative data) or new measures, HHS and its constituent agencies will 
commit to an annual review and update of the HHS Action Plan Targets and Metrics. The process for annual review and update will include 
representatives from appropriate federal agencies, state and local health agencies, scientific and clinical experts on HAI prevention and 
performance measurement, healthcare providers, professional organizations, accreditation organizations, consumer groups, and other key 
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National 5-Year Prevention Target Coordinator of 
Measurement 
System 
Is the metric 
NQF 
endorsed? 
1. CLABSI 1 CLABSIs per 1,000 
device days by ICU 
and other locations 








At least 50% reduction in central line-associated 
bloodstream infections in ICU and ward-located 
patients 
CDC Yes* 
2. CLIP 1 
(formerly 
CLABSI 4) 














100% adherence with central line bundle  CDC Yes† 
3a. C diff 1 Case rate per patient 
days; administrative/ 
discharge data for 
ICD-9 CM coded C. 
difficile Infections 
Hospitalizations  










At least 30% reduction in hospitalizations with 
C. difficile per 1,000 patient discharges  
  
AHRQ or CDC No 
3b. C diff 2 
(new) 





Reduce the facility-wide healthcare facility-
onset C. difficile LabID event SIR by at least 
30% from baseline 
CDC No 
4. CAUTI 2 # of symptomatic UTI 
per 1,000 urinary 
catheter days  





2009 for ICUs and 
other locations  
2009 for other 
hospital units 
(proposed 2009, in 
consultation with 
states) 
Reduce the CAUTI SIR by at least 25% from 
baseline in ICU and other locations 
  
CDC Yes* 
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5a. MRSA 1 Incidence rate 
(number per 100,000 





CDC EIP/ABCs 2007-2008 
 (for non-EIP 
states, MRSA 




At least a 50% reduction in incidence of 
healthcare-associated invasive MRSA infections
CDC No 
5b. MRSA 2 
(new) 





2009-2010 Reduce the facility-wide healthcare facility-
onset MRSA bacteremia LabID event SIR by at 
least 25% from baseline  
CDC No 
6. SSI 1 Deep incision and 
organ space infection 
rates using NHSN 
definitions (SCIP 
procedures) 









Reduce the admission and readmission SSI§ SIR 
by at least 25% from baseline  
 
CDC Yes¶ 









CMS SCIP To be determined 
by CMS 
At least 95% adherence to process measures to 
prevent surgical site infections 
CMS Yes 
 
* NHSN SIR metric is derived from NQF-endorsed metric data 
† NHSN does not collect information on daily review of line necessity, which is part of the NQF 
‡ LabID, events reported through laboratory detection methods that produce proxy measures for infection surveillance  
§ Inclusion of SSI events detected on admission and readmission reduces potential bias introduced by variability in post-discharge surveillance efforts   
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Understanding the Relationship between HAI Rate and SIR Comparison Metrics 
 
The Original HAI Elimination Metrics listed above are very useful for performing evaluations. Several of these metrics are based on the 
science employed in the NHSN.  For example, metric #1 (CLABSI 1) for CLABSI events measures the number of CLABSI events per 1,000 
device (central line) days by ICU and other locations. While national aggregate CLABSI data are published in the annual NHSN Reports 
these rates much be stratified by types of locations to be risk-adjusted. This scientifically sound risk-adjustment strategy creates a practical 
challenge to summarizing this information nationally, regionally, or even for an individual healthcare facility. For instance, when comparing 
CLABSI rates, there may be quite a number of different types of locations for which a CLABSI rate could be reported. Given CLABSI rates 
among 15 different types of locations, one may observe many different combinations of patterns of temporal changes. This raises the need for 
a way to combine CLABSI rate data across location types. 
 
A standardized infection ratio (SIR) is identical in concept to a standardized mortality ratio and can be used as an indirect standardization 
method for summarizing HAI experience across any number of stratified groups of data. To illustrate the method for calculating an SIR and 





Observed CLABSI Rates NHSN CLABSI Rates for 2008 
(Standard Population) 
 
Location Type #CLABSI #Central line-days CLABSI rate* #CLABSI #Central line-days CLABSI rate* 
ICU 170 100,000 1.7 1200 600,000 2.0 
WARD 58 58,000 1.0 600 400,000 1.5 






























          95%CI = (0.628,0.989) 
   *defined as the number of CLABSIs per 1000 central line-days 
 
In the table above, there are two strata to illustrate risk-adjustment by location type for which national data exist from NHSN. The SIR 
calculation is based on dividing the total number of observed CLABSI events by an “expected” number using the CLABSI rates from the 
standard population. This “expected” number is calculated by multiplying the national CLABSI rate from the standard population by the 
observed number of central line-days for each stratum which can also be understood as a prediction or projection. If the observed data 
represented a follow-up period such as 2009 one would state that an SIR of 0.79 implies that there was a 21% reduction in CLABSIs overall 
for the nation, region, or facility. 
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The SIR concept and calculation is completely based on the underlying CLABSI rate data that exist across a potentially large group of strata. 
Thus, the SIR provides a single metric for performing comparisons rather than attempting to perform multiple comparisons across many strata 
which makes the task cumbersome. Given the underlying CLABSI rate data, one retains the option to perform comparisons within a particular 
set of strata where observed rates may differ significantly from the standard populations. These types of more detailed comparisons could be 
very useful and necessary for identifying areas for more focused prevention efforts. 
 
The national 5-year prevention target for metric #1 could be implemented using the concept of an SIR equal to 0.25 as the goal. That is, an 
SIR value based on the observed CLABSI rate data at the 5-year mark could be calculated using NHSN CLABSI rate data stratified by 
location type as the baseline to assess whether the 75% reduction goal was met. There are statistical methods that allow for calculation of 
confidence intervals, hypothesis testing, and graphical presentation using this HAI summary comparison metric called the SIR. 
 
The SIR concept and calculation can be applied equitably to other HAI metrics list above. This is especially true for HAI metrics for which 
national data are available and reasonably precise using a measurement system such as the NHSN. The SIR calculation methods differ in the 
risk group stratification only. To better understand metric #6 (SSI 1) see the following example data and SIR calculation: 
 






Category #SSI† #procedures SSI rate* #SSI† #procedures SSI rate* 
CBGB 1 315 12,600 2.5 2100 70,000 3.0 
CBGB 2,3 210 7000 3.0 1000 20,000 5.0 
HPRO 1 111 7400 1.5 1020 60,000 1.7 
   
SIR = 
              † SSI, surgical site infection 
              * defined as the number of deep incision or organ space SSIs per 100 procedures 
 
This example uses SSI rate data stratified by procedure and risk index category. Nevertheless, an SIR can be calculated using the same 






































         95%CI = (0.649,0.851) 
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data is 0.74 which indicates there’s a 26% reduction in the number of SSI events based on the baseline NHSN SSI rates as representing the 
standard population. Once again, these data can reflect the national picture at the 5-year mark and the SIR can serve as metric that 
summarizes the SSI experience into a single comparison. 
 
There are clear advantages to reporting and comparing a single number for prevention assessment. However, since the SIR calculations are 
based on standard HAI rates among individual risk groups there is the ability to perform more detailed comparisons within any individual risk 
group should the need arise. Furthermore, the process for determining the best risk-adjustment for any HAI rate data is flexible and always 
based on more detailed risk factor analyses that provide ample scientific rigor supporting any SIR calculations. The extent to which any HAI 
rate data can be risk-adjusted is obviously related to the detail and volume of data that exist in a given measurement system. 
 
In addition to the simplicity of the SIR concept and the advantages listed above, it is important to note another benefit of using an SIR 
comparison metric for HAI data. If there was need at any level of aggregation (national, regional, facility-wide, etc.) to combine the SIR 
values across mutually-exclusive data one could do so. The below table demonstrates how the example data from the previous two metric 
settings could be summarized. 
    
 Observed HAIs Expected HAIs  
HAI Metric #CLABSI #SSI† #Combined HAI #CLABSI #SSI† #Combined HAI 
CLABSI 1 228   287   
SSI 1  636   853.8  
Combined HAI    228 + 636 = 864   287+853.8 = 1140.8 
   











      † SSI, surgical site infection 
